Vorinostat (Synonyms: SAHA; Suberoylanilide hydroxamic acid)

Name: Vorinostat
Brand: MedChemExpress
SKU: HY-10221
Rating: 5.0 (159 reviews)

Cat. No.: HY-10221 Purity: 99.96%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification.

For research use only. We do not sell to patients.

CAS No. : 149647-78-9

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
250 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	Get quote
50 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 159 publication(s) in Google Scholar

Other Forms of Vorinostat:

159 Publications Citing Use of MCE Vorinostat

: Vorinostat purchased from MedChemExpress. Usage Cited in: Commun Biol. 2021 Oct 29;4(1):1235. [Abstract]; TNBC model cells (MDA-MB-231 and BT-549) were treated with indicated HDACi (Vorinostat: 10 µM; Panobinostat: 1 µM; Romidepsin: 1 µM; Givinostat: 1 µM) for 24 h and expression of LIFR, p-STAT3(Y705), and STAT3 were determined using Western blotting.

: Vorinostat purchased from MedChemExpress. Usage Cited in: RSC Adv. 2018 May 11;8(31):17279-17292.; The NH2 cells expressing Tat. All tested cells are treated with SAHA for 24 h. The expression of GFP for tested J-Lat A2 and 2D10 cells is measured by FACS. Whole cell extracts for tested NH1 and NH2 cells are prepared and examined for the luciferase activities.

: Vorinostat purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Basis Dis. 2018 May 18;S1874-9399(18)30028-2. [Abstract]; Jurkat T cells are treated for various times with Vorinostat 1 μM and Chidamide at 0.6 μM. Levels of SALL2 and cleaved PARP are evaluated by Western blot analysis. β-actin is used as a loading control.

: Vorinostat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2017 Dec 20;8(1):2207. [Abstract]; HCT116 cells are treated with Vorinostat for 24 h, followed by by western blot analysis for the indicated proteins.

: Vorinostat purchased from MedChemExpress. Usage Cited in: Mol Psychiatry. 2017 May;22(5):711-723. [Abstract]; Oral SAHA administration increases brain plasma membrane calcium ATPase (PMCA) levels, reduces oxidative stress, improves behavioral deficits and prevents neurodegeneration in ASM knockout (ASMko) mice. (a,b) Western blot of hippocampal membrane extracts from wt (a) and ASMko (b) mice orally administered SAHA complexed to HOP-β-CDX (SAHA) or HOP-β-CDX (control), and probed for PMCA and ATP6V1A.

: Vorinostat purchased from MedChemExpress. Usage Cited in: Biol Pharm Bull. 2017;40(10):1747-1753. [Abstract]; Synergistic Decrease Bcl-2 Expression by the Combination of Vorinostat with BMS-354825 in MCF-7 Cells.

: Vorinostat purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 23;8(21):34362-34373. [Abstract]; Notch3 protein levels after treatment with SAHA at different concentrations or DMSO (vehicle control), determined by western blot.

: Vorinostat purchased from MedChemExpress. Usage Cited in: Universidad Autónoma de Madrid. 2015 Jun 15.; SAHA, a histone deacetylase inhibitor that is shown to increase PMCA levels and to enhance calcium clearance in a breast cancer cell model.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HDAC Isoform Specific Products:

View All Isoforms

HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

View All Filovirus Isoform Specific Products:

View All Isoforms

EBOV MARV ZEBOV

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis^[1]^[4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification^[7].

IC₅₀ & Target^[1]^[3]^[4]

HDAC1

10 nM (ID₅₀)

HDAC3

20 nM (ID₅₀)

HDAC2

HDAC7

HDAC11

Autophagy

Mitophagy

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	1.59 μM Compound: SAHA	Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33586434]
4T1	IC₅₀	12.12 μM Compound: SAHA	Antiproliferative activity against mouse 4T1 cells assessed as cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse 4T1 cells assessed as cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36097406]
4T1	IC₅₀	4.317 μM Compound: SAHA	Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
4T1	IC₅₀	4.76 μM Compound: Vorinostat	Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
518A2	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human 518A2 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human 518A2 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
518A2	IC₅₀	0.9 μM Compound: Vorinostat	Antiproliferative activity against human 518A2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human 518A2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
786-0	GI₅₀	3.2 μM Compound: SAHA, Zolinza	Growth inhibition of human 786-0 cells after 72 hrs by MTS assay Growth inhibition of human 786-0 cells after 72 hrs by MTS assay	[PMID: 22435669]
A-375	IC₅₀	1.4 μM Compound: Vorinostat	Antiproliferative activity against human A-375 cells Antiproliferative activity against human A-375 cells	[PMID: 37875056]
A-375	IC₅₀	2.68 μM Compound: SAHA	Antiproliferative activity against human A375 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
A-375	IC₅₀	2.827 μM Compound: SAHA	Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
A-375	IC₅₀	4.1 μM Compound: SAHA	Cytotoxicity against human A375 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human A375 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 28131715]
A-431	GI₅₀	4.48 μM Compound: SAHA, Vorinostat	Growth inhibition of human A431 cells by MTT assay Growth inhibition of human A431 cells by MTT assay	[PMID: 23601706]
A-431	IC₅₀	0.63 μM Compound: SAHA	Antiproliferative activity against human A-431 cells measured after 72 hrs by MTT assay Antiproliferative activity against human A-431 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
A-431	IC₅₀	1.47 μM Compound: Vorinostat	Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay	[PMID: 33493830]
A-431	IC₅₀	2.29 μM Compound: 8	Antiproliferative activity against human A431 cells expressing EGFR/HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human A431 cells expressing EGFR/HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27769671]
A-431	IC₅₀	3.13 μM Compound: Vorinostat	Antiproliferative activity against human A-431 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A-431 cells assessed as inhibition of cell growth by MTT assay	[PMID: 37875056]
A-431	IC₅₀	3.5 μM Compound: SAHA	Antiproliferative activity against human A431 cells after 72 hrs by SRB assay Antiproliferative activity against human A431 cells after 72 hrs by SRB assay	[PMID: 29150335]
A-431	IC₅₀	3.81 μM Compound: SAHA	Cytotoxicity against human A-431 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human A-431 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
A-431	IC₅₀	4.2 μM Compound: 2	Cytotoxicity against human A431 cells Cytotoxicity against human A431 cells	[PMID: 17691763]
A-431	IC₅₀	4.2 μM Compound: 2a	Cytotoxicity against human A431 cells overexpressing EGFR by resazurin dye reduction assay Cytotoxicity against human A431 cells overexpressing EGFR by resazurin dye reduction assay	[PMID: 21080629]
A-431	IC₅₀	5.13 μM Compound: Zolinza, SAHA	Antiproliferative activity against human A431 cells after 48 hrs by MTT assay Antiproliferative activity against human A431 cells after 48 hrs by MTT assay	[PMID: 22698782]
A20	IC₅₀	0.112 μM Compound: SAHA	In vitro for anti-HDAC1 (Histone deacetylase 1) activity in mouse A20 cells In vitro for anti-HDAC1 (Histone deacetylase 1) activity in mouse A20 cells	[PMID: 11960489]
A20	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against mouse A20 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse A20 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
A2780	CC₅₀	2600 nM Compound: 1	Antiproliferative activity against human A2780 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human A2780 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
A2780	EC₅₀	377.48 nM Compound: SAHA	Inhibition of HDAC1/2/3 in human A2780S cells assessed as histone H3 acetylation incubated for 6 hrs by cytoblot assay Inhibition of HDAC1/2/3 in human A2780S cells assessed as histone H3 acetylation incubated for 6 hrs by cytoblot assay	[PMID: 27186676]
A2780	EC₅₀	399.25 nM Compound: SAHA	Inhibition of HDAC6 in human A2780S cells assessed as tubulin acetylation incubated for 6 hrs by cytoblot assay Inhibition of HDAC6 in human A2780S cells assessed as tubulin acetylation incubated for 6 hrs by cytoblot assay	[PMID: 27186676]
A2780	GI₅₀	3150 nM Compound: SAHA, vorinostat	Antiproliferative activity against human A2780 cells after 72 hrs by WST-1 assay Antiproliferative activity against human A2780 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
A2780	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
A2780	IC₅₀	0.43 μM Compound: 3; SAHA	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36449947]
A2780	IC₅₀	0.44 μM Compound: SAHA, vorinostat	Inhibition of HDAC in cisplatin resistant human A2780 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human A2780 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
A2780	IC₅₀	0.53 μM Compound: SAHA, vorinostat	Inhibition of HDAC in human A2780 cells after 18 hrs by fluorescence assay Inhibition of HDAC in human A2780 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
A2780	IC₅₀	0.64 μM Compound: Vorinostat	Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and further incubation for 3 hrs by microplate reader based fluorescence assay Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and further incubation for 3 hrs by microplate reader based fluorescence assay	[PMID: 31431326]
A2780	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
A2780	IC₅₀	0.91 μM Compound: 1	Inhibition of HDAC in human A2780 cells Inhibition of HDAC in human A2780 cells	[PMID: 31787463]
A2780	IC₅₀	0.96 μM Compound: Vorinostat	Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and measured after 3 hrs by fluorescence assay Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and measured after 3 hrs by fluorescence assay	[PMID: 31762274]
A2780	IC₅₀	1.16 μM Compound: Vorinostat	Antiproliferative activity against human A2780 cells after 72 hrs by microplate reader based MTT assay Antiproliferative activity against human A2780 cells after 72 hrs by microplate reader based MTT assay	[PMID: 31431326]
A2780	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human A2780 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human A2780 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
A2780	IC₅₀	1.62 μM Compound: SAHA	Antiproliferative activity against human A2780 cells Antiproliferative activity against human A2780 cells	[PMID: 20451378]
A2780	IC₅₀	1.62 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human A2780 cells after 96 hrs by celltiter 96 assay Antiproliferative activity against human A2780 cells after 96 hrs by celltiter 96 assay	[PMID: 21634430]
A2780	IC₅₀	1.9 μM Compound: SAHA	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 23906422]
A2780	IC₅₀	2.04 μM Compound: 1	Cytotoxicity against human A2780 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability by MTT assay	[PMID: 31787463]
A2780	IC₅₀	2.1 μM Compound: SAHA	Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay	[PMID: 29150335]
A2780	IC₅₀	2.1 μM Compound: SAHA	Antiproliferative activity against human A2780 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human A2780 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
A2780	IC₅₀	2.42 μM Compound: SAHA, vorinostat	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 23252603]
A2780	IC₅₀	2.42 μM Compound: Vorinostat	Cytotoxicity against human A2780 cells assessed as reduction in cell survival measured after 72 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as reduction in cell survival measured after 72 hrs by MTT assay	[PMID: 31762274]
A2780	IC₅₀	2.42 μM Compound: Vorinostat	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33360560]
A2780	IC₅₀	2600 nM Compound: 1, vorinostat	Antiproliferative activity against human A2780 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human A2780 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
A2780	IC₅₀	3.12 μM Compound: SAHA, vorinostat	Cytotoxicity against cisplatin resistant human A2780 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human A2780 cells after 72 hrs by MTT assay	[PMID: 23252603]
A2780	IC₅₀	380 nM Compound: Vorinostat	Antiproliferative activity against human A2780 cells Antiproliferative activity against human A2780 cells	[PMID: 37875056]
A2780	IC₅₀	8.82 μM Compound: SAHA	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth by MTT assay	[PMID: 37116762]
A2780	IC₅₀	870 nM Compound: SAHA	Cytotoxicity against human A2780S cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human A2780S cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 27186676]
A2780	IC₅₀	> 1000 nM Compound: SAHA	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 26443078]
A2780S	IC₅₀	5541 nM Compound: SAHA	Antiproliferative activity against human A2780S cells after 72 hrs by MTT assay Antiproliferative activity against human A2780S cells after 72 hrs by MTT assay	[PMID: 31177073]
A498	GI₅₀	1.4 μM Compound: SAHA	Antiproliferative activity against human A498 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human A498 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
A498	GI₅₀	1.6 μM Compound: SAHA, Zolinza	Growth inhibition of human A498 cells after 72 hrs by MTS assay Growth inhibition of human A498 cells after 72 hrs by MTS assay	[PMID: 22435669]
A498	IC₅₀	25.08 μM Compound: SAHA	Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 34111829]
A549	CC₅₀	1800 nM Compound: 1	Antiproliferative activity against human P53 expressing A549 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human P53 expressing A549 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
A549	EC₅₀	1 μM Compound: SAHA	Inhibition of HDAC6 in human A549 cells assessed as induction of tubulin acetylation after 17 to 18 hrs by ELISA Inhibition of HDAC6 in human A549 cells assessed as induction of tubulin acetylation after 17 to 18 hrs by ELISA	[PMID: 25734520]
A549	EC₅₀	1.03 μM Compound: SAHA	Inhibition of HDAC6 in human A549 cells assessed as tubulin acetylation after 17 to 18 hrs by cytoblot assay Inhibition of HDAC6 in human A549 cells assessed as tubulin acetylation after 17 to 18 hrs by cytoblot assay	[PMID: 25238284]
A549	EC₅₀	12 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells measured after 72 hrs by WST1 assay Antiproliferative activity against human A549 cells measured after 72 hrs by WST1 assay	[PMID: 27597246]
A549	EC₅₀	8.3 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 23820574]
A549	GI₅₀	0.79 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 21712146]
A549	GI₅₀	1.02 μM Compound: 1; SAHA	Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31655430]
A549	GI₅₀	1.02 μM Compound: 1; SAHA	Growth inhibition of human A549 cells incubated for 48 hrs by SRB assay Growth inhibition of human A549 cells incubated for 48 hrs by SRB assay	[PMID: 32058238]
A549	GI₅₀	1.02 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 27344487]
A549	GI₅₀	1.02 μM Compound: SAHA; 1	Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 29567459]
A549	GI₅₀	1.6 μM Compound: SAHA, Zolinza	Growth inhibition of human A549/ATCC cells after 72 hrs by MTS assay Growth inhibition of human A549/ATCC cells after 72 hrs by MTS assay	[PMID: 22435669]
A549	GI₅₀	1.73 μM Compound: 1; SAHA	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
A549	GI₅₀	1.78 μM Compound: SAHA, Vorinostat	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 23601706]
A549	GI₅₀	1.85 μM Compound: 1, SAHA	Growth inhibition of human A549 cells after 48 hrs by SRB assay Growth inhibition of human A549 cells after 48 hrs by SRB assay	[PMID: 22439863]
A549	GI₅₀	19.45 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28629630]
A549	GI₅₀	2.62 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay	[PMID: 31924504]
A549	GI₅₀	3.1 μM Compound: SAHA, Zolinza	Growth inhibition of human A549 cells after 72 hrs by MTT assay Growth inhibition of human A549 cells after 72 hrs by MTT assay	[PMID: 22435669]
A549	GI₅₀	3.13 μM Compound: 1, SAHA	Growth inhibition of human A549 cells after 96 hrs by MTT assay Growth inhibition of human A549 cells after 96 hrs by MTT assay	[PMID: 26814680]
A549	GI₅₀	5.02 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells after 96 hrs by MTT assay Antiproliferative activity against human A549 cells after 96 hrs by MTT assay	[PMID: 29500130]
A549	GI₅₀	5.27 μM Compound: vorinostat, SAHA	Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
A549	GI₅₀	5.4 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	[PMID: 34500130]
A549	GI₅₀	5700 nM Compound: SAHA, vorinostat	Antiproliferative activity against human A549 cells after 72 hrs by WST-1 assay Antiproliferative activity against human A549 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
A549	GI₅₀	> 200 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 19822426]
A549	GI₅₀	> 410 nM Compound: Vorinostat	Cytotoxicity against human A549 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
A549	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
A549	IC₅₀	0.427 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 37563016]
A549	IC₅₀	0.493 μM Compound: Vorinostat	Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 37875056]
A549	IC₅₀	0.59 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34237620]
A549	IC₅₀	0.6 mM Compound: Vorinostat	Antiproliferative activity against human A549 cells after 2 days by MTT assay Antiproliferative activity against human A549 cells after 2 days by MTT assay	[PMID: 19608304]
A549	IC₅₀	0.61 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 37875056]
A549	IC₅₀	0.63 μM Compound: 8	Cytotoxicity against human A549 cells expressing EGFR and KRAS mutant assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells expressing EGFR and KRAS mutant assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27769671]
A549	IC₅₀	0.64 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability Antiproliferative activity against human A549 cells assessed as reduction in cell viability	[PMID: 35643262]
A549	IC₅₀	0.68 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay	[PMID: 37875056]
A549	IC₅₀	0.69 μM Compound: SAHA, Zolinza	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 21733698]
A549	IC₅₀	0.74 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21476600]
A549	IC₅₀	0.76 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs Antiproliferative activity against human A549 cells after 48 hrs	[PMID: 20576572]
A549	IC₅₀	0.84 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 48 hrs by resazurin based microplate reader analysis Antiproliferative activity against human A549 cells incubated for 48 hrs by resazurin based microplate reader analysis	[PMID: 37647727]
A549	IC₅₀	0.86 μM Compound: SAHA	Anti-proliferative activity against human A549 cells after 48 hrs by MTT assay Anti-proliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28947154]
A549	IC₅₀	0.868 μM Compound: SAHA	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 20855208]
A549	IC₅₀	0.89 μM Compound: 1	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
A549	IC₅₀	1.02 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 37875056]
A549	IC₅₀	1.079 μM Compound: SAHA	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 23644210]
A549	IC₅₀	1.079 μM Compound: vorinostat	Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay	[PMID: 26629860]
A549	IC₅₀	1.08 μM Compound: SAHA	Cytotoxicity against human A549 cells after 72 hrs by CellTiter-Glo assay Cytotoxicity against human A549 cells after 72 hrs by CellTiter-Glo assay	[PMID: 30245394]
A549	IC₅₀	1.08 μM Compound: SAHA, Vorinostat	Antiproliferative activity against human A549 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human A549 cells after 72 hrs by CellTiter-Glo assay	[PMID: 23792316]
A549	IC₅₀	1.1 μM Compound: 4; SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability Antiproliferative activity against human A549 cells assessed as reduction in cell viability	[PMID: 34314844]
A549	IC₅₀	1.23 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human A549 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
A549	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
A549	IC₅₀	1.25 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay	[PMID: 37086699]
A549	IC₅₀	1.35 μM Compound: Vorinostat	Cytotoxicity against human A549 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
A549	IC₅₀	1.5 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
A549	IC₅₀	1.54 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 24766560]
A549	IC₅₀	1.62 μM Compound: 1; SAHA	Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
A549	IC₅₀	1.65 μM Compound: SAHA, Zolinza	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
A549	IC₅₀	1.65 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 25953722]
A549	IC₅₀	1.67 μM Compound: SAHA	Dark toxicity in human A549 cells assessed as reduction in cell viability incubated under dark for 48 hrs measured after 48 hrs by CCK8 assay Dark toxicity in human A549 cells assessed as reduction in cell viability incubated under dark for 48 hrs measured after 48 hrs by CCK8 assay	[PMID: 33744687]
A549	IC₅₀	1.69 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 35858522]
A549	IC₅₀	1.7 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 29223096]
A549	IC₅₀	1.7 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32738414]
A549	IC₅₀	1.7 μM Compound: SAHA	Phototoxicity in human A549 cells assessed as reduction in cell viability irradiated 10 j/cm2 for 24 hrs followed by incubated for 24 hrs by CCK8 assay Phototoxicity in human A549 cells assessed as reduction in cell viability irradiated 10 j/cm2 for 24 hrs followed by incubated for 24 hrs by CCK8 assay	[PMID: 33744687]
A549	IC₅₀	1.79 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK-8 assay	[PMID: 37057760]
A549	IC₅₀	1.79 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38964169]
A549	IC₅₀	1.8 μM Compound: 2	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 17691763]
A549	IC₅₀	1.8 μM Compound: 2a	Cytotoxicity against human A549 cells overexpressing HDAC by resazurin dye reduction assay Cytotoxicity against human A549 cells overexpressing HDAC by resazurin dye reduction assay	[PMID: 21080629]
A549	IC₅₀	1.91 μM Compound: XII; SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
A549	IC₅₀	12.46 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	10.1039/C5MD00247H
A549	IC₅₀	12.5 nM Compound: 1; SAHA	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs in presence of SN-38 by SRB assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs in presence of SN-38 by SRB assay	[PMID: 32679451]
A549	IC₅₀	12.6 μM Compound: SAHA	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 18247554]
A549	IC₅₀	15.73 μM Compound: SAHA	Antiproliferative activity in human A549 cells assessed as inhibition of cell viability after 72 hrs by MTS assay Antiproliferative activity in human A549 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	[PMID: 32061484]
A549	IC₅₀	17.9 μM Compound: SAHA, vorinostat	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707260]
A549	IC₅₀	1746.95 nM Compound: SAHA	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 30115492]
A549	IC₅₀	1800 nM Compound: 1, SAHA	Antiproliferative activity against human A549 cells after 72 hrs by celltiter-blue viability assay Antiproliferative activity against human A549 cells after 72 hrs by celltiter-blue viability assay	[PMID: 18809328]
A549	IC₅₀	1800 nM Compound: 1, SAHA	Antiproliferative activity against human A549 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human A549 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19410459]
A549	IC₅₀	1800 nM Compound: 1, vorinostat	Antiproliferative activity against human A549 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human A549 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
A549	IC₅₀	1862 nM Compound: 1; SAHA	Antiproliferative activity against human A549 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
A549	IC₅₀	2.01 μM Compound: 1; SAHA	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
A549	IC₅₀	2.1 μM Compound: SAHA	Antiproliferative against human A549 cells assessed as reduction in cell viability by MTT assay Antiproliferative against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 33045329]
A549	IC₅₀	2.2 μM Compound: 6, SAHA	Cytotoxicity against human A549 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human A549 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
A549	IC₅₀	2.24 μM Compound: SAHA	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 30525585]
A549	IC₅₀	2.27 μM Compound: Vorinostat	Cytotoxicity against human A549 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay Cytotoxicity against human A549 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay	[PMID: 23829483]
A549	IC₅₀	2.36 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
A549	IC₅₀	2.39 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 28987602]
A549	IC₅₀	2.42 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 31413795]
A549	IC₅₀	2.43 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
A549	IC₅₀	2.47 μM Compound: 1; SAHA	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis	[PMID: 36215854]
A549	IC₅₀	2.57 μM Compound: SAHA	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 32961382]
A549	IC₅₀	2.61 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
A549	IC₅₀	2.63 μM Compound: 4; SAHA	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 29670692]
A549	IC₅₀	2.79 μM Compound: SAHA	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
A549	IC₅₀	2.9 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells by CCK8 assay Antiproliferative activity against human A549 cells by CCK8 assay	[PMID: 30660827]
A549	IC₅₀	2.92 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37875056]
A549	IC₅₀	2.93 μM Compound: 1; SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 32180916]
A549	IC₅₀	2651.1 nM Compound: 1; SAHA	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 32679451]
A549	IC₅₀	27.8 μM Compound: Zolinza, SAHA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 22698782]
A549	IC₅₀	3 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
A549	IC₅₀	3.14 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 96 hrs by resazurin assay Antiproliferative activity against human A549 cells incubated for 96 hrs by resazurin assay	[PMID: 32435375]
A549	IC₅₀	3.29 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
A549	IC₅₀	3.5 μM Compound: 2; SAHA	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34634618]
A549	IC₅₀	3.7 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs Antiproliferative activity against human A549 cells after 48 hrs	[PMID: 24262004]
A549	IC₅₀	3.7 μM Compound: Vorinostat	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
A549	IC₅₀	3.8 μM Compound: 1, SAHA	Inhibition of human A549 cell proliferation after 48 hrs by MTT assay Inhibition of human A549 cell proliferation after 48 hrs by MTT assay	[PMID: 23493449]
A549	IC₅₀	3.9 μM Compound: SA, SAHA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 24694055]
A549	IC₅₀	3.9 μM Compound: SAHA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 25462271]
A549	IC₅₀	35 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
A549	IC₅₀	4.11 μM Compound: SAHA	Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 38452727]
A549	IC₅₀	4.12 μM Compound: 1; SAHA	Cytotoxicity against human A549 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay Cytotoxicity against human A549 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay	[PMID: 31223439]
A549	IC₅₀	4.25 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 33493830]
A549	IC₅₀	4.3 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 34624191]
A549	IC₅₀	4.33 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
A549	IC₅₀	4.372 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by SRB assay	[PMID: 34454126]
A549	IC₅₀	4.4 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 29348808]
A549	IC₅₀	4.4 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 35608269]
A549	IC₅₀	4.5 μM Compound: SAHA	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23570542]
A549	IC₅₀	4.97 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C4MD00203B
A549	IC₅₀	476.86 nM Compound: 1; SAHA	Antiproliferative activity against human A549 cells measured after 48 hrs by sulforhodamine-B assay Antiproliferative activity against human A549 cells measured after 48 hrs by sulforhodamine-B assay	[PMID: 27886544]
A549	IC₅₀	5 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
A549	IC₅₀	5 μM Compound: SAHA	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 31546197]
A549	IC₅₀	5.32 μM Compound: SAHA	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26149591]
A549	IC₅₀	5.37 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	10.1039/C5MD00247H
A549	IC₅₀	5.48 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 39145486]
A549	IC₅₀	5.74 μM Compound: I-1; SAHA	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 35245830]
A549	IC₅₀	6.74 μM Compound: SAHA; 6	Antiproliferative activity against human A549 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human A549 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
A549	IC₅₀	7.06 μM Compound: SAHA	Antiproliferative activity against human A549 cells incubated for 24 hrs by CCK8 assay Antiproliferative activity against human A549 cells incubated for 24 hrs by CCK8 assay	[PMID: 32247729]
A549	IC₅₀	7.32 μM Compound: 1; SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	[PMID: 34656899]
A549	IC₅₀	7.44 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 35043615]
A549	IC₅₀	7.49 μM Compound: SAHA	Antiproliferative activity against human A549 cells measured after 72 hrs Antiproliferative activity against human A549 cells measured after 72 hrs	[PMID: 35697181]
A549	IC₅₀	78.76 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay	10.1039/C5MD00247H
A549	IC₅₀	80.3 μM Compound: SAHA, vorinostat	Cytotoxicity against SAHA-resistant human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against SAHA-resistant human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23707260]
A549	IC₅₀	9.13 μM Compound: Vorinostat	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay	[PMID: 35255412]
A549	IC₅₀	9.484 μM Compound: SAHA	Anticancer activity against human A549 cells assessed as inhibition of cell growth measured for 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell growth measured for 48 hrs by MTT assay	[PMID: 38897139]
A549	IC₅₀	> 10 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34116381]
A549	IC₅₀	> 10 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 35272009]
A549	IC₅₀	> 100 μM Compound: SAHA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
A549	IC₅₀	> 1000 nM Compound: SAHA	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 26443078]
ACHN	GI₅₀	0.65 μM Compound: SAHA	Growth inhibition of human ACHN cells after 21 hrs by MTT assay Growth inhibition of human ACHN cells after 21 hrs by MTT assay	[PMID: 17662606]
ACHN	GI₅₀	0.73 μM Compound: 1, SAHA	Growth inhibition of ACHN cells by SRB assay Growth inhibition of ACHN cells by SRB assay	[PMID: 17477518]
ACHN	GI₅₀	0.73 μM Compound: 2, SAHA	Antiproliferative activity against human ACHN cells by SRB assay Antiproliferative activity against human ACHN cells by SRB assay	[PMID: 16723227]
ACHN	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human ACHN cells after 72 hrs by MTS assay Growth inhibition of human ACHN cells after 72 hrs by MTS assay	[PMID: 22435669]
ACHN	GI₅₀	2.22 μM Compound: 2, SAHA	Growth inhibition of human ACHN cells by SRB assay Growth inhibition of human ACHN cells by SRB assay	[PMID: 17904843]
ACHN	GI₅₀	4.22 μM Compound: 1, SAHA	Growth inhibition of human ACHN cells Growth inhibition of human ACHN cells	[PMID: 20850971]
ACHN	GI₅₀	4.22 μM Compound: 1, SAHA, Zolinza, Vorinostat	Cytotoxicity against human ACHN cells assessed as growth inhibition by SRB assay Cytotoxicity against human ACHN cells assessed as growth inhibition by SRB assay	[PMID: 23163332]
ACHN	GI₅₀	4.22 μM Compound: SAHA	Growth inhibition of human ACHN cells after 5 days by sulforhodamine B assay Growth inhibition of human ACHN cells after 5 days by sulforhodamine B assay	[PMID: 25811792]
ACHN	GI₅₀	4.22 μM Compound: SAHA	Growth inhibition of human ACHN cells measured after 5 days by sulforhodamine-B assay Growth inhibition of human ACHN cells measured after 5 days by sulforhodamine-B assay	[PMID: 28011426]
ACHN	IC₅₀	2.08 μM Compound: SAHA	Antiproliferative activity against human ACHN cells after 72 hrs by MTT assay Antiproliferative activity against human ACHN cells after 72 hrs by MTT assay	[PMID: 29787262]
AGS	IC₅₀	4 μM Compound: SAHA	Cytotoxicity against human AGS cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human AGS cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
AGS	IC₅₀	4.23 μM Compound: SAHA	Antiproliferative activity against human AGS cells after 72 hrs by MTT assay Antiproliferative activity against human AGS cells after 72 hrs by MTT assay	[PMID: 29787262]
AGS	IC₅₀	> 10 μM Compound: SAHA	Antiproliferative activity against human AGS cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human AGS cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
AML12	IC₅₀	> 5 μM Compound: SAHA	Cytotoxicity against AML12 cells incubated for 72 hrs measured by MTT assay Cytotoxicity against AML12 cells incubated for 72 hrs measured by MTT assay	[PMID: 37498552]
ASPC1	GI₅₀	2.09 μM Compound: 1, SAHA	Growth inhibition of human Aspc-1 cells after 96 hrs by MTT assay Growth inhibition of human Aspc-1 cells after 96 hrs by MTT assay	[PMID: 26814680]
ASPC1	GI₅₀	5.44 μM Compound: 1; SAHA	Growth inhibition of human AsPC1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human AsPC1 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
ASPC1	IC₅₀	0.69 μg/mL Compound: SAHA	Cytotoxicity against human AsPC1 cells Cytotoxicity against human AsPC1 cells	[PMID: 22036991]
ASPC1	IC₅₀	100 μM Compound: 2	Cytotoxicity against human AsPC1 cells Cytotoxicity against human AsPC1 cells	[PMID: 17691763]
ASPC1	IC₅₀	3.09 μM Compound: SAHA	Antiproliferative activity against human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36097406]
ASPC1	IC₅₀	3.2 μM Compound: SAHA	Antiproliferative activity against human Aspc-1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human Aspc-1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
ASPC1	IC₅₀	3.2 μM Compound: Vorinostat	Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
ASPC1	IC₅₀	3.66 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human AsPC1 cells after 48 hrs by SRB assay Antiproliferative activity against human AsPC1 cells after 48 hrs by SRB assay	[PMID: 24185378]
ASPC1	IC₅₀	> 411 nM Compound: Vorinostat	Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
B16	IC₅₀	2.26 μM Compound: I-1; SAHA	Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 35245830]
B16	IC₅₀	4.44 μM Compound: 1, SAHA	Cytotoxicity against mouse B16 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against mouse B16 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26122774]
B16-F10	IC₅₀	11.36 μM Compound: SAHA	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 35043615]
B16-F10	IC₅₀	13.1 μM Compound: SAHA	Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 28131715]
B16-F10	IC₅₀	13.52 μM Compound: SAHA	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35152694]
B16-F10	IC₅₀	2.067 μM Compound: SAHA	Cytotoxicity against human B16-F10 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human B16-F10 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
BE(2)-C	IC₅₀	1.1 μM Compound: SAHA	Antiproliferative activity against human BE(2)-C cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human BE(2)-C cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25238284]
BE(2)-C	IC₅₀	2 μM Compound: SAHA, vorinostat	Antiproliferative activity against human BE(2)-C cells after 72 hrs by Alamar blue assay Antiproliferative activity against human BE(2)-C cells after 72 hrs by Alamar blue assay	[PMID: 22932316]
BE(2)-C	IC₅₀	2.112 μM Compound: SAHA	Antiproliferative activity against human BE2C cells incubated for 48 hrs by MTT assay Antiproliferative activity against human BE2C cells incubated for 48 hrs by MTT assay	[PMID: 37563016]
BEAS-2B	IC₅₀	> 50 μM Compound: 1; SAHA	Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 32180916]
BGC-823	GI₅₀	3.09 μM Compound: SAHA, Vorinostat	Growth inhibition of human BGC823 cells by MTT assay Growth inhibition of human BGC823 cells by MTT assay	[PMID: 23601706]
BGC-823	GI₅₀	4.26 μM Compound: vorinostat, SAHA	Antiproliferative activity against human BGC823 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human BGC823 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
BGC-823	IC₅₀	12.98 μM Compound: SAHA	Cytotoxicity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
BGC-823	IC₅₀	2.94 μM Compound: SAHA	Antiproliferative activity against human BGC823 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human BGC823 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
BGC-823	IC₅₀	9.34 μM Compound: SAHA	Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
BJ	IC₅₀	> 100 μM Compound: SAHA	Growth inhibition of human BJ cells after 48 hrs by MTT assay Growth inhibition of human BJ cells after 48 hrs by MTT assay	[PMID: 20143840]
BMDM	CC₅₀	5 μM Compound: 1	Cytotoxicity against Swiss mouse BMDM assessed as reduction in cell viability measured after 72 hrs by tryphan blue assay Cytotoxicity against Swiss mouse BMDM assessed as reduction in cell viability measured after 72 hrs by tryphan blue assay	[PMID: 32392053]
BT-474	IC₅₀	2.67 μM Compound: 8	Cytotoxicity against human BT474 cells expressing HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human BT474 cells expressing HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27769671]
BT-549	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human BT549 cells after 72 hrs by MTS assay Growth inhibition of human BT549 cells after 72 hrs by MTS assay	[PMID: 22435669]
BT-549	IC₅₀	2.3 μM Compound: SAHA	Cytotoxicity against human BT-549 cells harboring wild type BRCA1 and wild type BRCA2 assessed as reduction in cell viability Cytotoxicity against human BT-549 cells harboring wild type BRCA1 and wild type BRCA2 assessed as reduction in cell viability	[PMID: 36053318]
BT-549	IC₅₀	2.96 μM Compound: SAHA	Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33586434]
BT-549	IC₅₀	8.67 μM Compound: SAHA	Cytotoxicity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
BXPC-3	GI₅₀	5.56 μM Compound: Vorin	Cytotoxicity against human BxPC3 cells after 72 hrs by MTS assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTS assay	[PMID: 24900743]
BXPC-3	IC₅₀	2.1 μM Compound: SAHA	Antiproliferative activity against human BXPC-3 cells incubated for 48 hrs by resazurin based microplate reader analysis Antiproliferative activity against human BXPC-3 cells incubated for 48 hrs by resazurin based microplate reader analysis	[PMID: 37647727]
BXPC-3	IC₅₀	2.7 μM Compound: SAHA	Antiproliferative activity against human BxPC3 cells after hrs by ATP content assay Antiproliferative activity against human BxPC3 cells after hrs by ATP content assay	[PMID: 20143778]
BXPC-3	IC₅₀	4.74 μM Compound: SAHA	Antiproliferative activity against human BXPC-3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human BXPC-3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36097406]
BXPC-3	IC₅₀	5 μM Compound: 1a, SAHA	Growth inhibition of human BxPC3 cells after 72 hrs by MTS assay Growth inhibition of human BxPC3 cells after 72 hrs by MTS assay	[PMID: 20055418]
BXPC-3	IC₅₀	5 μM Compound: SAHA	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 18494463]
BXPC-3	IC₅₀	5 μM Compound: SAHA	Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 18642892]
BXPC-3	IC₅₀	5 μM Compound: SAHA	Antiproliferative activity against human BxPC3 cells by MTT assay Antiproliferative activity against human BxPC3 cells by MTT assay	[PMID: 19419863]
BaF3	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
BaF3	IC₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against mouse BaF3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse BaF3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
Bcap37	IC₅₀	3.098 μM Compound: SAHA	Cytotoxicity against human Bcap37 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human Bcap37 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
Bel-7402	IC₅₀	1.8 μM Compound: SAHA	Cytotoxicity against human Bel-7402 cells incubated for 72 hrs measured by MTT assay Cytotoxicity against human Bel-7402 cells incubated for 72 hrs measured by MTT assay	[PMID: 37498552]
Bel-7402	IC₅₀	27.35 μM Compound: SAHA	Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
Bel-7402	IC₅₀	4.207 μM Compound: SAHA	Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
Bel-7402	IC₅₀	4.7 μM Compound: SAHA	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 31120744]
Bel-7402	IC₅₀	4.72 μM Compound: SAHA	Antiproliferative activity against human Bel7402 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human Bel7402 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
Bel-7402	IC₅₀	7.1 μM Compound: 5; SAHA	Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 31117517]
Bel7402/5-FU	IC₅₀	9.83 μM Compound: SAHA	Antiproliferative activity against human Bel7402/5-FU cells incubated for 48 hrs by MTT assay Antiproliferative activity against human Bel7402/5-FU cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
C6	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against rat C6 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against rat C6 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
C6	IC₅₀	2.97 μM Compound: Vorinostat	Antiproliferative activity against rat C6 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against rat C6 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 37875056]
CAKI-1	GI₅₀	1.2 μM Compound: SAHA	Antiproliferative activity against human Caki1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human Caki1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
CAKI-1	IC₅₀	32.46 μM Compound: SAHA	Antiproliferative activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Antiproliferative activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 34111829]
CAKI-1	IC₅₀	517 nM Compound: 1; SAHA	Antiproliferative activity against human CAKI-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human CAKI-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
CAL-27	IC₅₀	0.36 μM Compound: SAHA, vorinostat	Inhibition of HDAC in cisplatin sensitive human CAL27 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin sensitive human CAL27 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
CAL-27	IC₅₀	0.59 μM Compound: 1	Inhibition of HDAC in human Cal27 cells Inhibition of HDAC in human Cal27 cells	[PMID: 31787463]
CAL-27	IC₅₀	0.61 μM Compound: SAHA, vorinostat	Inhibition of HDAC in cisplatin resistant human CAL27 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human CAL27 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
CAL-27	IC₅₀	1.5 μM Compound: 1	Cytotoxicity against human CAL27 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human CAL27 cells assessed as reduction in cell viability by MTT assay	[PMID: 31787463]
CAL-27	IC₅₀	1.96 μM Compound: Vorinostat	Inhibition of class 1 HDAC in human CAL27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.5 uM preincubated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 9.79 uM) Inhibition of class 1 HDAC in human CAL27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.5 uM preincubated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 9.79 uM)	[PMID: 31762274]
CAL-27	IC₅₀	1.98 μM Compound: Vorinostat	Antiproliferative activity against human CAL27 cells measured after 72 hrs by MTT assay Antiproliferative activity against human CAL27 cells measured after 72 hrs by MTT assay	[PMID: 28581289]
CAL-27	IC₅₀	1.98 μM Compound: Vorinostat	Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33360560]
CAL-27	IC₅₀	1.99 μM Compound: Vorinostat	Antiproliferative activity against human CAL27 cells after 72 hrs by microplate reader based MTT assay Antiproliferative activity against human CAL27 cells after 72 hrs by microplate reader based MTT assay	[PMID: 31431326]
CAL-27	IC₅₀	2.08 μM Compound: SAHA, vorinostat	Cytotoxicity against cisplatin resistant human CAL27 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human CAL27 cells after 72 hrs by MTT assay	[PMID: 23252603]
CAL-27	IC₅₀	2.64 μM Compound: SAHA, vorinostat	Cytotoxicity against cisplatin sensitive human CAL27 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin sensitive human CAL27 cells after 72 hrs by MTT assay	[PMID: 23252603]
CAL-27	IC₅₀	2.64 μM Compound: Vorinostat	Cytotoxicity against human CAL27 cells assessed as reduction in cell survival measured after 72 hrs by MTT assay Cytotoxicity against human CAL27 cells assessed as reduction in cell survival measured after 72 hrs by MTT assay	[PMID: 31762274]
CAL-27	IC₅₀	3.2 μM Compound: 2	Cytotoxicity against human Cal27 cells Cytotoxicity against human Cal27 cells	[PMID: 17691763]
CAL-27	IC₅₀	3.2 μM Compound: 2a	Cytotoxicity against human CAL27 cells overexpressing EGFR by resazurin dye reduction assay Cytotoxicity against human CAL27 cells overexpressing EGFR by resazurin dye reduction assay	[PMID: 21080629]
CAL-27	IC₅₀	3.72 μM Compound: SAHA	Antiproliferative activity against human CAL27 cells Antiproliferative activity against human CAL27 cells	[PMID: 20143778]
CAL-51	IC₅₀	1.04 μM Compound: SAHA	Antiproliferative activity against human CAL-51 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human CAL-51 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33586434]
CAPAN-1	IC₅₀	1.8 μM Compound: SAHA	Antiproliferative activity against human Capan1 cells after 72 hrs by SRB assay Antiproliferative activity against human Capan1 cells after 72 hrs by SRB assay	[PMID: 29150335]
CAPAN-1	IC₅₀	1.89 μM Compound: SAHA	Antiproliferative activity against human CAPAN-1 cells assessed as reduction in cell viability Antiproliferative activity against human CAPAN-1 cells assessed as reduction in cell viability	[PMID: 35643262]
CAPAN-1	IC₅₀	5.4 μM Compound: SAHA	Anticancer activity against human CAPAN-1 cells Anticancer activity against human CAPAN-1 cells	[PMID: 34107385]
CAPAN-1	IC₅₀	5.4 μM Compound: Vorinostat	Antiproliferative activity against human CAPAN-1 cells Antiproliferative activity against human CAPAN-1 cells	[PMID: 37875056]
CAPAN-1	IC₅₀	7.3 μM Compound: SAHA	Antiproliferative activity against human Capan1 cells after hrs by ATP content assay Antiproliferative activity against human Capan1 cells after hrs by ATP content assay	[PMID: 20143778]
CCRF-CEM	CC₅₀	2.5 μM Compound: SAHA	Cytotoxicity against human CEM cells assessed as cell death incubated for 20 hrs measured by DNS assay Cytotoxicity against human CEM cells assessed as cell death incubated for 20 hrs measured by DNS assay	[PMID: 34006099]
CCRF-CEM	GI₅₀	0.7 μM Compound: SAHA	Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
CCRF-CEM	GI₅₀	0.8 μM Compound: SAHA, Zolinza	Growth inhibition of human CCRF-CEM cells after 72 hrs by MTS assay Growth inhibition of human CCRF-CEM cells after 72 hrs by MTS assay	[PMID: 22435669]
CCRF-CEM	IC₅₀	0.33 μM Compound: SAHA	Inhibition of HDAC in human leukemic CEM cells Inhibition of HDAC in human leukemic CEM cells	[PMID: 16420064]
CCRF-CEM	IC₅₀	0.33 μM Compound: SAHA	Inhibition of HDAC in human CEM cells Inhibition of HDAC in human CEM cells	[PMID: 18247554]
CCRF-CEM	IC₅₀	0.8 μM Compound: 2	Cytotoxicity against human CCRF-CEM cells Cytotoxicity against human CCRF-CEM cells	[PMID: 17691763]
CCRF-CEM	IC₅₀	0.8 μM Compound: 6, SAHA	Cytotoxicity against human CCRF-CEM cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
CCRF-CEM	IC₅₀	0.95 μM Compound: 2	Cytotoxicity against vincristine resistant human CCRF-CEM cells Cytotoxicity against vincristine resistant human CCRF-CEM cells	[PMID: 17691763]
CCRF-CEM	IC₅₀	1.9 μM Compound: SAHA	Inhibition of human leukemic CEM cell viability Inhibition of human leukemic CEM cell viability	[PMID: 16420064]
CCRF-CEM	IC₅₀	1.9 μM Compound: SAHA	Inhibition of human CEM cells assessed as viability Inhibition of human CEM cells assessed as viability	[PMID: 18247554]
CESS	IC₅₀	1.78 μM Compound: SAHA; 6	Antiproliferative activity against human CESS cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human CESS cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
CHP-134	IC₅₀	1.74 μM Compound: Vorinostat	Antiproliferative activity against human CHP134 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay Antiproliferative activity against human CHP134 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay	[PMID: 31391882]
CMK	IC₅₀	439.3 nM Compound: SAHA	Antiproliferative activity against human CMK cells after 72 hrs by MTT assay Antiproliferative activity against human CMK cells after 72 hrs by MTT assay	[PMID: 27505848]
CMK	IC₅₀	490.2 nM Compound: SAHA	Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs by MTT assay Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs by MTT assay	[PMID: 27505848]
CNE-2	IC₅₀	1.3 μM Compound: SAHA	Antiproliferative activity against human CNE-2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human CNE-2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
COLO 205	GI₅₀	0.79 μM Compound: SAHA, Zolinza	Growth inhibition of human COLO205 cells after 72 hrs by MTS assay Growth inhibition of human COLO205 cells after 72 hrs by MTS assay	[PMID: 22435669]
COLO 205	GI₅₀	4 μM Compound: SAHA, Zolinza	Growth inhibition of human COLO205 cells after 72 hrs by MTS assay Growth inhibition of human COLO205 cells after 72 hrs by MTS assay	[PMID: 22435669]
COLO 205	IC₅₀	1.8 μM Compound: SAHA	Cytotoxicity against human COLO205 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
COLO 205	IC₅₀	2.12 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter 96 assay Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter 96 assay	[PMID: 21634430]
COLO 205	IC₅₀	2.2 μM Compound: SAHA	Inhibition of HDAC1 in human COLO205 cells assessed as induction of histone H3 acetylation Inhibition of HDAC1 in human COLO205 cells assessed as induction of histone H3 acetylation	[PMID: 20451378]
COLO 205	IC₅₀	2.9 μM Compound: SAHA	Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter assay Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter assay	[PMID: 19181524]
COR-L23	GI₅₀	1100 nM Compound: SAHA, vorinostat	Antiproliferative activity against human COR-L23 cells after 72 hrs by WST-1 assay Antiproliferative activity against human COR-L23 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
COR-L23	GI₅₀	3300 nM Compound: SAHA, vorinostat	Antiproliferative activity against doxorubicin-resistant human COR-L23 cells after 72 hrs by WST-1 assay Antiproliferative activity against doxorubicin-resistant human COR-L23 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
CT26	GI₅₀	2.35 μM Compound: 3; SAHA	Antiproliferative activity against mouse CT26 cells after 72 hrs by CCK-8 assay Antiproliferative activity against mouse CT26 cells after 72 hrs by CCK-8 assay	[PMID: 35390714]
CT26	GI₅₀	2.7 μM Compound: 7; SAHA	Antiproliferative activity against mouse CT26 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against mouse CT26 cells measured after 72 hrs by CCK8 assay	[PMID: 34783558]
CT26	IC₅₀	5.65 μM Compound: I-1; SAHA	Antiproliferative activity against mouse CT26 cells after 72 hrs by MTT assay Antiproliferative activity against mouse CT26 cells after 72 hrs by MTT assay	[PMID: 35245830]
CT26	IC₅₀	5.97 μM Compound: 4; SAHA	Antiproliferative activity against mouse CT26 cells after 48 hrs by CCK-8 assay Antiproliferative activity against mouse CT26 cells after 48 hrs by CCK-8 assay	[PMID: 29670692]
Caco-2	IC₅₀	0.037 μM Compound: SAHA	Induction of HDAC-mediated histone acetylation in human Caco-2 cells at 5 uM after 6 hrs by indirect ELISA Induction of HDAC-mediated histone acetylation in human Caco-2 cells at 5 uM after 6 hrs by indirect ELISA	[PMID: 20143840]
Caco-2	IC₅₀	0.119 μM Compound: SAHA	Ex vivo inhibition of human HDAC1 in human Caco-2 cells by fluorometric cellular activity assay Ex vivo inhibition of human HDAC1 in human Caco-2 cells by fluorometric cellular activity assay	[PMID: 20143840]
Caco-2	IC₅₀	0.147 μM Compound: SAHA	Ex vivo inhibition of human HDAC3 in human Caco-2 cells by fluorometric cellular activity assay Ex vivo inhibition of human HDAC3 in human Caco-2 cells by fluorometric cellular activity assay	[PMID: 20143840]
Caco-2	IC₅₀	12.6 μM Compound: SAHA	Ex vivo inhibition of human HDAC5 in human Caco-2 cells by fluorometric cellular activity assay Ex vivo inhibition of human HDAC5 in human Caco-2 cells by fluorometric cellular activity assay	[PMID: 20143840]
Caco-2	IC₅₀	3 μM Compound: SAHA	Cytotoxicity against human Caco2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
Caco-2	IC₅₀	41 μM Compound: SAHA	Ex vivo inhibition of human HDAC7 in human Caco-2 cells by fluorometric cellular activity assay Ex vivo inhibition of human HDAC7 in human Caco-2 cells by fluorometric cellular activity assay	[PMID: 20143840]
Caco-2	IC₅₀	8.1 μM Compound: SAHA	Growth inhibition of human Caco-2 cells after 48 hrs by MTT assay Growth inhibition of human Caco-2 cells after 48 hrs by MTT assay	[PMID: 20143840]
Calu-3	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human Calu-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human Calu-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
Capan-2	IC₅₀	3 μM Compound: 5; SAHA	Antiproliferative activity against human Capan2 cells after 96 hrs by MTT assay Antiproliferative activity against human Capan2 cells after 96 hrs by MTT assay	[PMID: 31117517]
DG-75	IC₅₀	2.1 μM Compound: SAHA	Antiproliferative activity against human DG75 cells after 72 hrs by MTT assay Antiproliferative activity against human DG75 cells after 72 hrs by MTT assay	[PMID: 29150335]
DLD-1	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human DLD-1 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human DLD-1 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
DLD-1	IC₅₀	> 10 μM Compound: SAHA	Antiproliferative activity against human DLD1 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay Antiproliferative activity against human DLD1 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay	[PMID: 32153186]
DMS-114	GI₅₀	2.9 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human DMS114 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human DMS114 cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
DOHH-2	IC₅₀	0.58 μM Compound: SAHA	Antiproliferative activity against human DOHH-2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human DOHH-2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
DOHH-2	IC₅₀	366 nM Compound: 1; SAHA	Antiproliferative activity against human DOHH-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human DOHH-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
DU-145	EC₅₀	1.6 μM Compound: SAHA	Inhibition of human DU145 cells Inhibition of human DU145 cells	[PMID: 18247554]
DU-145	EC₅₀	1.6 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human DU-145 cells Effective Concentration of compound to inhibit the growth of human DU-145 cells	[PMID: 15715470]
DU-145	EC₅₀	2.11 μM Compound: SAHA	Viability of human DU145 cells after 72 hrs by MTS assay Viability of human DU145 cells after 72 hrs by MTS assay	[PMID: 18397827]
DU-145	EC₅₀	2.12 μM Compound: SAHA	Viability of human DU145 cells after 72 hrs by trypan blue staining Viability of human DU145 cells after 72 hrs by trypan blue staining	[PMID: 18397827]
DU-145	EC₅₀	2.12 μM Compound: SAHA	Cytotoxicity against human DU145 cells after 72 hrs by trypan blue exclusion assay Cytotoxicity against human DU145 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19093884]
DU-145	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human DU145 cells after 72 hrs by MTS assay Growth inhibition of human DU145 cells after 72 hrs by MTS assay	[PMID: 22435669]
DU-145	GI₅₀	1.36 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay Cytotoxicity against human DU145 cells after 48 hrs by SRB assay	[PMID: 24015327]
DU-145	GI₅₀	1050 nM Compound: SAHA, vorinostat	Antiproliferative activity against human DU145 cells after 72 hrs by WST-1 assay Antiproliferative activity against human DU145 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
DU-145	GI₅₀	1590 nM Compound: SAHA	Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay	[PMID: 26331334]
DU-145	GI₅₀	6.86 μM Compound: SAHA, Vorinostat	Growth inhibition of human DU145 cells by MTT assay Growth inhibition of human DU145 cells by MTT assay	[PMID: 23601706]
DU-145	IC₅₀	0.47 μM Compound: SAHA	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability	[PMID: 35643262]
DU-145	IC₅₀	0.64 μM Compound: 1; SAHA	Antiproliferative activity against human DU-145 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human DU-145 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
DU-145	IC₅₀	0.68 μM Compound: Vorinostat	Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay	[PMID: 37875056]
DU-145	IC₅₀	0.79 μM Compound: 1; SAHA	Antiproliferative activity against human DU-145 cells incubated for 48 hrs by Sulforhodamine B staining method Antiproliferative activity against human DU-145 cells incubated for 48 hrs by Sulforhodamine B staining method	[PMID: 33077264]
DU-145	IC₅₀	0.87 μM Compound: SAHA	Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay	[PMID: 29150335]
DU-145	IC₅₀	1.2 μM Compound: SAHA	Antiproliferative activity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 25993269]
DU-145	IC₅₀	1.2 μM Compound: SAHA	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33965842]
DU-145	IC₅₀	1.8 μM Compound: 5; SAHA	Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay	[PMID: 31117517]
DU-145	IC₅₀	2.12 μM Compound: SAHA	Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay	[PMID: 22260166]
DU-145	IC₅₀	2.12 μM Compound: SAHA, Vorinostat	Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	[PMID: 23622981]
DU-145	IC₅₀	2.49 μM Compound: SAHA	Cytotoxicity against androgen-independent human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against androgen-independent human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 24304348]
DU-145	IC₅₀	2.49 μM Compound: SAHA	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 25240614]
DU-145	IC₅₀	2.58 μM Compound: Vorinostat	Cytotoxicity against human DU145 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay Cytotoxicity against human DU145 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay	[PMID: 23829483]
DU-145	IC₅₀	24.19 μM Compound: SAHA	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 3 to 5 days by CCK-8 assay Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 3 to 5 days by CCK-8 assay	[PMID: 38367494]
DU-145	IC₅₀	27.2 μM Compound: SAHA, vorinostat	Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707260]
DU-145	IC₅₀	3.45 μM Compound: SAHA	Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
DU-145	IC₅₀	3.7 μM Compound: SAHA, vorinostat	Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
Daudi	IC₅₀	0.493 μM Compound: Vorinostat	Cytotoxicity against human Daudi cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human Daudi cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 37875056]
EA.hy 926	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human EA.hy 926 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human EA.hy 926 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
EB-3	GI₅₀	2.8 μM Compound: 1, SAHA	Cytotoxic activity against human EB3 cells after 3 days by MTT assay Cytotoxic activity against human EB3 cells after 3 days by MTT assay	[PMID: 25380299]
EB-3	GI₅₀	2.8 μM Compound: SAHA, Zolinza	Antiproliferative activity against human EB3 cells assessed as growth inhibition incubated for 3 days by MTT assay Antiproliferative activity against human EB3 cells assessed as growth inhibition incubated for 3 days by MTT assay	10.1039/C4MD00252K
EBC-1	IC₅₀	1.3 μM Compound: SAHA	Antiproliferative activity against human EBC1 cells after 72 hrs by SRB assay Antiproliferative activity against human EBC1 cells after 72 hrs by SRB assay	[PMID: 28835797]
EJ	IC₅₀	5.46 μM Compound: Vorinostat	Cytotoxicity against human EJ cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human EJ cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
EKVX	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human EKVX cells after 72 hrs by MTS assay Growth inhibition of human EKVX cells after 72 hrs by MTS assay	[PMID: 22435669]
EL4	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against mouse EL4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse EL4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
EL4	IC₅₀	1.9 μM Compound: SAHA	Antiproliferative activity against mouse EL4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse EL4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
EOL1	IC₅₀	1 μM Compound: 2	Cytotoxicity against human EOL1cells Cytotoxicity against human EOL1cells	[PMID: 17691763]
EOL1	IC₅₀	1 μM Compound: 6, SAHA	Cytotoxicity against human EOL-1 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human EOL-1 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
ES-2	IC₅₀	0.53 μM Compound: SAHA	Antiproliferative activity against human ES2 cells assessed as reduction in cell viability measured after 7 days Antiproliferative activity against human ES2 cells assessed as reduction in cell viability measured after 7 days	[PMID: 35643262]
ES-2	IC₅₀	414 nM Compound: 1; SAHA	Antiproliferative activity against human ES2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human ES2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
Epithelial cell	IC₅₀	1.3 μM Compound: SAHA	Cytotoxicity against nontransformed human microvascular epithelial cells Cytotoxicity against nontransformed human microvascular epithelial cells	[PMID: 18494463]
Epithelial cell	IC₅₀	14000 nM Compound: 1, vorinostat	Antiproliferative activity against human renal epithelial cells by CellTiter-Blue cell viability assay Antiproliferative activity against human renal epithelial cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
Erythrocyte	IC₅₀	> 2.2 μM Compound: SAHA, Vorinostat	Cytotoxicity against erythrocytes (unknown origin) Cytotoxicity against erythrocytes (unknown origin)	[PMID: 24904967]
Erythroleukemia cell line	IC₅₀	2 μM Compound: SAHA	Anticancer activity against mouse Erythroleukemia cell line assessed as inhibition of cell growth Anticancer activity against mouse Erythroleukemia cell line assessed as inhibition of cell growth	[PMID: 34591474]
FHC	IC₅₀	2.59 μM Compound: Vorinostat	Cytotoxicity against human FHC cells assessed as reduction of cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human FHC cells assessed as reduction of cell viability incubated for 72 hrs by MTT assay	[PMID: 33493830]
FaDu	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human FaDu cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human FaDu cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
FaDu	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human FaDu cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human FaDu cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
FaDu	IC₅₀	5.42 μM Compound: XII; SAHA	Antiproliferative activity against human FaDu cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human FaDu cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
Fibroblast	EC₅₀	> 10 μM Compound: SAHA	Cytotoxicity against human primary lung fibroblasts after 72 hrs by trypan blue exclusion assay Cytotoxicity against human primary lung fibroblasts after 72 hrs by trypan blue exclusion assay	[PMID: 19093884]
Fibroblast	IC₅₀	> 300 μM Compound: SBHA	Toxicity in neonatal foreskin fibroblasts Toxicity in neonatal foreskin fibroblasts	[PMID: 18212103]
Friend leukemia cell line	IC₅₀	0.11 μM Compound: SAHA	Antiproliferative activity against mouse Friend leukemia cell line assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse Friend leukemia cell line assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
Friend leukemia cell line	IC₅₀	0.99 μM Compound: 1 (SAHA)	Inhibitory concentration against friend cells proliferation Inhibitory concentration against friend cells proliferation	[PMID: 14613312]
Friend leukemia cell line	IC₅₀	0.99 μM Compound: 6a	Tested in vivo for the inhibition of proliferation of friend leukemic cells Tested in vivo for the inhibition of proliferation of friend leukemic cells	[PMID: 12109913]
G-401	CC₅₀	1000 nM Compound: 1	Antiproliferative activity against human G401 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human G401 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
G-401	IC₅₀	1000 nM Compound: 1, vorinostat	Antiproliferative activity against human G401 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human G401 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
G55T2	IC₅₀	0.78 μM Compound: Vorinostat	Antiproliferative activity against human G55T2 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay Antiproliferative activity against human G55T2 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	[PMID: 31391882]
GES1	IC₅₀	0.61 μM Compound: SAHA	Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of fedratinib by MTT assay Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of fedratinib by MTT assay	[PMID: 37796543]
GES1	IC₅₀	233 μM Compound: SAHA	Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
GES1	IC₅₀	4690 nM Compound: SAHA	Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
GES1	IC₅₀	48.3 μM Compound: SAHA	Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37796543]
GES1	IC₅₀	9.18 μM Compound: SAHA	Cytotoxicity against human GES1 cells harboring low LSD1 expression assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay Cytotoxicity against human GES1 cells harboring low LSD1 expression assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay	[PMID: 37086699]
HAL-01	IC₅₀	0.299 μM Compound: Vorinostat	Cytotoxicity against human HAL-01 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human HAL-01 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 36351184]
HAL-01	IC₅₀	0.3 μM Compound: Vorinostat	Cytotoxicity against human HAL-01 cells measured for 72 hrs by celltiter-glo assay Cytotoxicity against human HAL-01 cells measured for 72 hrs by celltiter-glo assay	[PMID: 38714044]
HCC 2998	GI₅₀	1.9 μM Compound: SAHA	Antiproliferative activity against human HCC2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human HCC2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
HCC1937	IC₅₀	3.73 μM Compound: SAHA	Antiproliferative activity against human HCC1937 cells assessed as reduction in cell viability Antiproliferative activity against human HCC1937 cells assessed as reduction in cell viability	[PMID: 35643262]
HCC1937	IC₅₀	4.23 μM Compound: SAHA	Antiproliferative activity against human HCC1937 cells after 3 days by MTT assay Antiproliferative activity against human HCC1937 cells after 3 days by MTT assay	[PMID: 28601509]
HCC827	IC₅₀	1.18 μM Compound: SAHA	Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay	[PMID: 28601509]
HCC827	IC₅₀	1.8 μM Compound: SAHA	Antiproliferative activity against human HCC827 cells after hrs by ATP content assay Antiproliferative activity against human HCC827 cells after hrs by ATP content assay	[PMID: 20143778]
HCCLM3	IC₅₀	6.52 μM Compound: 1; SAHA	Antiproliferative activity against human HCCLM3 cells after 48 hrs by MTT assay Antiproliferative activity against human HCCLM3 cells after 48 hrs by MTT assay	[PMID: 30455152]
HCT-116	CC₅₀	1000 nM Compound: 1	Antiproliferative activity against human P53 expressing HCT116 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human P53 expressing HCT116 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
HCT-116	EC₅₀	0.57 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 23820574]
HCT-116	EC₅₀	0.58 μM Compound: SAHA	Inhibition of human HCT116 cells Inhibition of human HCT116 cells	[PMID: 18247554]
HCT-116	EC₅₀	0.58 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human HCT116 cells Effective Concentration of compound to inhibit the growth of human HCT116 cells	[PMID: 15715470]
HCT-116	EC₅₀	1.6 μM Compound: 1, SAHA	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 18954984]
HCT-116	EC₅₀	2 μM Compound: SAHA	Cytotoxicity against human HCT116 cells after 71 hrs by MTS assay Cytotoxicity against human HCT116 cells after 71 hrs by MTS assay	[PMID: 20392638]
HCT-116	EC₅₀	3 μM Compound: Vorinostat	Antiproliferative activity against human HCT116 cells measured after 72 hrs by WST1 assay Antiproliferative activity against human HCT116 cells measured after 72 hrs by WST1 assay	[PMID: 27597246]
HCT-116	GI₅₀	0.15 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 27344487]
HCT-116	GI₅₀	0.15 μM Compound: SAHA; 1	Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 29567459]
HCT-116	GI₅₀	0.37 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 24015327]
HCT-116	GI₅₀	0.4 μM Compound: 2, SAHA, Vorinostat	Cytotoxicity against human HCT116 cells after 96 hrs by MTS-PMS assay Cytotoxicity against human HCT116 cells after 96 hrs by MTS-PMS assay	[PMID: 24164245]
HCT-116	GI₅₀	0.4 μM Compound: SAHA, Zolinza	Growth inhibition of human HCT116 cells after 72 hrs by MTS assay Growth inhibition of human HCT116 cells after 72 hrs by MTS assay	[PMID: 22435669]
HCT-116	GI₅₀	0.44 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay	[PMID: 31924504]
HCT-116	GI₅₀	0.55 μM Compound: 1; SAHA	Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31655430]
HCT-116	GI₅₀	0.58 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
HCT-116	GI₅₀	0.6 μM Compound: SAHA	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 20605448]
HCT-116	GI₅₀	0.6 μM Compound: SAHA	Growth inhibition of human HCT116 cells after 5 days by alamar blue assay Growth inhibition of human HCT116 cells after 5 days by alamar blue assay	[PMID: 21978679]
HCT-116	GI₅₀	0.65 μM Compound: Vorinostat	Growth inhibition of human HCT116 cells after 72 hrs by CellTiter Glo assay Growth inhibition of human HCT116 cells after 72 hrs by CellTiter Glo assay	[PMID: 25182565]
HCT-116	GI₅₀	0.878 μM Compound: SAHA	Cytotoxicity against human HCT116 cells after 48 hrs by Sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by Sulforhodamine B assay	[PMID: 23639537]
HCT-116	GI₅₀	0.94 μM Compound: 1, SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 24119555]
HCT-116	GI₅₀	1 μM Compound: SAHA	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 23538115]
HCT-116	GI₅₀	1.04 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 25800646]
HCT-116	GI₅₀	2.03 μM Compound: 1, SAHA	Growth inhibition of human HCT116 cells after 96 hrs by MTT assay Growth inhibition of human HCT116 cells after 96 hrs by MTT assay	[PMID: 26814680]
HCT-116	GI₅₀	2.5 μM Compound: Vorin	Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 24900743]
HCT-116	GI₅₀	2.69 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 19822426]
HCT-116	GI₅₀	4.64 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
HCT-116	GI₅₀	740 nM Compound: SAHA, vorinostat	Antiproliferative activity against human HCT116 cells after 72 hrs by WST-1 assay Antiproliferative activity against human HCT116 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
HCT-116	GI₅₀	750 nM Compound: SAHA	Growth inhibition of human HCT116 cells after 72 hrs by SRB assay Growth inhibition of human HCT116 cells after 72 hrs by SRB assay	[PMID: 20884208]
HCT-116	GI₅₀	> 410 nM Compound: Vorinostat	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
HCT-116	IC₅₀	0.08 mM Compound: Vorinostat	Antiproliferative activity against human HCT116 cells after 2 days by MTT assay Antiproliferative activity against human HCT116 cells after 2 days by MTT assay	[PMID: 19608304]
HCT-116	IC₅₀	0.15 μM Compound: Vorinostat	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 37875056]
HCT-116	IC₅₀	0.27 μM Compound: 1	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
HCT-116	IC₅₀	0.3 μM Compound: 1; SAHA	Antiproliferative activity against human HCT-116 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
HCT-116	IC₅₀	0.31 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs Antiproliferative activity against human HCT116 cells after 72 hrs	[PMID: 19084294]
HCT-116	IC₅₀	0.31 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs	[PMID: 24742384]
HCT-116	IC₅₀	0.31 μM Compound: SAHA	Antiproliferative activity human HCT116 cells assessed as reduction in cell number after 72 hrs by cell counter analysis Antiproliferative activity human HCT116 cells assessed as reduction in cell number after 72 hrs by cell counter analysis	[PMID: 26890116]
HCT-116	IC₅₀	0.33 μM Compound: SAHA, Zolinza	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 26100440]
HCT-116	IC₅₀	0.34 μM Compound: SAHA, Zolinza	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 21733698]
HCT-116	IC₅₀	0.49 μM Compound: 3; SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36449947]
HCT-116	IC₅₀	0.55 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32738414]
HCT-116	IC₅₀	0.6 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 5 days by Alamar blue assay Antiproliferative activity against human HCT116 cells after 5 days by Alamar blue assay	[PMID: 21420859]
HCT-116	IC₅₀	0.6 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 5 days by Alamar Blue assay Antiproliferative activity against human HCT116 cells after 5 days by Alamar Blue assay	[PMID: 22877635]
HCT-116	IC₅₀	0.6 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 5 days by Alamar Blue assay Antiproliferative activity against human HCT116 cells after 5 days by Alamar Blue assay	[PMID: 25746815]
HCT-116	IC₅₀	0.61 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 24766560]
HCT-116	IC₅₀	0.67 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
HCT-116	IC₅₀	0.68 μM Compound: Vorinostat	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 37875056]
HCT-116	IC₅₀	0.69 μM Compound: 1; SAHA	Antiproliferative activity against human HCT-116 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human HCT-116 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
HCT-116	IC₅₀	0.7 μM Compound: SAHA	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 21745740]
HCT-116	IC₅₀	0.7 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
HCT-116	IC₅₀	0.72 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
HCT-116	IC₅₀	0.757 μM Compound: SAHA	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 23644210]
HCT-116	IC₅₀	0.757 μM Compound: vorinostat	Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay	[PMID: 26629860]
HCT-116	IC₅₀	0.76 μM Compound: SAHA	Cytotoxicity against human HCT116 cells after 72 hrs by CellTiter-Glo assay Cytotoxicity against human HCT116 cells after 72 hrs by CellTiter-Glo assay	[PMID: 30245394]
HCT-116	IC₅₀	0.76 μM Compound: SAHA, Vorinostat	Antiproliferative activity against human HCT116 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human HCT116 cells after 72 hrs by CellTiter-Glo assay	[PMID: 23792316]
HCT-116	IC₅₀	0.79 mM Compound: vorinostat, SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 20171895]
HCT-116	IC₅₀	0.797 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 35272009]
HCT-116	IC₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24095018]
HCT-116	IC₅₀	0.81 μM Compound: 1, SAHA, Zolinza	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 21742496]
HCT-116	IC₅₀	0.877 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29100734]
HCT-116	IC₅₀	0.89 μM Compound: 4; SAHA	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability	[PMID: 34314844]
HCT-116	IC₅₀	0.9 μM Compound: SAHA	Inhibition of human HCT116 cells Inhibition of human HCT116 cells	[PMID: 18247554]
HCT-116	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
HCT-116	IC₅₀	0.9 μM Compound: Vorinostat	Antiproliferative activity against human wild type HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human wild type HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
HCT-116	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29100734]
HCT-116	IC₅₀	1 μM Compound: Vorinostat	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay	[PMID: 30660827]
HCT-116	IC₅₀	1.03 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
HCT-116	IC₅₀	1.03 μM Compound: Vorinostat	Antiproliferative activity against human HCT-116 cells Antiproliferative activity against human HCT-116 cells	[PMID: 37875056]
HCT-116	IC₅₀	1.08 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
HCT-116	IC₅₀	1.18 μM Compound: 1; SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
HCT-116	IC₅₀	1.18 μM Compound: SAHA	Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay	[PMID: 36244186]
HCT-116	IC₅₀	1.2 μM Compound: 2, SAHA	Growth inhibition of human HCT116 cells after 48 hrs by SRB assay Growth inhibition of human HCT116 cells after 48 hrs by SRB assay	[PMID: 21073160]
HCT-116	IC₅₀	1.2 μM Compound: SAHA	Cytotoxicity against human HCT116 cells after 24 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 24 hrs by sulforhodamine B assay	[PMID: 19359173]
HCT-116	IC₅₀	1.2 μM Compound: SAHA	Growth inhibition of human HCT116 cells after 72 hrs Growth inhibition of human HCT116 cells after 72 hrs	[PMID: 26376355]
HCT-116	IC₅₀	1.2 μM Compound: SAHA, vorinostat	Growth inhibition of human HCT116 cells by SRB assay Growth inhibition of human HCT116 cells by SRB assay	[PMID: 17892933]
HCT-116	IC₅₀	1.26 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
HCT-116	IC₅₀	1.27 μM Compound: 1; SAHA	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
HCT-116	IC₅₀	1.28 μM Compound: SAHA, Zolinza	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
HCT-116	IC₅₀	1.31 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by CellTiter 96 AQueous Non-Radioactive assay Antiproliferative activity against human HCT116 cells after 72 hrs by CellTiter 96 AQueous Non-Radioactive assay	[PMID: 28213282]
HCT-116	IC₅₀	1.31 μM Compound: SAHA	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	[PMID: 35984756]
HCT-116	IC₅₀	1.39 μM Compound: Vorinostat	Cytotoxicity against human HCT116 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay Cytotoxicity against human HCT116 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay	[PMID: 23829483]
HCT-116	IC₅₀	1.4 μM Compound: SAHA	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
HCT-116	IC₅₀	1.4 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 28835797]
HCT-116	IC₅₀	1.41 μM Compound: Vorinostat	Antiproliferative activity against human HCT-116 cells by MTT assay Antiproliferative activity against human HCT-116 cells by MTT assay	[PMID: 37875056]
HCT-116	IC₅₀	1.43 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 20451378]
HCT-116	IC₅₀	1.47 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells measured after 72 hrs Antiproliferative activity against human HCT-116 cells measured after 72 hrs	[PMID: 35697181]
HCT-116	IC₅₀	1.489 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells incubated for 48 hrs by MTT assay	[PMID: 37563016]
HCT-116	IC₅₀	1.55 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
HCT-116	IC₅₀	1.8 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells after 48 hrs by CCK-8 assay	[PMID: 35939996]
HCT-116	IC₅₀	1.8 μM Compound: SAHA, 3	Cytotoxicity against human HCT116 cells assessed as cell viability after 96 hrs by MTS reduction assay Cytotoxicity against human HCT116 cells assessed as cell viability after 96 hrs by MTS reduction assay	[PMID: 18348516]
HCT-116	IC₅₀	1.81 μM Compound: SAHA	Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 26211462]
HCT-116	IC₅₀	1.81 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 31413795]
HCT-116	IC₅₀	1.85 μM Compound: 1; SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 27541357]
HCT-116	IC₅₀	1.85 μM Compound: 2	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28953386]
HCT-116	IC₅₀	1.85 μM Compound: 4	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 29945795]
HCT-116	IC₅₀	1.85 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 33957387]
HCT-116	IC₅₀	1.9 μM Compound: 4	Concentration required to inhibit the HCT116 cell growth by 50%. Concentration required to inhibit the HCT116 cell growth by 50%.	[PMID: 11831887]
HCT-116	IC₅₀	1.9 μM Compound: 5; SAHA	Antiproliferative activity against human HCT116 cells after 96 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 96 hrs by MTT assay	[PMID: 31117517]
HCT-116	IC₅₀	1.93 μM Compound: 3, SAHA	Antiproliferative activity against HCT116 cells Antiproliferative activity against HCT116 cells	[PMID: 16904890]
HCT-116	IC₅₀	1000 nM Compound: 1, SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by celltiter-blue viability assay Antiproliferative activity against human HCT116 cells after 72 hrs by celltiter-blue viability assay	[PMID: 18809328]
HCT-116	IC₅₀	1000 nM Compound: 1, SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human HCT116 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19410459]
HCT-116	IC₅₀	1000 nM Compound: 1, vorinostat	Antiproliferative activity against human HCT116 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human HCT116 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
HCT-116	IC₅₀	11.8 nM Compound: 1; SAHA	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs in presence of SN-38 by SRB assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs in presence of SN-38 by SRB assay	[PMID: 32679451]
HCT-116	IC₅₀	1450 nM Compound: SAHA	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 27186676]
HCT-116	IC₅₀	1488.6 nM Compound: 1; SAHA	Antiproliferative activity against human HCT116 cells measured after 48 hrs by sulforhodamine-B assay Antiproliferative activity against human HCT116 cells measured after 48 hrs by sulforhodamine-B assay	[PMID: 27886544]
HCT-116	IC₅₀	1617.76 nM Compound: SAHA	Cytotoxicity against human HCT-116 cells after 72 hrs by SRB assay Cytotoxicity against human HCT-116 cells after 72 hrs by SRB assay	[PMID: 30819618]
HCT-116	IC₅₀	1930 nM Compound: SAHA (1)	Inhibitory activity against HCT116 human colon cell growth Inhibitory activity against HCT116 human colon cell growth	[PMID: 14521422]
HCT-116	IC₅₀	2 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
HCT-116	IC₅₀	2.2 μM Compound: 4	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30243158]
HCT-116	IC₅₀	2.35 μM Compound: SAHA	Anti-proliferative activity against human HCT116 cells after 48 hrs by MTT assay Anti-proliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 28947154]
HCT-116	IC₅₀	2.41 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 35043615]
HCT-116	IC₅₀	2.43 μM Compound: Vorinostat	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
HCT-116	IC₅₀	2.5 μM Compound: Vorinostat	Antiproliferative activity against human HCT-116 cells measured after 24 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 24 hrs by MTT assay	[PMID: 37875056]
HCT-116	IC₅₀	2.52 μM Compound: SAHA	Inhibition of HCT116 cell proliferation (mean of two experiments) Inhibition of HCT116 cell proliferation (mean of two experiments)	[PMID: 17095213]
HCT-116	IC₅₀	2.52 μM Compound: SAHA	Inhibition of HCT116 cell proliferation (mean of two experiments) Inhibition of HCT116 cell proliferation (mean of two experiments)	[PMID: 17107790]
HCT-116	IC₅₀	2.59 μM Compound: SAHA	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34043359]
HCT-116	IC₅₀	2.7 μM Compound: 1; SAHA	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
HCT-116	IC₅₀	2.8 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 24296013]
HCT-116	IC₅₀	2.81 μM Compound: SA, SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 24694055]
HCT-116	IC₅₀	2.81 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 25462271]
HCT-116	IC₅₀	2.85 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human HCT116 cells after 96 hrs by celltiter 96 assay Antiproliferative activity against human HCT116 cells after 96 hrs by celltiter 96 assay	[PMID: 21634430]
HCT-116	IC₅₀	3.05 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay	[PMID: 37086699]
HCT-116	IC₅₀	3.07 μM Compound: 4; SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 48 hrs by CCK-8 assay	[PMID: 29670692]
HCT-116	IC₅₀	3.1 μM Compound: 1; SAHA	Cytotoxicity in human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity in human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28885834]
HCT-116	IC₅₀	3.13 μM Compound: Vorinostat	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay	[PMID: 37875056]
HCT-116	IC₅₀	3.45 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by WST8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by WST8 assay	[PMID: 25261927]
HCT-116	IC₅₀	3.59 μM Compound: 1; SAHA	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	[PMID: 34656899]
HCT-116	IC₅₀	3.7 μM Compound: SAHA	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25815139]
HCT-116	IC₅₀	3.7 μM Compound: SAHA	Phototoxicity in human HCT-116 cells assessed as reduction in cell viability irradiated 10 j/cm2 for 24 hrs followed by incubated for 24 hrs by CCK8 assay Phototoxicity in human HCT-116 cells assessed as reduction in cell viability irradiated 10 j/cm2 for 24 hrs followed by incubated for 24 hrs by CCK8 assay	[PMID: 33744687]
HCT-116	IC₅₀	3.75 μM Compound: SAHA	Dark toxicity in human HCT-116 cells assessed as reduction in cell viability incubated under dark for 48 hrs measured after 48 hrs by CCK8 assay Dark toxicity in human HCT-116 cells assessed as reduction in cell viability incubated under dark for 48 hrs measured after 48 hrs by CCK8 assay	[PMID: 33744687]
HCT-116	IC₅₀	32.46 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by MTT assay	10.1039/C5MD00247H
HCT-116	IC₅₀	4.2 μM Compound: 1; SAHA	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33668008]
HCT-116	IC₅₀	4.2 μM Compound: Vorinostat	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay	[PMID: 37989057]
HCT-116	IC₅₀	4.23 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
HCT-116	IC₅₀	4.25 μM Compound: 1, SAHA	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26122774]
HCT-116	IC₅₀	4.25 μM Compound: 6, SAHA	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25906087]
HCT-116	IC₅₀	4.9 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32151834]
HCT-116	IC₅₀	4.95 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells by MTT assay Antiproliferative activity against human HCT116 cells by MTT assay	[PMID: 31546197]
HCT-116	IC₅₀	4.97 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
HCT-116	IC₅₀	5 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 29100734]
HCT-116	IC₅₀	5.06 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	10.1039/C5MD00247H
HCT-116	IC₅₀	5.53 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
HCT-116	IC₅₀	5.53 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29288941]
HCT-116	IC₅₀	5.53 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30108831]
HCT-116	IC₅₀	5.66 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay	[PMID: 37116762]
HCT-116	IC₅₀	561.32 nM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 30115492]
HCT-116	IC₅₀	6 μM Compound: 1, SAHA	Inhibition of human HCT116 cell proliferation after 48 hrs by MTT assay Inhibition of human HCT116 cell proliferation after 48 hrs by MTT assay	[PMID: 23493449]
HCT-116	IC₅₀	6.15 μM Compound: SAHA	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26349626]
HCT-116	IC₅₀	720 nM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 31177073]
HCT-116	IC₅₀	810 nM Compound: 1, SAHA	Antiproliferative activity against human HCT116 cells assessed as growth inhibition Antiproliferative activity against human HCT116 cells assessed as growth inhibition	[PMID: 21650221]
HCT-116	IC₅₀	882.5 nM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30629434]
HCT-116	IC₅₀	895 nM Compound: 1; SAHA	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 32679451]
HCT-116	IC₅₀	9.6 μM Compound: SAHA	Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 29348808]
HCT-116	IC₅₀	< 1 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29954683]
HCT-116	IC₅₀	< 1.18 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	10.1039/C5MD00247H
HCT-116	IC₅₀	> 10 μM Compound: SAHA	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay	[PMID: 32153186]
HCT-116	IC₅₀	> 10 μM Compound: SAHA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
HCT-116	IC₅₀	> 1000 nM Compound: SAHA	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 26443078]
HCT-15	GI₅₀	0.82 μM Compound: 1, SAHA	Growth inhibition of HCT15 cells by SRB assay Growth inhibition of HCT15 cells by SRB assay	[PMID: 17477518]
HCT-15	GI₅₀	0.82 μM Compound: 2, SAHA	Antiproliferative activity against human HCT15 cells by SRB assay Antiproliferative activity against human HCT15 cells by SRB assay	[PMID: 16723227]
HCT-15	GI₅₀	0.95 μM Compound: SAHA	Growth inhibition of human HCT15 cells after 21 hrs by MTT assay Growth inhibition of human HCT15 cells after 21 hrs by MTT assay	[PMID: 17662606]
HCT-15	GI₅₀	2.49 μM Compound: 1, SAHA	Growth inhibition of human HCT15 cells Growth inhibition of human HCT15 cells	[PMID: 20850971]
HCT-15	GI₅₀	2.49 μM Compound: 1, SAHA, Zolinza, Vorinostat	Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay	[PMID: 23163332]
HCT-15	GI₅₀	2.49 μM Compound: 2, SAHA	Growth inhibition of human HCT15 cells by SRB assay Growth inhibition of human HCT15 cells by SRB assay	[PMID: 17904843]
HCT-15	GI₅₀	2.49 μM Compound: SAHA	Growth inhibition of human HCT15 cells after 5 days by sulforhodamine B assay Growth inhibition of human HCT15 cells after 5 days by sulforhodamine B assay	[PMID: 25811792]
HCT-15	GI₅₀	2.49 μM Compound: SAHA	Growth inhibition of human HCT15 cells measured after 5 days by sulforhodamine-B assay Growth inhibition of human HCT15 cells measured after 5 days by sulforhodamine-B assay	[PMID: 28011426]
HCT-15	GI₅₀	2.5 μM Compound: SAHA, Zolinza	Growth inhibition of human HCT15 cells after 72 hrs by MTS assay Growth inhibition of human HCT15 cells after 72 hrs by MTS assay	[PMID: 22435669]
HCT-15	IC₅₀	3.9 μM Compound: 2	Cytotoxicity against human HCT15 cells Cytotoxicity against human HCT15 cells	[PMID: 17691763]
HCT-8	IC₅₀	0.35 μM Compound: 5; SAHA	Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 31117517]
HEC-1-A	IC₅₀	1 μM Compound: 2	Cytotoxicity against human Hec-1-A cells Cytotoxicity against human Hec-1-A cells	[PMID: 17691763]
HEK-293T	EC₅₀	> 1 μM Compound: SAHA	Cytotoxicity against human HEK293T cells assessed as cell growth inhibition Cytotoxicity against human HEK293T cells assessed as cell growth inhibition	[PMID: 33356214]
HEK-293T	IC₅₀	4.5 μM Compound: Vorinostat	Cytotoxicity against HEK293T cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against HEK293T cells incubated for 72 hrs by CCK-8 assay	[PMID: 35175762]
HEK-293T	IC₅₀	8.221 μM Compound: SAHA	Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
HEK293	CC₅₀	100 μM Compound: SAHA, Vorinostat	Cytotoxicity against HEK293 cells assessed as reduction in cell viability Cytotoxicity against HEK293 cells assessed as reduction in cell viability	[PMID: 26264503]
HEK293	CC₅₀	2.3 μM Compound: Vorinostat	Cytotoxicity against HEK293 cells assessed as reduction in cell growth incubated for 48 hrs by MTS assay Cytotoxicity against HEK293 cells assessed as reduction in cell growth incubated for 48 hrs by MTS assay	[PMID: 30973727]
HEK293	GI₅₀	13 μM Compound: 1, SAHA	Growth inhibition of human HEK293 cells after 72 hrs by XTT assay Growth inhibition of human HEK293 cells after 72 hrs by XTT assay	[PMID: 24900500]
HEK293	GI₅₀	3.38 μM Compound: 1, SAHA	Cytotoxicity against HEK293 cells assessed as growth inhibition after 96 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as growth inhibition after 96 hrs by MTT assay	[PMID: 26814680]
HEK293	IC₅₀	0.01 μM Compound: SAHA	Inhibition of recombinant human GST-fused HDAC1 expressed in HEK293 cells Fluor-de-lys as substrate measured after 60 mins by fluorescence assay Inhibition of recombinant human GST-fused HDAC1 expressed in HEK293 cells Fluor-de-lys as substrate measured after 60 mins by fluorescence assay	[PMID: 30245394]
HEK293	IC₅₀	0.013 μM Compound: 2, SAHA	Inhibition of human recombinant HDAC1 expressed in human HEK293 cells using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay Inhibition of human recombinant HDAC1 expressed in human HEK293 cells using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay	10.1039/C2MD00317A
HEK293	IC₅₀	0.016 μM Compound: SAHA	Inhibition of full length human N-terminal FLAG-tagged HDAC6 (1 to 1215 residues) expressed in HEK293 cells preincubated for 15 mins followed by acetyl-Gly-Ala-[acetyl-Lys]-AMC substrate addition measured after 30 mins by fluorimetric method Inhibition of full length human N-terminal FLAG-tagged HDAC6 (1 to 1215 residues) expressed in HEK293 cells preincubated for 15 mins followed by acetyl-Gly-Ala-[acetyl-Lys]-AMC substrate addition measured after 30 mins by fluorimetric method	[PMID: 30613344]
HEK293	IC₅₀	0.019 μM Compound: SAHA	Inhibition of recombinant HDAC6 expressed in HEK293 cells Inhibition of recombinant HDAC6 expressed in HEK293 cells	[PMID: 18558669]
HEK293	IC₅₀	0.02 μM Compound: 6, SAHA	Inhibition of human recombinant HDAC1 expressed in HEK293 cells Inhibition of human recombinant HDAC1 expressed in HEK293 cells	[PMID: 19301902]
HEK293	IC₅₀	0.021 μM Compound: 2a	Inhibition of human recombinant HDAC1 expressed in HEK293 cells Inhibition of human recombinant HDAC1 expressed in HEK293 cells	[PMID: 21080629]
HEK293	IC₅₀	0.025 μM Compound: 2a	Inhibition of human recombinant HDAC6 expressed in HEK293 cells Inhibition of human recombinant HDAC6 expressed in HEK293 cells	[PMID: 21080629]
HEK293	IC₅₀	0.033 μM Compound: SAHA	Inhibition of recombinant HDAC1 expressed in HEK293 cells Inhibition of recombinant HDAC1 expressed in HEK293 cells	[PMID: 18558669]
HEK293	IC₅₀	0.052 μM Compound: 6, SAHA	Inhibition of human recombinant HDAC6 expressed in HEK293 cells Inhibition of human recombinant HDAC6 expressed in HEK293 cells	[PMID: 19301902]
HEK293	IC₅₀	0.122 μM Compound: SAHA	Inhibition of HDAC1 (unknown origin) expressed in HEK293 cells cotransfected with nano-luciferase incubated for 2 hrs followed by NanoBRET NanoGlo Substrate addition by NanoBRET assay Inhibition of HDAC1 (unknown origin) expressed in HEK293 cells cotransfected with nano-luciferase incubated for 2 hrs followed by NanoBRET NanoGlo Substrate addition by NanoBRET assay	[PMID: 31414801]
HEK293	IC₅₀	0.241 μM Compound: SAHA	Inhibition of HDAC6 CD2 (unknown origin) expressed in HEK293 cells cotransfected with nano-luciferase incubated for 2 hrs followed by NanoBRET NanoGlo Substrate addition by NanoBRET assay Inhibition of HDAC6 CD2 (unknown origin) expressed in HEK293 cells cotransfected with nano-luciferase incubated for 2 hrs followed by NanoBRET NanoGlo Substrate addition by NanoBRET assay	[PMID: 31414801]
HEK293	IC₅₀	0.669 μM Compound: SAHA	Inhibition of full length human N-terminal FLAG-tagged HDAC8 (1 to 377 residues) expressed in HEK293 cells preincubated for 15 mins followed by Boc-[trifluoroacetyl-Lys]-AMC substrate addition measured after 30 mins by fluorimetric method Inhibition of full length human N-terminal FLAG-tagged HDAC8 (1 to 377 residues) expressed in HEK293 cells preincubated for 15 mins followed by Boc-[trifluoroacetyl-Lys]-AMC substrate addition measured after 30 mins by fluorimetric method	[PMID: 30613344]
HEK293	IC₅₀	1637 nM Compound: 1; SAHA	Antiproliferative activity against human HEK293 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HEK293 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
HEK293	IC₅₀	2.48 μM Compound: SAHA	Cytotoxicity against HEK293 cells Cytotoxicity against HEK293 cells	[PMID: 34107385]
HEK293	IC₅₀	2.48 μM Compound: SAHA	Cytotoxicity HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs Cytotoxicity HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs	[PMID: 38056296]
HEK293	IC₅₀	30 nM Compound: 1	Inhibition of human C-terminal FLAG-tagged HDAC1 in HEK293 cells Inhibition of human C-terminal FLAG-tagged HDAC1 in HEK293 cells	[PMID: 19441846]
HEK293	IC₅₀	30 nM Compound: vorinostat, zolinza, SAHA	Inhibition of HDAC1 in HEK293 cells Inhibition of HDAC1 in HEK293 cells	[PMID: 18308563]
HEK293	IC₅₀	43 nM Compound: vorinostat, zolinza, SAHA	Inhibition of HDAC6 in HEK293 cells Inhibition of HDAC6 in HEK293 cells	[PMID: 18308563]
HEK293	IC₅₀	5170 nM Compound: SAHA	Cytotoxicity against HEK293 cells after 48 hrs by resazurin dye based assay Cytotoxicity against HEK293 cells after 48 hrs by resazurin dye based assay	[PMID: 30245402]
HEK293	IC₅₀	57 nM Compound: 1	Inhibition of human C-terminal FLAG-tagged HDAC3 in HEK293 cells Inhibition of human C-terminal FLAG-tagged HDAC3 in HEK293 cells	[PMID: 19441846]
HEK293	IC₅₀	57 nM Compound: vorinostat, zolinza, SAHA	Inhibition of HDAC3 in HEK293 cells Inhibition of HDAC3 in HEK293 cells	[PMID: 18308563]
HEK293	IC₅₀	82 nM Compound: 1	Inhibition of human C-terminal FLAG-tagged HDAC2 in HEK293 cells Inhibition of human C-terminal FLAG-tagged HDAC2 in HEK293 cells	[PMID: 19441846]
HEK293	IC₅₀	> 250 μM Compound: SAHA	Cytotoxicity against HEK293 cells incubated for 24 hrs by Neutral Red Uptake assay Cytotoxicity against HEK293 cells incubated for 24 hrs by Neutral Red Uptake assay	[PMID: 39208744]
HEK293	IC₅₀	> 30 μM Compound: SAHA	Inhibition of recombinant human ERG expressed in HEK293 cells at -80 mV holding potential measured for 9 mins by Qpatch clamp method Inhibition of recombinant human ERG expressed in HEK293 cells at -80 mV holding potential measured for 9 mins by Qpatch clamp method	[PMID: 28947154]
HEL	GI₅₀	0.76 μM Compound: SAHA	Antiproliferative activity against human HEL cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human HEL cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay	[PMID: 25800646]
HEL	IC₅₀	0.02 μM Compound: SAHA	Antiproliferative activity against HEL cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against HEL cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35152694]
HEL	IC₅₀	0.15 μM Compound: SAHA	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 29533873]
HEL	IC₅₀	0.18 μM Compound: 1; SAHA	Antiproliferative activity against human HEL cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HEL cells incubated for 48 hrs by CCK8 assay	[PMID: 37037787]
HEL	IC₅₀	0.18 μM Compound: SAHA	Antiproliferative activity against HEL cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against HEL cells incubated for 72 hrs by CCK-8 assay	[PMID: 37057760]
HEL	IC₅₀	0.18 μM Compound: SAHA	Cytotoxicity against HEL cells assessed as reduction in cell growth incubated for 72 hrs by WST assay Cytotoxicity against HEL cells assessed as reduction in cell growth incubated for 72 hrs by WST assay	[PMID: 38964169]
HEL	IC₅₀	0.19 μM Compound: SAHA	Antiproliferative activity against human HEL cells after 72 hrs by MTT assay Antiproliferative activity against human HEL cells after 72 hrs by MTT assay	[PMID: 29787262]
HEL	IC₅₀	0.21 μM Compound: SAHA	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 28336407]
HEL	IC₅₀	0.21 μM Compound: Vorinostat	Antiproliferative activity against human HEL cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HEL cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
HEL	IC₅₀	0.21 μM Compound: Vorinostat	Cytotoxicity against HEL cells assessed as reduction in cell viability incubated for 72 hrs by WST assay Cytotoxicity against HEL cells assessed as reduction in cell viability incubated for 72 hrs by WST assay	[PMID: 38107170]
HEL	IC₅₀	0.25 μM Compound: Vorinostat	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 28371677]
HEL	IC₅₀	0.3 μM Compound: 3; SAHA	Synergistic antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as reduction in cell viability after 48 hrs in presence of ruxolitinib by MTT assay Synergistic antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as reduction in cell viability after 48 hrs in presence of ruxolitinib by MTT assay	[PMID: 30901208]
HEL	IC₅₀	0.4 μM Compound: 1; SAHA	Antiproliferative activity against human HEL cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay Antiproliferative activity against human HEL cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay	[PMID: 36622852]
HEL	IC₅₀	0.49 μM Compound: SA, SAHA	Antiproliferative activity against HEL cells after 48 hrs by MTT assay Antiproliferative activity against HEL cells after 48 hrs by MTT assay	[PMID: 24694055]
HEL	IC₅₀	0.49 μM Compound: SAHA	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 25462271]
HEL	IC₅₀	0.5 μM Compound: 1; SAHA	Antiproliferative activity against human HEL cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HEL cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay	[PMID: 36622852]
HEL	IC₅₀	0.52 μM Compound: SAHA	Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay	[PMID: 35939996]
HEL	IC₅₀	0.65 μM Compound: 1	Antiproliferative activity against HEL cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against HEL cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
HEL	IC₅₀	0.65 μM Compound: 3; SAHA	Antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30901208]
HEL	IC₅₀	0.72 μM Compound: SAHA	Antiproliferative activity against HEL cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against HEL cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
HEL	IC₅₀	0.79 μM Compound: SAHA	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 29500131]
HEL	IC₅₀	0.86 μM Compound: 2; SAHA	Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay	[PMID: 29940115]
HEL	IC₅₀	0.89 μM Compound: SAHA	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 30879863]
HEL	IC₅₀	1.27 μM Compound: SAHA	Cytotoxicity against human HEL cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HEL cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26349626]
HEL	IC₅₀	1.74 μM Compound: SAHA, Zolinza	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 26100440]
HEL	IC₅₀	2.42 μM Compound: 1, SAHA	Cytotoxicity against HEL cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against HEL cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26122774]
HEL	IC₅₀	2.42 μM Compound: 6, SAHA	Cytotoxicity against human HEL cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HEL cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25906087]
HEL 92.1.7	IC₅₀	0.49 μM Compound: 1; SAHA	Antiproliferative activity against HEL 92.1.7 cells harboring JAK2 V617F mutant after 36 hrs by PrestoBlue dye based assay Antiproliferative activity against HEL 92.1.7 cells harboring JAK2 V617F mutant after 36 hrs by PrestoBlue dye based assay	[PMID: 27541357]
HEL 92.1.7	IC₅₀	0.49 μM Compound: 2	Antiproliferative activity against human HEL 92.1.7 cells after 36 hrs by PrestoBlue dye based assay Antiproliferative activity against human HEL 92.1.7 cells after 36 hrs by PrestoBlue dye based assay	[PMID: 28953386]
HEL 92.1.7	IC₅₀	0.49 μM Compound: 4	Antiproliferative activity against human HEL 92.1.7 cells after 72 hrs by MTT assay Antiproliferative activity against human HEL 92.1.7 cells after 72 hrs by MTT assay	[PMID: 30243158]
HET-1A	IC₅₀	960 nM Compound: SAHA	Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
HGC-27	IC₅₀	0.35 μM Compound: 5; SAHA	Antiproliferative activity against human HGC27 cells after 96 hrs by MTT assay Antiproliferative activity against human HGC27 cells after 96 hrs by MTT assay	[PMID: 31117517]
HGC-27	IC₅₀	3 μM Compound: Vorinostat	Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
HGC-27	IC₅₀	5.4 μM Compound: SAHA, vorinostat	Cytotoxicity against human HGC27 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HGC27 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707260]
HGC-27	IC₅₀	5.79 μM Compound: SAHA	Cytotoxicity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
HGC-27	IC₅₀	> 10 μM Compound: SAHA	Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
HH	EC₅₀	1.03 μM Compound: SAHA	Cytotoxicity against human HH cells assessed as cell proliferation after 70 hrs by MTS assay Cytotoxicity against human HH cells assessed as cell proliferation after 70 hrs by MTS assay	[PMID: 25974739]
HH	IC₅₀	0.86 μM Compound: 1; SAHA	Cytotoxicity against human HH cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HH cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HH	IC₅₀	2.53 μM Compound: XII; SAHA	Antiproliferative activity against human HH cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HH cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
HL-60	EC₅₀	1.2 μM Compound: 1a, SAHA	Antiproliferative activity against human HL60 cells after 48 hrs by cell titer-glo assay Antiproliferative activity against human HL60 cells after 48 hrs by cell titer-glo assay	[PMID: 20218673]
HL-60	EC₅₀	1.3 μM Compound: SAHA	Induction of ATRA-induced human HL60 cell differentiation pretreated for 1 hr followed by ATRA addition measured after 3 days by Wright-Giemsa staining based microscopic analysis Induction of ATRA-induced human HL60 cell differentiation pretreated for 1 hr followed by ATRA addition measured after 3 days by Wright-Giemsa staining based microscopic analysis	[PMID: 28549889]
HL-60	GI₅₀	0.08 μM Compound: SAHA	Cytotoxicity against human HL60 cells after 72 hrs by cell titre 96 aqueous cell proliferation assay Cytotoxicity against human HL60 cells after 72 hrs by cell titre 96 aqueous cell proliferation assay	[PMID: 26653328]
HL-60	GI₅₀	0.55 μM Compound: SAHA	Antiproliferative activity against human HL60 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human HL60 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay	[PMID: 25800646]
HL-60	GI₅₀	0.75 μM Compound: Vorinostat	Growth inhibition of human HL60 cells after 72 hrs by CellTiter Glo assay Growth inhibition of human HL60 cells after 72 hrs by CellTiter Glo assay	[PMID: 25182565]
HL-60	GI₅₀	0.93 μM Compound: 1, SAHA	Growth inhibition of human HL60 cells after 72 hrs by XTT assay Growth inhibition of human HL60 cells after 72 hrs by XTT assay	[PMID: 24900500]
HL-60	GI₅₀	1.74 μM Compound: SAHA	Antiproliferative activity against human HL60 cells after 48 hrs by SRB assay Antiproliferative activity against human HL60 cells after 48 hrs by SRB assay	[PMID: 27344487]
HL-60	GI₅₀	1.74 μM Compound: SAHA; 1	Antiproliferative activity against human HL60 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HL60 cells after 48 hrs by sulforhodamine B assay	[PMID: 29567459]
HL-60	IC₅₀	0.18 μg/mL Compound: Vorinostat	Antiproliferative activity against human HL-60 cells Antiproliferative activity against human HL-60 cells	[PMID: 31945642]
HL-60	IC₅₀	0.18 μg/mL Compound: Vorinostat	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
HL-60	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
HL-60	IC₅₀	0.22 μM Compound: Vorinostat	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 36351184]
HL-60	IC₅₀	0.22 μM Compound: Vorinostat	Cytotoxicity against human HL-60 cells measured for 72 hrs by celltiter-glo assay Cytotoxicity against human HL-60 cells measured for 72 hrs by celltiter-glo assay	[PMID: 38714044]
HL-60	IC₅₀	0.32 μM Compound: SAHA	Inhibition of cell viability in human HL-60 cells incubated for 4 days in presence of GSK5032 by CCK8 assay Inhibition of cell viability in human HL-60 cells incubated for 4 days in presence of GSK5032 by CCK8 assay	[PMID: 39264152]
HL-60	IC₅₀	0.39 μM Compound: SAHA	Antiproliferative activity against human HL-60 cells incubated for 48 hrs by resazurin based microplate reader analysis Antiproliferative activity against human HL-60 cells incubated for 48 hrs by resazurin based microplate reader analysis	[PMID: 37647727]
HL-60	IC₅₀	0.42 μM Compound: SAHA	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition after 72 hrs by trypan blue staining based cell counting assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition after 72 hrs by trypan blue staining based cell counting assay	[PMID: 31883490]
HL-60	IC₅₀	0.48 μM Compound: 1; SAHA	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HL-60	IC₅₀	0.5 μM Compound: SAHA	Antiproliferative activity against human HL-60 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HL-60 cells incubated for 72 hrs by CCK-8 assay	[PMID: 37057760]
HL-60	IC₅₀	0.52 μM Compound: SAHA	Antiproliferative activity against human HL60 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HL60 cells incubated for 48 hrs by MTT assay	[PMID: 31413795]
HL-60	IC₅₀	0.54 μM Compound: 1; SAHA	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
HL-60	IC₅₀	0.64 μM Compound: SAHA	Inhibition of cell viability in human HL-60 cells incubated for 4 days by CCK8 assay Inhibition of cell viability in human HL-60 cells incubated for 4 days by CCK8 assay	[PMID: 39264152]
HL-60	IC₅₀	0.69 μM Compound: 1; SAHA	Antiproliferative activity against human HL-60 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HL-60 cells incubated for 48 hrs by CCK8 assay	[PMID: 37037787]
HL-60	IC₅₀	0.69 μM Compound: Vorinostat	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
HL-60	IC₅₀	0.9 μM Compound: SAHA	Cytotoxicity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by ATPlite assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by ATPlite assay	[PMID: 34185525]
HL-60	IC₅₀	0.93 μM Compound: 1; SAHA	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	[PMID: 34656899]
HL-60	IC₅₀	1 μM Compound: SAHA	Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
HL-60	IC₅₀	1.1 μM Compound: SAHA	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
HL-60	IC₅₀	1.3 μM Compound: 1; SAHA	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay	[PMID: 36622852]
HL-60	IC₅₀	1.4 μM Compound: 1; SAHA	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay	[PMID: 36622852]
HL-60	IC₅₀	1.4 μM Compound: Vorinostat	Antiproliferative activity against human HL-60 cells Antiproliferative activity against human HL-60 cells	[PMID: 37875056]
HL-60	IC₅₀	1.5 μM Compound: 2; SAHA	Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay	[PMID: 29940115]
HL-60	IC₅₀	1.52 μM Compound: SAHA	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 36272186]
HL-60	IC₅₀	1331 nM Compound: SAHA	Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs by MTT assay	[PMID: 27505848]
HL-60	IC₅₀	2.21 μM Compound: 1; SAHA	Anticancer activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis Anticancer activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis	[PMID: 36215854]
HL-60	IC₅₀	2.28 μM Compound: 1; SAHA	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 27541357]
HL-60	IC₅₀	2.28 μM Compound: 2	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 28953386]
HL-60	IC₅₀	2.91 μM Compound: XII; SAHA	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
HL-60	IC₅₀	3 μM Compound: Vorinostat	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
HL-60	IC₅₀	3.04 μM Compound: SAHA	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
HL-60	IC₅₀	4.26 μM Compound: SA, SAHA	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 24694055]
HL-60	IC₅₀	4.26 μM Compound: SAHA	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 25462271]
HL-60	IC₅₀	570.5 nM Compound: SAHA	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 27505848]
HL-60	IC₅₀	729 nM Compound: SAHA	Growth inhibition of human HL60 cells assessed as ATP level after 72 hrs by CellTiterGlo assay Growth inhibition of human HL60 cells assessed as ATP level after 72 hrs by CellTiterGlo assay	10.1039/C3MD00285C
HL-60	IC₅₀	76.5 μM Compound: Zolinza, SAHA	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 22698782]
HL-60	IC₅₀	> 200 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 21476600]
HL-60	IC₅₀	> 3.78 mM Compound: vorinostat, SAHA	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 20171895]
HL-60(TB)	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human HL-60(TB) cells after 72 hrs by MTS assay Growth inhibition of human HL-60(TB) cells after 72 hrs by MTS assay	[PMID: 22435669]
HMEC	EC₅₀	> 10 μM Compound: SAHA	Cytotoxicity against HMEC after 72 hrs by trypan blue exclusion assay Cytotoxicity against HMEC after 72 hrs by trypan blue exclusion assay	[PMID: 19093884]
HMEC	GI₅₀	5.8 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human HMEC after 72 hrs by WST1 assay Cytotoxicity against human HMEC after 72 hrs by WST1 assay	[PMID: 24015327]
HMEC	IC₅₀	1.3 μM Compound: SAHA	Cytotoxicity against HMEC after 72 hrs by MTT assay Cytotoxicity against HMEC after 72 hrs by MTT assay	[PMID: 18642892]
HMEC	IC₅₀	10.7 μM Compound: Vorinostat	Cytotoxicity against HMEC cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay Cytotoxicity against HMEC cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay	[PMID: 36262394]
HMEC	IC₅₀	4.41 μM Compound: 1; SAHA	Cytotoxicity against human HMEC cells assessed as inhibition of cell viability incubated for 3 days by AlamarBlue based fluorescence analysis Cytotoxicity against human HMEC cells assessed as inhibition of cell viability incubated for 3 days by AlamarBlue based fluorescence analysis	[PMID: 37847303]
HOP-62	GI₅₀	1.6 μM Compound: SAHA	Antiproliferative activity against human HOP62 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human HOP62 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
HOP-62	IC₅₀	2.91 μM Compound: SAHA	Cytotoxicity against human HOP-62 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HOP-62 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 35858522]
HOP-92	GI₅₀	2.9 μM Compound: SAHA	Antiproliferative activity against human HOP92 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human HOP92 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
HOP-92	GI₅₀	4 μM Compound: SAHA, Zolinza	Growth inhibition of human HOP92 cells after 72 hrs by MTS assay Growth inhibition of human HOP92 cells after 72 hrs by MTS assay	[PMID: 22435669]
HSC-3	IC₅₀	0.71 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human HSC3 cells by MTT assay Cytotoxicity against human HSC3 cells by MTT assay	[PMID: 24766560]
HT-1080	GI₅₀	1.79 μM Compound: vorinostat, SAHA	Antiproliferative activity against human HT1080 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human HT1080 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
HT-1080	GI₅₀	4.87 μM Compound: SAHA, Vorinostat	Growth inhibition of human HT1080 cells by MTT assay Growth inhibition of human HT1080 cells by MTT assay	[PMID: 23601706]
HT-1080	IC₅₀	2.4 nM Compound: SAHA	Inhibition of human HT1080 cells Inhibition of human HT1080 cells	[PMID: 18247554]
HT-1080	IC₅₀	2.4 μM Compound: 1	Concentration required for the antiproliferation of Human HT1080 fibrosarcoma cells Concentration required for the antiproliferation of Human HT1080 fibrosarcoma cells	[PMID: 12270175]
HT-1080	IC₅₀	2.4 μM Compound: 1	Antiproliferative activity against human HT1080 fibrosarcoma cell line Antiproliferative activity against human HT1080 fibrosarcoma cell line	[PMID: 14552787]
HT-1080	IC₅₀	2.4 μM Compound: 3 (SAHA)	Antiproliferative activity against HT1080 (human fibrosarcoma) cell line. Antiproliferative activity against HT1080 (human fibrosarcoma) cell line.	[PMID: 12749893]
HT-1080	IC₅₀	2.54 μM Compound: SAHA	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 29787262]
HT-1080	IC₅₀	24 nM Compound: 1; SAHA	Antiproliferative activity against human HT1080 cells Antiproliferative activity against human HT1080 cells	[PMID: 31655430]
HT-1080	IC₅₀	2400 nM Compound: 1 (SAHA)	Inhibitory concentration against HT1080 cells proliferation Inhibitory concentration against HT1080 cells proliferation	[PMID: 14613312]
HT-1080	IC₅₀	3.56 μM Compound: SAHA	Anticancer activity against human HT-1080 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay Anticancer activity against human HT-1080 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay	[PMID: 36244186]
HT-1080	IC₅₀	7.5 μM Compound: SAHA	Cytotoxicity against human HT1080 cells Cytotoxicity against human HT1080 cells	[PMID: 23953690]
HT-29	EC₅₀	2 μM Compound: 1a, SAHA	Antiproliferative activity against human HT-29 cells after 48 hrs by cell titer-glo assay Antiproliferative activity against human HT-29 cells after 48 hrs by cell titer-glo assay	[PMID: 20218673]
HT-29	GI₅₀	0.79 μM Compound: SAHA, Zolinza	Growth inhibition of human HT-29 cells after 72 hrs by MTS assay Growth inhibition of human HT-29 cells after 72 hrs by MTS assay	[PMID: 22435669]
HT-29	GI₅₀	2.88 μM Compound: 1, SAHA	Growth inhibition of human HT-29 cells after 96 hrs by MTT assay Growth inhibition of human HT-29 cells after 96 hrs by MTT assay	[PMID: 26814680]
HT-29	IC₅₀	0.56 μM Compound: SAHA	Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
HT-29	IC₅₀	0.72 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 24766560]
HT-29	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
HT-29	IC₅₀	1.51 μM Compound: SAHA	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 29787262]
HT-29	IC₅₀	1.59 μM Compound: SAHA	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
HT-29	IC₅₀	1.78 μM Compound: 4; SAHA	Antiproliferative activity against human HT-29 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HT-29 cells after 48 hrs by CCK-8 assay	[PMID: 29670692]
HT-29	IC₅₀	2.2 μM Compound: SAHA	Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay	[PMID: 29150335]
HT-29	IC₅₀	2.33 μM Compound: 1; SAHA	Antiproliferative activity against human HT-29 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
HT-29	IC₅₀	2.37 μM Compound: SAHA	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 30879863]
HT-29	IC₅₀	2.57 μM Compound: SAHA	Anticancer activity against human HT-29 cells assessed as inhibition of cell growth measured for 48 hrs by MTT assay Anticancer activity against human HT-29 cells assessed as inhibition of cell growth measured for 48 hrs by MTT assay	[PMID: 38897139]
HT-29	IC₅₀	3.33 μM Compound: SAHA	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
HT-29	IC₅₀	5.01 μM Compound: Vorinostat	Antiproliferative activity against human HT-29 cells Antiproliferative activity against human HT-29 cells	[PMID: 37875056]
HT-29	IC₅₀	> 1000 nM Compound: SAHA	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 26443078]
HUVEC	GI₅₀	8.13 μM Compound: SAHA, Vorinostat	Growth inhibition of HUVEC by MTT assay Growth inhibition of HUVEC by MTT assay	[PMID: 23601706]
HUVEC	IC₅₀	0.85 μM Compound: SAHA	Inhibition of HDAC in HUVEC using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition and measured after 4 hrs by fluorimetry Inhibition of HDAC in HUVEC using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition and measured after 4 hrs by fluorimetry	[PMID: 32347094]
HUVEC	IC₅₀	120 nM Compound: 1; SAHA	Inhibition of total HDAC in human HUVEC cells using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition measured after 6 hrs by microtiter plate reader analysis Inhibition of total HDAC in human HUVEC cells using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition measured after 6 hrs by microtiter plate reader analysis	[PMID: 37037787]
HUVEC	IC₅₀	2.72 μM Compound: SAHA	Cytotoxicity against HUVEC cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against HUVEC cells assessed as inhibition of cell growth by MTT assay	[PMID: 37116762]
HUVEC	IC₅₀	2.84 μM Compound: SAHA	Antiproliferative activity against human HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
HUVEC	IC₅₀	26.4 μM Compound: SAHA	Cytotoxicity against HUVEC cells assessed as inhibition of cell growth Cytotoxicity against HUVEC cells assessed as inhibition of cell growth	[PMID: 35944852]
HUVEC	IC₅₀	3610 nM Compound: SAHA	Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
HUVEC	IC₅₀	5.9 μM Compound: 1; SAHA	Cytotoxicity against HUVECs assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Cytotoxicity against HUVECs assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 37037787]
HUVEC	IC₅₀	8.58 μM Compound: SAHA	Cytotoxicity against HUVEC cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against HUVEC cells incubated for 72 hrs by CCK-8 assay	[PMID: 36182802]
HUVEC	IC₅₀	> 50 μM Compound: SAHA	Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 37079967]
HaCaT	IC₅₀	1.85 μM Compound: SAHA	Cytotoxicity against human HaCaT cells assessed as inhibition of cell growth Cytotoxicity against human HaCaT cells assessed as inhibition of cell growth	[PMID: 34742014]
HeLa	CC₅₀	2.8 μM Compound: SAHA	Cytotoxicity against human HeLa cells assessed as cell death incubated for 20 hrs measured by DNS assay Cytotoxicity against human HeLa cells assessed as cell death incubated for 20 hrs measured by DNS assay	[PMID: 34006099]
HeLa	CC₅₀	460 nM Compound: 1	Antiproliferative activity against human P53-deficient HeLa cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human P53-deficient HeLa cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
HeLa	EC₅₀	0.0217 μM Compound: 1; SAHA; vorinostat	Inhibition of HDAC6 in human HeLa cells assessed as inhibition of tubulin deacetylation incubated for overnight by cELISA Inhibition of HDAC6 in human HeLa cells assessed as inhibition of tubulin deacetylation incubated for overnight by cELISA	[PMID: 26611919]
HeLa	EC₅₀	0.55 μM Compound: 1, SAHA	Inhibition of histone deacetylase in human HeLa cells assessed as induction of histone H3 hyperacetylation Inhibition of histone deacetylase in human HeLa cells assessed as induction of histone H3 hyperacetylation	[PMID: 18954984]
HeLa	EC₅₀	14.2 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs by XTT assay Antiproliferative activity against human HeLa cells after 48 hrs by XTT assay	[PMID: 21548582]
HeLa	EC₅₀	4.7 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 72 hrs by XTT assay Antiproliferative activity against human HeLa cells after 72 hrs by XTT assay	[PMID: 21548582]
HeLa	EC₅₀	4.8 μM Compound: SAHA	Inhibition of HDAC in human HeLa cells assessed as induction of histone H3 hyperacetylation after 24 hrs Inhibition of HDAC in human HeLa cells assessed as induction of histone H3 hyperacetylation after 24 hrs	[PMID: 18558669]
HeLa	EC₅₀	43 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 24 hrs by XTT assay Antiproliferative activity against human HeLa cells after 24 hrs by XTT assay	[PMID: 21548582]
HeLa	EC₅₀	6.67 μM Compound: 2	Inhibition of HDAC in HeLa cells assessed as induction of human histone H3 hyperacetylation Inhibition of HDAC in HeLa cells assessed as induction of human histone H3 hyperacetylation	[PMID: 17691763]
HeLa	EC₅₀	6.7 μM Compound: 6, SAHA	Inhibition of HDAC in human HeLa cells assessed as induction of cellular histone H3 hyperacetylation Inhibition of HDAC in human HeLa cells assessed as induction of cellular histone H3 hyperacetylation	[PMID: 19301902]
HeLa	GI₅₀	1460 nM Compound: SAHA	Growth inhibition of human HeLa cells after 72 hrs by SRB assay Growth inhibition of human HeLa cells after 72 hrs by SRB assay	[PMID: 20884208]
HeLa	GI₅₀	19.21 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28629630]
HeLa	GI₅₀	2.5 μM Compound: 1, SAHA	Growth inhibition of human HeLa cells after 72 hrs by XTT assay Growth inhibition of human HeLa cells after 72 hrs by XTT assay	[PMID: 24900500]
HeLa	GI₅₀	2.7 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	[PMID: 34500130]
HeLa	GI₅₀	3.2 μM Compound: vorinostat, SAHA	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
HeLa	GI₅₀	3.36 μM Compound: SAHA, Vorinostat	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 23601706]
HeLa	IC₅₀	0.02 μM Compound: 2	Inhibition of recombinant HDAC1 in HeLa cells Inhibition of recombinant HDAC1 in HeLa cells	[PMID: 17691763]
HeLa	IC₅₀	0.053 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell extract using Fluor deLys as substrate by fluorimetric assay Inhibition of HDAC in human HeLa cell extract using Fluor deLys as substrate by fluorimetric assay	[PMID: 23820574]
HeLa	IC₅₀	0.055 μM Compound: 1, SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence-based assay Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence-based assay	[PMID: 26814680]
HeLa	IC₅₀	0.063 μM Compound: 2, SAHA	Inhibition of HDAC in human HeLa cells using Boc-K(Ac)-AMC as substrate preincubated for 4 hrs before substrate addition measured after 3 hrs by fluorescence assay Inhibition of HDAC in human HeLa cells using Boc-K(Ac)-AMC as substrate preincubated for 4 hrs before substrate addition measured after 3 hrs by fluorescence assay	10.1039/C2MD00317A
HeLa	IC₅₀	0.07 μM Compound: 2	Inhibition of HDAC in HeLa cells Inhibition of HDAC in HeLa cells	[PMID: 17691763]
HeLa	IC₅₀	0.07 μM Compound: 2a	Inhibition of HDAC in human HeLa cell nuclear extracts Inhibition of HDAC in human HeLa cell nuclear extracts	[PMID: 21080629]
HeLa	IC₅₀	0.076 μM Compound: SAHA	Inhibition of HDAC6 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis Inhibition of HDAC6 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	[PMID: 26555243]
HeLa	IC₅₀	0.079 μM Compound: 2, SAHA	Inhibition of HDAC in human HeLa cell nuclear extracts using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extracts using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay	10.1039/C2MD00317A
HeLa	IC₅₀	0.079 μM Compound: SAHA	Inhibition of HDAC in human HeLa cells by fluorescent activity assay Inhibition of HDAC in human HeLa cells by fluorescent activity assay	[PMID: 21420859]
HeLa	IC₅₀	0.079 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell extract assessed as fluorophore release by fluorescence spectrophotometry Inhibition of HDAC in human HeLa cell extract assessed as fluorophore release by fluorescence spectrophotometry	[PMID: 21978679]
HeLa	IC₅₀	0.079 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell extracts using Fluor de Lys as substrate by fluorescence assay Inhibition of HDAC in human HeLa cell extracts using Fluor de Lys as substrate by fluorescence assay	[PMID: 22877635]
HeLa	IC₅₀	0.083 μM Compound: SAHA	Inhibition of nuclear HDAC isolated from human HeLa cells Inhibition of nuclear HDAC isolated from human HeLa cells	[PMID: 18558669]
HeLa	IC₅₀	0.09 μM Compound: SAHA, Vorinostat	Inhibition of human HDAC in HeLa cells after 30 mins by Fluor de Lys fluorescence assay Inhibition of human HDAC in HeLa cells after 30 mins by Fluor de Lys fluorescence assay	[PMID: 21889343]
HeLa	IC₅₀	0.1 μM Compound: SAHA	Inhibition of HDAC2 in human HeLa cells Inhibition of HDAC2 in human HeLa cells	[PMID: 19084294]
HeLa	IC₅₀	0.1 μM Compound: SAHA	Inhibition of HDAC in human HeLa cells extracts after 60 mins by fluorescence assay Inhibition of HDAC in human HeLa cells extracts after 60 mins by fluorescence assay	[PMID: 20576572]
HeLa	IC₅₀	0.1 μM Compound: SAHA	Inhibition of HDAC2 in human HeLa cells using KI-104 as substrate after 40 mins by fluorescence analysis Inhibition of HDAC2 in human HeLa cells using KI-104 as substrate after 40 mins by fluorescence analysis	[PMID: 24742384]
HeLa	IC₅₀	0.102 μM Compound: SAHA	Inhibition of HDAC in human Hela cell nuclear extract after 15 mins Inhibition of HDAC in human Hela cell nuclear extract after 15 mins	[PMID: 23644210]
HeLa	IC₅₀	0.102 μM Compound: vorinostat	Inhibition of HDAC in human HeLa cells nuclear extract using Fluor de lys as substrate after 15 mins by fluorometric analysis Inhibition of HDAC in human HeLa cells nuclear extract using Fluor de lys as substrate after 15 mins by fluorometric analysis	[PMID: 26629860]
HeLa	IC₅₀	0.106 μM Compound: Vorinostat, SAHA, Zolinza	Inhibition of full length FLAG-tagged recombinant HDAC3 (unknown origin) transfected in human HeLa cells assessed as deacetylation of [3H]-acetylated histones after 2 hrs by scintillation counting analysis Inhibition of full length FLAG-tagged recombinant HDAC3 (unknown origin) transfected in human HeLa cells assessed as deacetylation of [3H]-acetylated histones after 2 hrs by scintillation counting analysis	[PMID: 23964961]
HeLa	IC₅₀	0.107 μM Compound: 1, SAHA, Vorinostat	Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader	[PMID: 21476600]
HeLa	IC₅₀	0.11 μM Compound: 1, SAHA	Inhibition of HDAC in HeLa cells by fluorescent activity assay Inhibition of HDAC in HeLa cells by fluorescent activity assay	[PMID: 17477518]
HeLa	IC₅₀	0.11 μM Compound: 2, SAHA	Inhibition of HeLa cell HDAC Inhibition of HeLa cell HDAC	[PMID: 16723227]
HeLa	IC₅₀	0.11 μM Compound: 2, SAHA	Inhibition of HDAC in HeLa cell lysates Inhibition of HDAC in HeLa cell lysates	[PMID: 17904843]
HeLa	IC₅₀	0.11 μM Compound: 6, SAHA	Inhibition of HDAC1/HDAC2 in human HeLa cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay Inhibition of HDAC1/HDAC2 in human HeLa cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 25906087]
HeLa	IC₅₀	0.11 μM Compound: SAHA	Inhibition of HDAC1/3/5/8 in human HeLa cell extract using Boc-Lys-(acetyl)-AMC as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorometric analysis Inhibition of HDAC1/3/5/8 in human HeLa cell extract using Boc-Lys-(acetyl)-AMC as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorometric analysis	[PMID: 23510562]
HeLa	IC₅₀	0.11 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using Fluor de Lys as substrate incubated with compound for 30 mins by microtiter-plate reading flourimeter analysis Inhibition of HDAC in human HeLa cell nuclear extract using Fluor de Lys as substrate incubated with compound for 30 mins by microtiter-plate reading flourimeter analysis	[PMID: 25811792]
HeLa	IC₅₀	0.11 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using acetylated lysine side chain of histone as substrate measured after 30 mins by fluorometric assay Inhibition of HDAC in human HeLa cell nuclear extract using acetylated lysine side chain of histone as substrate measured after 30 mins by fluorometric assay	[PMID: 28011426]
HeLa	IC₅₀	0.11 μM Compound: SAHA, Zolinza	Inhibition of HDAC1/2 in human HeLa cell nuclear extract using Boc-Lys (acetyl)-AMC as substrate preincubated for 30 mins before substrate addition measured after 20 mins by UV-vis spectrophotometer analysis Inhibition of HDAC1/2 in human HeLa cell nuclear extract using Boc-Lys (acetyl)-AMC as substrate preincubated for 30 mins before substrate addition measured after 20 mins by UV-vis spectrophotometer analysis	[PMID: 26100440]
HeLa	IC₅₀	0.119 μM Compound: Vorinostat, SAHA, Zolinza	Inhibition of full length FLAG-tagged recombinant HDAC1 (unknown origin) transfected in human HeLa cells assessed as deacetylation of [3H]-acetylated histones after 2 hrs by scintillation counting analysis Inhibition of full length FLAG-tagged recombinant HDAC1 (unknown origin) transfected in human HeLa cells assessed as deacetylation of [3H]-acetylated histones after 2 hrs by scintillation counting analysis	[PMID: 23964961]
HeLa	IC₅₀	0.12 μM Compound: SAHA	Inhibition of HDAC1/HDAC2 in human HeLa cells nuclear extract preincubated for 5 mins before Boc-Lys (acetyl)-AMC substrate addition for 30 mins by microplate reader analysis Inhibition of HDAC1/HDAC2 in human HeLa cells nuclear extract preincubated for 5 mins before Boc-Lys (acetyl)-AMC substrate addition for 30 mins by microplate reader analysis	[PMID: 26629857]
HeLa	IC₅₀	0.122 μM Compound: SAHA	Inhibition of HDAC in human HeLa cells using Fluor de Lys as substrate by fluorescence assay Inhibition of HDAC in human HeLa cells using Fluor de Lys as substrate by fluorescence assay	[PMID: 23639537]
HeLa	IC₅₀	0.13 μM Compound: 1, SAHA	Inhibition of HDAC1/2 in human HeLa cell extracts using acetylated histone peptide as substrate after 30 mins Inhibition of HDAC1/2 in human HeLa cell extracts using acetylated histone peptide as substrate after 30 mins	[PMID: 24525003]
HeLa	IC₅₀	0.13 μM Compound: SAHA, Vorinostat	Inhibition of HDAC in human HeLa cell extract using fluor de Lys as substrate after 15 mins by fluorometric analysis Inhibition of HDAC in human HeLa cell extract using fluor de Lys as substrate after 15 mins by fluorometric analysis	[PMID: 23792316]
HeLa	IC₅₀	0.14 μM Compound: SAHA	Inhibition of HDAC1/HDAC2 isolated from human HeLa cells incubated for 30 mins by Color de Lys assay Inhibition of HDAC1/HDAC2 isolated from human HeLa cells incubated for 30 mins by Color de Lys assay	10.1039/C4MD00203B
HeLa	IC₅₀	0.14 μM Compound: SAHA	Inhibition of HDAC in HeLa cells Inhibition of HDAC in HeLa cells	[PMID: 17662606]
HeLa	IC₅₀	0.147 μM Compound: SAHA	Inhibition of HDAC in human HeLa cytosolic extract using Fluor-de-lys as substrate measured after 60 mins by fluorescence assay Inhibition of HDAC in human HeLa cytosolic extract using Fluor-de-lys as substrate measured after 60 mins by fluorescence assay	[PMID: 30245394]
HeLa	IC₅₀	0.16 μM Compound: SAHA	Inhibition of HDAC6 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay Inhibition of HDAC6 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay	[PMID: 30245394]
HeLa	IC₅₀	0.16 μM Compound: SAHA	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	[PMID: 30879863]
HeLa	IC₅₀	0.168 μM Compound: 3; SAHA	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	[PMID: 30901208]
HeLa	IC₅₀	0.17 μM Compound: 2	Inhibition of HDAC in human HeLa cells nuclear extracts by fluorometric assay Inhibition of HDAC in human HeLa cells nuclear extracts by fluorometric assay	[PMID: 23116147]
HeLa	IC₅₀	0.18 μM Compound: SAHA	Inhibition of HDAC2 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay Inhibition of HDAC2 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay	[PMID: 30245394]
HeLa	IC₅₀	0.19 μM Compound: 1, SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(acetyl)-AMC as substrate preincubated with enzyme for 5 mins prior to substrate addition measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(acetyl)-AMC as substrate preincubated with enzyme for 5 mins prior to substrate addition measured after 30 mins by fluorescence assay	[PMID: 23493449]
HeLa	IC₅₀	0.19 μM Compound: SAHA	Inhibition of HDAC1 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis Inhibition of HDAC1 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	[PMID: 26555243]
HeLa	IC₅₀	0.19 μM Compound: SAHA	Inhibition of HDAC1/HDAC2 in human HeLa nuclear extract Inhibition of HDAC1/HDAC2 in human HeLa nuclear extract	[PMID: 30245394]
HeLa	IC₅₀	0.193 μM Compound: SAHA	Inhibition of HDAC1/2 in human HeLa cells nuclear extracts using acetylated histone peptide as substrate after 30 mins by Color de Lys assay Inhibition of HDAC1/2 in human HeLa cells nuclear extracts using acetylated histone peptide as substrate after 30 mins by Color de Lys assay	[PMID: 26216016]
HeLa	IC₅₀	0.195 μM Compound: 1, SAHA, Vorinostat	Inhibition of HDAC6 in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader Inhibition of HDAC6 in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader	[PMID: 21476600]
HeLa	IC₅₀	0.231 μM Compound: SAHA	Inhibition of HDAC in human HeLa nuclear extract using Fluor-de-lys as substrate measured after 60 mins by fluorescence assay Inhibition of HDAC in human HeLa nuclear extract using Fluor-de-lys as substrate measured after 60 mins by fluorescence assay	[PMID: 30245394]
HeLa	IC₅₀	0.26 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using acetylated lysine as substrate after 30 mins by spectrophotometric analysis Inhibition of HDAC in human HeLa cell nuclear extract using acetylated lysine as substrate after 30 mins by spectrophotometric analysis	[PMID: 24702857]
HeLa	IC₅₀	0.28 μM Compound: 2, (SAHA, vorinostat)	Inhibition of HDAC in human HeLa cell nuclear extracts by fluorimetry Inhibition of HDAC in human HeLa cell nuclear extracts by fluorimetry	[PMID: 19419205]
HeLa	IC₅₀	0.28 μM Compound: SAHA	Inhibitory concentration against histone deacetylase of HeLa cells Inhibitory concentration against histone deacetylase of HeLa cells	[PMID: 15603949]
HeLa	IC₅₀	0.28 μM Compound: SAHA	Inhibition of HDAC from human HeLa cells Inhibition of HDAC from human HeLa cells	[PMID: 18247554]
HeLa	IC₅₀	0.33 μM Compound: SAHA	Inhibition of HDAC8 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis Inhibition of HDAC8 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	[PMID: 26555243]
HeLa	IC₅₀	0.35 μM Compound: SAHA	Inhibition of class 1 HDAC n human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC addition and measured after 30 mins by fluorescence based assay Inhibition of class 1 HDAC n human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC addition and measured after 30 mins by fluorescence based assay	[PMID: 32267687]
HeLa	IC₅₀	0.48 μM Compound: 1, SAHA, Vorinostat	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC as substrate after 30 mins by fluorimetric analysis Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC as substrate after 30 mins by fluorimetric analysis	[PMID: 24766560]
HeLa	IC₅₀	0.48 μM Compound: SAHA	Inhibition of HDAC in human HeLa nuclear extract Inhibition of HDAC in human HeLa nuclear extract	[PMID: 30245394]
HeLa	IC₅₀	0.48 μM Compound: SAHA	Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay	[PMID: 34847495]
HeLa	IC₅₀	0.56 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	[PMID: 26555243]
HeLa	IC₅₀	0.6 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell extract incubated for 1 hr by colorimetric activity assay Inhibition of HDAC in human HeLa cell extract incubated for 1 hr by colorimetric activity assay	10.1039/C4MD00350K
HeLa	IC₅₀	0.7 μM Compound: SAHA	Inhibition of HDAC from human HeLa cells by fluorogenic enzyme assay Inhibition of HDAC from human HeLa cells by fluorogenic enzyme assay	[PMID: 19457659]
HeLa	IC₅₀	0.72 μM Compound: SAHA	Growth inhibition of human HeLa cells after 48 hrs by MTT assay Growth inhibition of human HeLa cells after 48 hrs by MTT assay	[PMID: 24702857]
HeLa	IC₅₀	0.98 μM Compound: Zolinza, SAHA	Inhibition of HDAC derived from human HeLa cell nuclear extract using Boc-Lys(acetyl)-AMC as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorimetry Inhibition of HDAC derived from human HeLa cell nuclear extract using Boc-Lys(acetyl)-AMC as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorimetry	[PMID: 22698782]
HeLa	IC₅₀	1.1 μM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extract by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract by fluorescence assay	[PMID: 20036560]
HeLa	IC₅₀	1.17 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
HeLa	IC₅₀	1.41 μM Compound: SAHA	Inhibition of HDAC8 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay Inhibition of HDAC8 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay	[PMID: 30245394]
HeLa	IC₅₀	1.5 μM Compound: 2a	Cytotoxicity against human HeLa cells overexpressing HDAC by resazurin dye reduction assay Cytotoxicity against human HeLa cells overexpressing HDAC by resazurin dye reduction assay	[PMID: 21080629]
HeLa	IC₅₀	1.72 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28336407]
HeLa	IC₅₀	1.72 μM Compound: Vorinostat	Cytotoxicity against human HeLa cells assessed as cell growth inhibition Cytotoxicity against human HeLa cells assessed as cell growth inhibition	[PMID: 38107170]
HeLa	IC₅₀	1.75 μM Compound: 2	Cytotoxicity against HeLa cells Cytotoxicity against HeLa cells	[PMID: 17691763]
HeLa	IC₅₀	1.84 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29500131]
HeLa	IC₅₀	1.9 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29533873]
HeLa	IC₅₀	107.8 nM Compound: 1, SAHA	Inhibition of HDAC1/2 in human HeLa cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by fluorescence assay Inhibition of HDAC1/2 in human HeLa cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by fluorescence assay	[PMID: 26122774]
HeLa	IC₅₀	11 nM Compound: Vorinostat	Inhibition of HDAC1/HDAC2 in human HeLa cell nuclear extract preincubated for 20 mins followed by addition of HDAC green as substrate measured after 60 mins by fluorescence analysis Inhibition of HDAC1/HDAC2 in human HeLa cell nuclear extract preincubated for 20 mins followed by addition of HDAC green as substrate measured after 60 mins by fluorescence analysis	[PMID: 27597246]
HeLa	IC₅₀	11.5 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Leu-Gly-Lys (Ac)-AMC as substrate after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Leu-Gly-Lys (Ac)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 27186676]
HeLa	IC₅₀	12 nM Compound: Vorinostat	Inhibition of human HDAC in HeLa cell nuclear extract by fluorometric assay using Fluor de Lys substrate Inhibition of human HDAC in HeLa cell nuclear extract by fluorometric assay using Fluor de Lys substrate	[PMID: 26475519]
HeLa	IC₅₀	12.28 μM Compound: 1, SAHA	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26122774]
HeLa	IC₅₀	12.28 μM Compound: 6, SAHA	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25906087]
HeLa	IC₅₀	120.06 nM Compound: 1; SAHA	Inhibition of HDAC activity in human HeLa cell nuclear extract using fluorometric substrate measured after 30 mins by fluorescence assay Inhibition of HDAC activity in human HeLa cell nuclear extract using fluorometric substrate measured after 30 mins by fluorescence assay	[PMID: 27886544]
HeLa	IC₅₀	121 nM Compound: SAHA	Inhibition of HDAC1/2 in human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay Inhibition of HDAC1/2 in human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay	[PMID: 32267687]
HeLa	IC₅₀	1270 nM Compound: 1; SAHA	Antiproliferative activity against human HeLa cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
HeLa	IC₅₀	131.26 nM Compound: 1; SAHA	Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Lys(Ac)-pNA as substrate after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Lys(Ac)-pNA as substrate after 30 mins by fluorescence assay	[PMID: 28395150]
HeLa	IC₅₀	135 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell extracts assessed as inhibition of substrate deacetylation using Boc-Lys (acetyl)-AMC as substrate by fluorescence based assay Inhibition of HDAC in human HeLa cell extracts assessed as inhibition of substrate deacetylation using Boc-Lys (acetyl)-AMC as substrate by fluorescence based assay	[PMID: 32247729]
HeLa	IC₅₀	141 nM Compound: 1, SAHA	Inhibition of HDAC in human HeLa cell nuclear extracts using Fluor de Lys as substrate by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extracts using Fluor de Lys as substrate by fluorescence assay	[PMID: 24119555]
HeLa	IC₅₀	144.8 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell extract using Boc-Lys (acetyl)-AMC as substrate incubated for 10 mins prior to substrate addition measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell extract using Boc-Lys (acetyl)-AMC as substrate incubated for 10 mins prior to substrate addition measured after 30 mins by fluorescence assay	[PMID: 25462271]
HeLa	IC₅₀	147 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21476600]
HeLa	IC₅₀	15 nM Compound: Vorinostat	Inhibition of HDAC in human HeLa cell nuclear extracts preincubated for 15 mins followed by addition of Fluor de Lys as substrate for 1 hr by fluorometric assay Inhibition of HDAC in human HeLa cell nuclear extracts preincubated for 15 mins followed by addition of Fluor de Lys as substrate for 1 hr by fluorometric assay	[PMID: 26741358]
HeLa	IC₅₀	154.8 nM Compound: SAHA	Inhibition of Class 1 histone deacetylase isolated from human HeLa cell nuclear extracts using Boc-Lys (acetyl)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence assay Inhibition of Class 1 histone deacetylase isolated from human HeLa cell nuclear extracts using Boc-Lys (acetyl)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence assay	[PMID: 26349626]
HeLa	IC₅₀	159 nM Compound: Vorinostat	Inhibition of HDAC1/2 in human HeLa cell nuclear extract using COLOR DE LYS as substrate pretreated for 5 mins followed by substrate addition measured after 30 mins by UV-absorption method Inhibition of HDAC1/2 in human HeLa cell nuclear extract using COLOR DE LYS as substrate pretreated for 5 mins followed by substrate addition measured after 30 mins by UV-absorption method	[PMID: 28371677]
HeLa	IC₅₀	160.8 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extracts using (Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extracts using (Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	[PMID: 28336407]
HeLa	IC₅₀	161 nM Compound: SAHA	Inhibition of HDAC1/2 in human HeLa cell nuclear extracts preincubated for 5 mins followed by substrate addition measured after 0.5 hrs by Color de Lys assay Inhibition of HDAC1/2 in human HeLa cell nuclear extracts preincubated for 5 mins followed by substrate addition measured after 0.5 hrs by Color de Lys assay	[PMID: 26149591]
HeLa	IC₅₀	176.6 μM Compound: SAHA	Inhibition of HDAC1/2 in human HeLa cells using Boc-Lys (acetyl)-AMC as substrate incubated for 2 hrs prior to substrate addition measured after 30 mins by fluorescence assay Inhibition of HDAC1/2 in human HeLa cells using Boc-Lys (acetyl)-AMC as substrate incubated for 2 hrs prior to substrate addition measured after 30 mins by fluorescence assay	[PMID: 26386821]
HeLa	IC₅₀	18 nM Compound: 2, SAHA	Inhibition of HDAC6 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry Inhibition of HDAC6 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	[PMID: 21984958]
HeLa	IC₅₀	18.9 μM Compound: SAHA	Inhibition of class 2 HDAC n human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay Inhibition of class 2 HDAC n human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay	[PMID: 32267687]
HeLa	IC₅₀	1860 nM Compound: SAHA	Inhibition of HDAC8 from human HeLa cells nuclear extract by cell free fluorimetric assay Inhibition of HDAC8 from human HeLa cells nuclear extract by cell free fluorimetric assay	[PMID: 19093884]
HeLa	IC₅₀	196 nM Compound: SAHA	Inhibition of human HDAC in human HeLa cell nuclear extract after 15 mins by colorimetric assay Inhibition of human HDAC in human HeLa cell nuclear extract after 15 mins by colorimetric assay	[PMID: 20167479]
HeLa	IC₅₀	1989 nM Compound: SAHA	Inhibition of HDAC8 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis Inhibition of HDAC8 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	[PMID: 22260166]
HeLa	IC₅₀	1989 nM Compound: SAHA, Vorinostat	Inhibition of HDAC8 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay Inhibition of HDAC8 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay	[PMID: 23622981]
HeLa	IC₅₀	2.04 μM Compound: SAHA	Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay	[PMID: 36244186]
HeLa	IC₅₀	2.06 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 28601509]
HeLa	IC₅₀	2.06 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29787262]
HeLa	IC₅₀	2.12 μM Compound: SAHA	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
HeLa	IC₅₀	2.2 μM Compound: 6, SAHA	Cytotoxicity against human HeLa cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human HeLa cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
HeLa	IC₅₀	2.41 μM Compound: SAHA	Antiproliferative activity against human Hela cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Hela cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
HeLa	IC₅₀	2.5 μM Compound: Vorinostat	Antiproliferative activity against human HeLa cells measured after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells measured after 24 hrs by MTT assay	[PMID: 37875056]
HeLa	IC₅₀	2.59 μM Compound: SAHA	Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK-8 assay	[PMID: 37057760]
HeLa	IC₅₀	2.59 μM Compound: SAHA, Vorinostat	Inhibition of HDAC in human HeLa cell nuclear extracts using Color de LysTM after 30 mins Inhibition of HDAC in human HeLa cell nuclear extracts using Color de LysTM after 30 mins	[PMID: 24095016]
HeLa	IC₅₀	2.6 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs Antiproliferative activity against human HeLa cells after 48 hrs	[PMID: 24262004]
HeLa	IC₅₀	2.6 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay	[PMID: 35939996]
HeLa	IC₅₀	2.65 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33021789]
HeLa	IC₅₀	2.7 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 24296013]
HeLa	IC₅₀	2.7 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay	[PMID: 29150335]
HeLa	IC₅₀	2.7 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 34624191]
HeLa	IC₅₀	2.74 μM Compound: SAHA	Antiproliferative activity against human HeLa cells incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 39145486]
HeLa	IC₅₀	2.8 μM Compound: SAHA, vorinostat	Inhibition of HDAC isolated from human HeLa cell nuclear extract after 30 mins by fluorescence assay Inhibition of HDAC isolated from human HeLa cell nuclear extract after 30 mins by fluorescence assay	[PMID: 23707260]
HeLa	IC₅₀	2.85 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
HeLa	IC₅₀	2.9 μM Compound: Vorinostat	Antiproliferative activity against human HeLa cells by CCK8 assay Antiproliferative activity against human HeLa cells by CCK8 assay	[PMID: 30660827]
HeLa	IC₅₀	2000 nM Compound: 2, SAHA	Inhibition of HDAC8 in human HeLa cells nuclear extract using Arg-His-Lys(Ac)-Lys(Ac)-AMC as substrate after 30 mins by spectrophotometry Inhibition of HDAC8 in human HeLa cells nuclear extract using Arg-His-Lys(Ac)-Lys(Ac)-AMC as substrate after 30 mins by spectrophotometry	[PMID: 21984958]
HeLa	IC₅₀	27 nM Compound: SAHA	Inhibition of HDAC6 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis Inhibition of HDAC6 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	[PMID: 22260166]
HeLa	IC₅₀	27 nM Compound: SAHA, Vorinostat	Inhibition of HDAC6 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay Inhibition of HDAC6 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay	[PMID: 23622981]
HeLa	IC₅₀	29 nM Compound: SAHA	Selectivity ratio IC50 for HDAC8 to IC50 for HDAC in human HeLa cells nuclear extract Selectivity ratio IC50 for HDAC8 to IC50 for HDAC in human HeLa cells nuclear extract	[PMID: 20669972]
HeLa	IC₅₀	3.1 μM Compound: II, SAHA	Antiproliferative activity against human HeLa cells after 4 hrs by WST-1 assay Antiproliferative activity against human HeLa cells after 4 hrs by WST-1 assay	[PMID: 18672316]
HeLa	IC₅₀	3.55 μM Compound: Vorinostat	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28371677]
HeLa	IC₅₀	3.56 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
HeLa	IC₅₀	3.7 μM Compound: SAHA	Cytotoxicity against human HeLa cells after 72 hrs by MTS assay Cytotoxicity against human HeLa cells after 72 hrs by MTS assay	[PMID: 25899338]
HeLa	IC₅₀	3.823 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition after 72 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition after 72 hrs by SRB assay	[PMID: 34454126]
HeLa	IC₅₀	38 nM Compound: SAHA	Inhibition of HDAC1 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis Inhibition of HDAC1 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	[PMID: 22260166]
HeLa	IC₅₀	38 nM Compound: SAHA, Vorinostat	Inhibition of HDAC1 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay Inhibition of HDAC1 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay	[PMID: 23622981]
HeLa	IC₅₀	4.5 μM Compound: SAHA	Inhibition of HDAC in human HeLa cells Inhibition of HDAC in human HeLa cells	[PMID: 18558669]
HeLa	IC₅₀	4.52 μM Compound: SAHA	Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation	[PMID: 35944852]
HeLa	IC₅₀	4.52 μM Compound: Vorinostat	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method	[PMID: 33261898]
HeLa	IC₅₀	4.52 μM Compound: Vorinostat	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay	[PMID: 35255412]
HeLa	IC₅₀	4.52 μM Compound: Vorinostat	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth by MTT assay	[PMID: 35477142]
HeLa	IC₅₀	4.61 μM Compound: SAHA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30879863]
HeLa	IC₅₀	4.66 μM Compound: SAHA	Antiproliferative activity against siRNA-induced BAX knock down human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against siRNA-induced BAX knock down human HeLa cells after 48 hrs by MTT assay	[PMID: 33021789]
HeLa	IC₅₀	40 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extract Inhibition of HDAC in human HeLa cell nuclear extract	[PMID: 20143778]
HeLa	IC₅₀	41 nM Compound: 2, SAHA	Inhibition of HDAC1 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry Inhibition of HDAC1 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	[PMID: 21984958]
HeLa	IC₅₀	41 nM Compound: 2, SAHA	Inhibition of HDAC3-NCoR2 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry Inhibition of HDAC3-NCoR2 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	[PMID: 21984958]
HeLa	IC₅₀	416 nM Compound: SAHA	Inhibition of HDAC1/HDAC2 in human HeLa cell extract incubated for 5 mins prior to substrate addition measured after 30 mins by microtitre plate reader analysis Inhibition of HDAC1/HDAC2 in human HeLa cell extract incubated for 5 mins prior to substrate addition measured after 30 mins by microtitre plate reader analysis	[PMID: 25311567]
HeLa	IC₅₀	460 nM Compound: 1, SAHA	Antiproliferative activity against human HeLa cells after 72 hrs by celltiter-blue viability assay Antiproliferative activity against human HeLa cells after 72 hrs by celltiter-blue viability assay	[PMID: 18809328]
HeLa	IC₅₀	460 nM Compound: 1, vorinostat	Antiproliferative activity against human HeLa cells by CellTiter-Blue cell viability assay Antiproliferative activity against human HeLa cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
HeLa	IC₅₀	460 nM Compound: SAHA	Inhibition of HeLa cell proliferation Inhibition of HeLa cell proliferation	[PMID: 16987657]
HeLa	IC₅₀	49 nM Compound: SAHA	Inhibition of HDAC1/2 from human HeLa cells Inhibition of HDAC1/2 from human HeLa cells	[PMID: 19854643]
HeLa	IC₅₀	5 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32151834]
HeLa	IC₅₀	5.21 μM Compound: 1; SAHA	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
HeLa	IC₅₀	5.45 μM Compound: SAHA, Zolinza	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26100440]
HeLa	IC₅₀	6.07 μM Compound: SAHA	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C4MD00203B
HeLa	IC₅₀	65 nM Compound: SAHA	Inhibition of human HDAC in HeLa cells by flour de lys assay Inhibition of human HDAC in HeLa cells by flour de lys assay	[PMID: 18397827]
HeLa	IC₅₀	65 nM Compound: SAHA	Inhibition of HDAC1/2 from human HeLa cells nuclear extract by cell free fluorimetric assay Inhibition of HDAC1/2 from human HeLa cells nuclear extract by cell free fluorimetric assay	[PMID: 19093884]
HeLa	IC₅₀	65 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay	[PMID: 19914074]
HeLa	IC₅₀	65 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extracts Inhibition of HDAC in human HeLa cell nuclear extracts	[PMID: 20669972]
HeLa	IC₅₀	65 nM Compound: SAHA	Inhibition of HDAC1/2 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis Inhibition of HDAC1/2 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	[PMID: 22260166]
HeLa	IC₅₀	65 nM Compound: SAHA, Vorinostat	Inhibition of HDAC in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay Inhibition of HDAC in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay	[PMID: 23622981]
HeLa	IC₅₀	67 nM Compound: SAHA, Vorinostat	Inhibition of HDAC in human HeLa cells using Ac-Arg-Gly-Lys(Ac)-AMC as fluorescent substrate after 20 mins by fluorescence assay Inhibition of HDAC in human HeLa cells using Ac-Arg-Gly-Lys(Ac)-AMC as fluorescent substrate after 20 mins by fluorescence assay	[PMID: 21621883]
HeLa	IC₅₀	67 nM Compound: SAHA, Zolinza	Inhibition of HDAC in human HeLa cell nuclear extracts using Ac-Arg-Gly-Lys(Ac)-AMC substrate by fluorimetry Inhibition of HDAC in human HeLa cell nuclear extracts using Ac-Arg-Gly-Lys(Ac)-AMC substrate by fluorimetry	[PMID: 22435669]
HeLa	IC₅₀	7.13 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	10.1039/C5MD00247H
HeLa	IC₅₀	711 nM Compound: SAHA	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 26443078]
HeLa	IC₅₀	73.2 nM Compound: SAHA	Inhibition of HDAC in human HeLA cell nuclear extracts Inhibition of HDAC in human HeLA cell nuclear extracts	[PMID: 31400938]
HeLa	IC₅₀	8.96 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	10.1039/C5MD00247H
HeLa	IC₅₀	80 nM Compound: SAHA	Inhibition of human HDAC in HeLa cells by fluorescent activity assay Inhibition of human HDAC in HeLa cells by fluorescent activity assay	[PMID: 19223622]
HeLa	IC₅₀	85.5 nM Compound: SAHA	Inhibition of HDAC6 from human HeLa cells nuclear extract by cell free fluorimetric assay Inhibition of HDAC6 from human HeLa cells nuclear extract by cell free fluorimetric assay	[PMID: 19093884]
HeLa	IC₅₀	86 nM Compound: SAHA	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate compound pretreated for 30 mins before substrate addition by fluorescence assay Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate compound pretreated for 30 mins before substrate addition by fluorescence assay	[PMID: 23089527]
HeLa	IC₅₀	87 nM Compound: II, SAHA	Inhibition of HDAC from human HeLa cells Inhibition of HDAC from human HeLa cells	[PMID: 18672316]
HeLa	IC₅₀	87 nM Compound: SAHA	Inhibition of HDAC in human HeLa cell nuclear extracts by fluorimetric assay Inhibition of HDAC in human HeLa cell nuclear extracts by fluorimetric assay	[PMID: 20884208]
HeLa	IC₅₀	87 nM Compound: SAHA, vorinostat	Inhibition of HDAC in human HeLa cells nuclear extract using fluor de Lys as substrate preincubated for 5 mins by fluorometric analysis Inhibition of HDAC in human HeLa cells nuclear extract using fluor de Lys as substrate preincubated for 5 mins by fluorometric analysis	[PMID: 21080647]
HeLa	IC₅₀	9.19 μM Compound: SAHA	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	10.1039/C5MD00247H
HeLa	IC₅₀	9.69 μM Compound: SAHA, Vorinostat	Growth inhibition of human HeLa cells after 48 hrs by MTT assay Growth inhibition of human HeLa cells after 48 hrs by MTT assay	[PMID: 24095016]
HeLa	IC₅₀	91 nM Compound: SAHA	Inhibition of HDAC1/2 in human HeLa cell nuclear extract using color de Lys as substrate preincubated for 5 mins followed by substrate addition measured after 30 min by microtiter plate reader analysis Inhibition of HDAC1/2 in human HeLa cell nuclear extract using color de Lys as substrate preincubated for 5 mins followed by substrate addition measured after 30 min by microtiter plate reader analysis	[PMID: 26907204]
HeLa	IC₅₀	96.4 nM Compound: 1, SAHA	Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader	[PMID: 22439863]
HeLa	IC₅₀	98.35 μM Compound: 1; SAHA	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay	[PMID: 31655430]
HeLa	IC₅₀	>= 0.05 μM Compound: SAHA, vorinostat	Inhibition of HDAC2 in HeLa cell lysates Inhibition of HDAC2 in HeLa cell lysates	[PMID: 17892933]
HeLa S3	IC₅₀	0.02 μM Compound: SAHA	Inhibition of HDAC3 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA Inhibition of HDAC3 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	[PMID: 28337317]
HeLa S3	IC₅₀	0.033 μM Compound: SAHA	Inhibition of HDAC1 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA Inhibition of HDAC1 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	[PMID: 28337317]
HeLa S3	IC₅₀	0.033 μM Compound: SAHA	Inhibition of HDAC6 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA Inhibition of HDAC6 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	[PMID: 28337317]
HeLa S3	IC₅₀	0.096 μM Compound: SAHA	Inhibition of HDAC2 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA Inhibition of HDAC2 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	[PMID: 28337317]
Hep 3B2	GI₅₀	0.69 μM Compound: 1, SAHA	Growth inhibition of human Hep3B cells after 48 hrs by SRB assay Growth inhibition of human Hep3B cells after 48 hrs by SRB assay	[PMID: 22439863]
Hep 3B2	GI₅₀	1.21 μM Compound: SAHA	Antiproliferative activity against human Hep3B cells after 48 hrs by SRB assay Antiproliferative activity against human Hep3B cells after 48 hrs by SRB assay	[PMID: 21712146]
Hep 3B2	GI₅₀	> 410 nM Compound: Vorinostat	Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
Hep 3B2	IC₅₀	2.1 μM Compound: SAHA	Cytotoxicity against human Hep3B cells Cytotoxicity against human Hep3B cells	[PMID: 23906422]
Hep 3B2	IC₅₀	2.3 μM Compound: Vorinostat	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human Hep3B cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
Hep 3B2	IC₅₀	2.44 μM Compound: SAHA	Antiproliferative activity against human Hep3B2 cells after hrs by ATP content assay Antiproliferative activity against human Hep3B2 cells after hrs by ATP content assay	[PMID: 20143778]
Hep 3B2	IC₅₀	2.6 μM Compound: Vor; SAHA	Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
Hep 3B2	IC₅₀	5.4 μM Compound: SAHA, vorinostat	Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707260]
Hep 3B2	IC₅₀	5.58 μM Compound: SAHA	Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
HepG2	CC₅₀	12 μM Compound: Vorinostat	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by CellTiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by CellTiter-Glo assay	[PMID: 30973727]
HepG2	EC₅₀	12.2 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23820574]
HepG2	EC₅₀	2.5 μM Compound: suberoylanilide	Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis	[PMID: 20966043]
HepG2	EC₅₀	3.8 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 72 hrs by XTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by XTT assay	[PMID: 21548582]
HepG2	EC₅₀	35.5 μM Compound: suberoylanilide	Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis	[PMID: 20966043]
HepG2	EC₅₀	8.4 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 48 hrs by XTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by XTT assay	[PMID: 21548582]
HepG2	EC₅₀	> 50 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 24 hrs by XTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by XTT assay	[PMID: 21548582]
HepG2	GI₅₀	21.96 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 29500130]
HepG2	GI₅₀	3.4 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	[PMID: 34500130]
HepG2	GI₅₀	3.5 μM Compound: SAHA, Zolinza	Growth inhibition of human HepG2 cells after 72 hrs by MTT assay Growth inhibition of human HepG2 cells after 72 hrs by MTT assay	[PMID: 22435669]
HepG2	GI₅₀	4600 nM Compound: SAHA, vorinostat	Antiproliferative activity against human HepG2 cells after 72 hrs by WST-1 assay Antiproliferative activity against human HepG2 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
HepG2	GI₅₀	63.48 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 19822426]
HepG2	IC₅₀	0.14 μM Compound: SAHA, Vorinostat	Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells after 48 hrs Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells after 48 hrs	[PMID: 24904967]
HepG2	IC₅₀	0.15 μM Compound: SAHA, Vorinostat	Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells	[PMID: 24904967]
HepG2	IC₅₀	0.18 μM Compound: Vorinostat	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
HepG2	IC₅₀	0.18 μg/mL Compound: Vorinostat	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 31945642]
HepG2	IC₅₀	0.18 μg/mL Compound: Vorinostat	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
HepG2	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
HepG2	IC₅₀	0.41 μM Compound: 1	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
HepG2	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
HepG2	IC₅₀	0.6 nM Compound: SAHA	Inhibition of human HepG2 cells Inhibition of human HepG2 cells	[PMID: 18247554]
HepG2	IC₅₀	0.61 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 37875056]
HepG2	IC₅₀	0.68 μM Compound: Vorinostat	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay	[PMID: 37875056]
HepG2	IC₅₀	0.85 μM Compound: SAHA	Cytotoxicity against human Hep-G2 cells assessed as inhibition of cell proliferation measured after 72 hrs by ATPlite assay Cytotoxicity against human Hep-G2 cells assessed as inhibition of cell proliferation measured after 72 hrs by ATPlite assay	[PMID: 34185525]
HepG2	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
HepG2	IC₅₀	1.14 μM Compound: SAHA	Cytotoxicity against human HepG2 cells incubated for 72 hrs measured by MTT assay Cytotoxicity against human HepG2 cells incubated for 72 hrs measured by MTT assay	[PMID: 37498552]
HepG2	IC₅₀	1.18 μM Compound: Vorinostat	Cytotoxicity against human HepG2 cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by CCK-8 assay	[PMID: 35175762]
HepG2	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
HepG2	IC₅₀	1.27 μM Compound: Vor; SAHA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
HepG2	IC₅₀	1.43 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34237620]
HepG2	IC₅₀	1.49 μM Compound: SAHA, Vorinostat	Cytotoxicity against human HepG2 cells after 48 hrs Cytotoxicity against human HepG2 cells after 48 hrs	[PMID: 24904967]
HepG2	IC₅₀	1.54 μM Compound: 1; SAHA	Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis	[PMID: 36215854]
HepG2	IC₅₀	1.54 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 29150335]
HepG2	IC₅₀	1.66 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after hrs by ATP content assay Antiproliferative activity against human HepG2 cells after hrs by ATP content assay	[PMID: 20143778]
HepG2	IC₅₀	1.7 μM Compound: SAHA; 112	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation by CCK-8 assay	[PMID: 31881454]
HepG2	IC₅₀	1.7 μM Compound: Vorinostat	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability Cytotoxicity against human HepG2 cells assessed as reduction in cell viability	[PMID: 30660827]
HepG2	IC₅₀	10.52 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	10.1039/C5MD00247H
HepG2	IC₅₀	10.77 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	10.1039/C5MD00247H
HepG2	IC₅₀	13 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 35608269]
HepG2	IC₅₀	2 μM Compound: 5; SAHA	Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 31117517]
HepG2	IC₅₀	2.1 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
HepG2	IC₅₀	2.26 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
HepG2	IC₅₀	2.265 μM Compound: SAHA	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
HepG2	IC₅₀	2.4 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35152694]
HepG2	IC₅₀	2.43 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
HepG2	IC₅₀	2.5 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells measured after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 24 hrs by MTT assay	[PMID: 37875056]
HepG2	IC₅₀	2.57 μM Compound: Vorinostat	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
HepG2	IC₅₀	2.8 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
HepG2	IC₅₀	2.9 μM Compound: Vorinostat	Antiproliferative activity against human HepG2 cells by CCK8 assay Antiproliferative activity against human HepG2 cells by CCK8 assay	[PMID: 30660827]
HepG2	IC₅₀	23.62 μM Compound: SAHA	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 26211462]
HepG2	IC₅₀	3.2 ng/mL Compound: SAHA; 1	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 3 days by trypan blue assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 3 days by trypan blue assay	[PMID: 35586423]
HepG2	IC₅₀	3.33 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 29396364]
HepG2	IC₅₀	3.4 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 34624191]
HepG2	IC₅₀	3.81 μM Compound: SAHA	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
HepG2	IC₅₀	3385 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by SRB assay	[PMID: 34454126]
HepG2	IC₅₀	4.1 μM Compound: 1; SAHA	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28885834]
HepG2	IC₅₀	4.5 μM Compound: 1; SAHA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30455152]
HepG2	IC₅₀	4.95 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 31546197]
HepG2	IC₅₀	5.75 μM Compound: 1; SAHA	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
HepG2	IC₅₀	5.9 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 31120744]
HepG2	IC₅₀	5.94 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
HepG2	IC₅₀	514.5 nM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 31177073]
HepG2	IC₅₀	6 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells after 48 hrs by CCK-8 assay	[PMID: 35939996]
HepG2	IC₅₀	6.26 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29288941]
HepG2	IC₅₀	6.26 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30108831]
HepG2	IC₅₀	7.19 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
HepG2	IC₅₀	7.6 μM Compound: SAHA	Cytotoxicity against human HepG2-A16-CD81EGFP cells assessed as inhibition of cell growth incubated for 24 hrs followed by medium transfer and incubation in multimode plate for 48 hrs by CellTiterGlo reagent based luminescence assay Cytotoxicity against human HepG2-A16-CD81EGFP cells assessed as inhibition of cell growth incubated for 24 hrs followed by medium transfer and incubation in multimode plate for 48 hrs by CellTiterGlo reagent based luminescence assay	[PMID: 33360801]
HepG2	IC₅₀	8.78 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	10.1039/C5MD00247H
HepG2	IC₅₀	9.06 μM Compound: I-1; SAHA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 35245830]
HepG2	IC₅₀	9.1 μM Compound: SAHA	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 29348808]
HepG2	IC₅₀	9.3 μM Compound: SAHA	Growth inhibition of human HepG2 cells after 48 hrs by MTT assay Growth inhibition of human HepG2 cells after 48 hrs by MTT assay	[PMID: 20143840]
HepG2	IC₅₀	> 1000 nM Compound: SAHA	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 26443078]
HepG2	IC₅₀	> 50 μM Compound: SAHA	Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
Hepatocyte	EC₅₀	> 500 μM Compound: SAHA	Compound was tested for anti-proliferative activity in human hepatocytes Compound was tested for anti-proliferative activity in human hepatocytes	[PMID: 14698179]
Hepatocyte	GI₅₀	> 500 μM Compound: SAHA	Growth inhibition of human hepatocytes after 21 hrs by MTT assay Growth inhibition of human hepatocytes after 21 hrs by MTT assay	[PMID: 17662606]
Hs-578T	GI₅₀	3.6 μM Compound: SAHA	Antiproliferative activity against human Hs578T cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human Hs578T cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
Hs-578T	GI₅₀	4.83 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay	[PMID: 24015327]
Hs-578T	GI₅₀	5 μM Compound: SAHA, Zolinza	Growth inhibition of human Hs 578T cells after 72 hrs by MTS assay Growth inhibition of human Hs 578T cells after 72 hrs by MTS assay	[PMID: 22435669]
Hs68	IC₅₀	4.6 μM Compound: SAHA	Cytotoxicity against human HS68 cells after 72 hrs by MTT assay Cytotoxicity against human HS68 cells after 72 hrs by MTT assay	[PMID: 23570542]
HuP-T3	IC₅₀	0.8 μM Compound: 1a, SAHA	Growth inhibition of human HUPT3 cells after 72 hrs by MTS assay Growth inhibition of human HUPT3 cells after 72 hrs by MTS assay	[PMID: 20055418]
HuP-T3	IC₅₀	0.8 μM Compound: SAHA	Cytotoxicity against human Hup T3 cells after 72 hrs by MTT assay Cytotoxicity against human Hup T3 cells after 72 hrs by MTT assay	[PMID: 18494463]
HuP-T3	IC₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human HupT3 cells after 72 hrs by MTT assay Antiproliferative activity against human HupT3 cells after 72 hrs by MTT assay	[PMID: 18642892]
HuP-T3	IC₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human HUPT3 cells by MTT assay Antiproliferative activity against human HUPT3 cells by MTT assay	[PMID: 19419863]
HuT78	EC₅₀	290 nM Compound: 1	Pro-apoptotic activity in human HUT78 cells after 18 hrs by caspase-Glo 3/7 assay Pro-apoptotic activity in human HUT78 cells after 18 hrs by caspase-Glo 3/7 assay	[PMID: 30122227]
HuT78	GI₅₀	2.1 μM Compound: Vorin	Cytotoxicity against human HUT78 cells after 72 hrs by MTS assay Cytotoxicity against human HUT78 cells after 72 hrs by MTS assay	[PMID: 24900743]
HuT78	GI₅₀	295 nM Compound: SAHA, vorinostat	Antiproliferative activity against human HUT78 cells after 72 hrs by WST-1 assay Antiproliferative activity against human HUT78 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
HuT78	GI₅₀	3 μM Compound: 2, SAHA, Vorinostat	Cytotoxicity against human HUT78 cells after 72 hrs by MTS-PMS assay Cytotoxicity against human HUT78 cells after 72 hrs by MTS-PMS assay	[PMID: 24164245]
HuT78	GI₅₀	300 nM Compound: SAHA	Growth inhibition of human HUT78 cells after 72 hrs by SRB assay Growth inhibition of human HUT78 cells after 72 hrs by SRB assay	[PMID: 20884208]
HuT78	IC₅₀	0.68 μM Compound: Vorinostat	Cytotoxicity against human HuT78 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay Cytotoxicity against human HuT78 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay	[PMID: 37875056]
HuT78	IC₅₀	0.71 μM Compound: 1; SAHA	Cytotoxicity against human HuT78 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HuT78 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
Huh-7	CC₅₀	0.64 μM Compound: Vorinostat	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 31201063]
Huh-7	CC₅₀	1.9 μM Compound: 5, SAHA	Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay	[PMID: 25490700]
Huh-7	EC₅₀	0.36 μM Compound: 5, SAHA	Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay	[PMID: 25490700]
Huh-7	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
Huh-7	IC₅₀	0.9 μM Compound: Vorinostat	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
Huh-7	IC₅₀	1.2 μM Compound: SAHA	Antiproliferative activity against human HuH7 cells after 72 hrs by CellTiter blue-reagent based assay Antiproliferative activity against human HuH7 cells after 72 hrs by CellTiter blue-reagent based assay	[PMID: 30645113]
Huh-7	IC₅₀	1.65 μM Compound: SAHA	Cytotoxicity against human Huh-7 cells incubated for 72 hrs measured by MTT assay Cytotoxicity against human Huh-7 cells incubated for 72 hrs measured by MTT assay	[PMID: 37498552]
Huh-7	IC₅₀	1.95 μM Compound: Vor; SAHA	Antiproliferative activity against human HuH-7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human HuH-7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
Huh-7	IC₅₀	3.88 μM Compound: SAHA	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
Huh-7	IC₅₀	4.3 μM Compound: 5; SAHA	Antiproliferative activity against human HuH7 cells after 96 hrs by MTT assay Antiproliferative activity against human HuH7 cells after 96 hrs by MTT assay	[PMID: 31117517]
Huh-7	IC₅₀	4.95 μM Compound: SAHA	Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay	[PMID: 29288941]
Huh-7	IC₅₀	5.1 μM Compound: SAHA	Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay	[PMID: 31120744]
IGROV-1	GI₅₀	1.1 μM Compound: SAHA	Antiproliferative activity against human IGROV1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human IGROV1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
IGROV-1	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human IGROV1 cells after 72 hrs by MTS assay Growth inhibition of human IGROV1 cells after 72 hrs by MTS assay	[PMID: 22435669]
IGROV-1	IC₅₀	2.2 μM Compound: SAHA	Antiproliferative activity against cisplatin-resistant human IGROV1 cells after 72 hrs Antiproliferative activity against cisplatin-resistant human IGROV1 cells after 72 hrs	[PMID: 19084294]
IGROV-1	IC₅₀	2.2 μM Compound: SAHA	Antiproliferative activity against human IGROV1 cells after 72 hrs Antiproliferative activity against human IGROV1 cells after 72 hrs	[PMID: 19084294]
IGROV-1	IC₅₀	2.2 μM Compound: SAHA	Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs	[PMID: 24742384]
IGROV-1	IC₅₀	2.2 μM Compound: SAHA	Antiproliferative activity against p53 defective cis-platinum-resistant human IGROV1/Pt1 cells assessed as growth inhibition after 72 hrs Antiproliferative activity against p53 defective cis-platinum-resistant human IGROV1/Pt1 cells assessed as growth inhibition after 72 hrs	[PMID: 24742384]
IGROV-1	IC₅₀	2.2 μM Compound: SAHA	Growth inhibition of human IGROV1 cells after 72 hrs Growth inhibition of human IGROV1 cells after 72 hrs	[PMID: 26376355]
IGROV-1	IC₅₀	2.2 μM Compound: SAHA	Growth inhibition of human IGROV1/Pt1 cells after 72 hrs Growth inhibition of human IGROV1/Pt1 cells after 72 hrs	[PMID: 26376355]
IGROV-1	IC₅₀	2.2 μM Compound: SAHA	Antiproliferative activity against human IGROV1 cells assessed as reduction in cell number after 72 hrs by cell counter analysis Antiproliferative activity against human IGROV1 cells assessed as reduction in cell number after 72 hrs by cell counter analysis	[PMID: 26890116]
IMR-32	IC₅₀	0.62 μM Compound: Vorinostat	Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay	[PMID: 31391882]
JeKo-1	IC₅₀	0.18 μM Compound: SAHA	Antiproliferative activity against human JeKo-1 cells incubated for 48 hrs by resazurin based microplate reader analysis Antiproliferative activity against human JeKo-1 cells incubated for 48 hrs by resazurin based microplate reader analysis	[PMID: 37647727]
JeKo-1	IC₅₀	0.42 μM Compound: SAHA	Antiproliferative activity against human JeKo1 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay Antiproliferative activity against human JeKo1 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	[PMID: 26890114]
JeKo-1	IC₅₀	285 nM Compound: 1; SAHA	Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin staining based assay Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin staining based assay	[PMID: 39047608]
JeKo-1	IC₅₀	3.5 μM Compound: SAHA	Antiproliferative activity against human JeKo1 cells after 72 hrs by MTT assay Antiproliferative activity against human JeKo1 cells after 72 hrs by MTT assay	[PMID: 29150335]
JeKo-1	IC₅₀	638.6 nM Compound: SAHA	Antiproliferative activity against human JeKo1 cells after 72 hrs by MTT assay Antiproliferative activity against human JeKo1 cells after 72 hrs by MTT assay	[PMID: 31177073]
Jurkat	EC₅₀	0.72 μM Compound: SAHA	Growth inhibition of human Jurkat cells after 44 hrs by MTT assay Growth inhibition of human Jurkat cells after 44 hrs by MTT assay	[PMID: 28337317]
Jurkat	EC₅₀	0.87 μM Compound: 1a, SAHA	Antiproliferative activity against human Jurkat JA16 cells after 48 hrs by cell titer-glo assay Antiproliferative activity against human Jurkat JA16 cells after 48 hrs by cell titer-glo assay	[PMID: 20218673]
Jurkat	EC₅₀	1.66 μM Compound: SAHA	Cytotoxicity against human Jurkat cells assessed as cell proliferation after 70 hrs by MTS assay Cytotoxicity against human Jurkat cells assessed as cell proliferation after 70 hrs by MTS assay	[PMID: 25974739]
Jurkat	EC₅₀	1600 nM Compound: Vorinostat	Inhibition of class 1 HDAC in human Jurkat model of HIV latency assessed as reactivation of HIV latency incubated for 20 hrs in presence of 5% NHS by Steady-Glo luciferase assay Inhibition of class 1 HDAC in human Jurkat model of HIV latency assessed as reactivation of HIV latency incubated for 20 hrs in presence of 5% NHS by Steady-Glo luciferase assay	[PMID: 32676157]
Jurkat	EC₅₀	2.3 μM Compound: SAHA	Compound was tested for anti-proliferative activity in Jurkat human leukemia cell line Compound was tested for anti-proliferative activity in Jurkat human leukemia cell line	[PMID: 14698179]
Jurkat	GI₅₀	0.9 μM Compound: Vorin	Cytotoxicity against human Jurkat cells after 72 hrs by MTS assay Cytotoxicity against human Jurkat cells after 72 hrs by MTS assay	[PMID: 24900743]
Jurkat	GI₅₀	1.1 μM Compound: 1, SAHA	Growth inhibition of human Jurkat cells after 72 hrs by XTT assay Growth inhibition of human Jurkat cells after 72 hrs by XTT assay	[PMID: 24900500]
Jurkat	GI₅₀	2.4 μM Compound: 1	Growth inhibition of human Jurkat cells Growth inhibition of human Jurkat cells	[PMID: 37429084]
Jurkat	IC₅₀	0.04 μM Compound: 4, SAHA	Inhibition of HDAC4 in human Jurkat E6.1 cells using Boc-Lys-Ac as substrate incubated for 2 hrs prior to substrate addition measured after 3 hrs by fluorescence assay Inhibition of HDAC4 in human Jurkat E6.1 cells using Boc-Lys-Ac as substrate incubated for 2 hrs prior to substrate addition measured after 3 hrs by fluorescence assay	[PMID: 24261862]
Jurkat	IC₅₀	0.1 μM Compound: 1; SAHA	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33668008]
Jurkat	IC₅₀	0.1 μM Compound: Vorinostat	Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay	[PMID: 37989057]
Jurkat	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
Jurkat	IC₅₀	0.27 μM Compound: 3; SAHA	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30901208]
Jurkat	IC₅₀	0.3 μM Compound: SAHA	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35043615]
Jurkat	IC₅₀	0.35 μM Compound: SAHA	Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 29533873]
Jurkat	IC₅₀	0.38 μM Compound: SAHA	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
Jurkat	IC₅₀	0.47 μM Compound: Vorinostat	Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 36351184]
Jurkat	IC₅₀	0.47 μM Compound: Vorinostat	Cytotoxicity against human Jurkat cells measured for 72 hrs by celltiter-glo assay Cytotoxicity against human Jurkat cells measured for 72 hrs by celltiter-glo assay	[PMID: 38714044]
Jurkat	IC₅₀	0.59 μM Compound: 1; SAHA	Antiproliferative activity against human Jurkat cells Antiproliferative activity against human Jurkat cells	[PMID: 27541357]
Jurkat	IC₅₀	0.59 μM Compound: 2	Antiproliferative activity against human Jurkat cells Antiproliferative activity against human Jurkat cells	[PMID: 28953386]
Jurkat	IC₅₀	0.59 μM Compound: 4	Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 30243158]
Jurkat	IC₅₀	0.61 μM Compound: Vorinostat	Antiproliferative activity against human Jurkat cells Antiproliferative activity against human Jurkat cells	[PMID: 37875056]
Jurkat	IC₅₀	0.68 μM Compound: Vorinostat	Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based assay	[PMID: 37875056]
Jurkat	IC₅₀	0.7 μM Compound: 1; SAHA	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs MTT assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs MTT assay	[PMID: 33668008]
Jurkat	IC₅₀	1.18 μM Compound: SAHA	Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 29500131]
Jurkat	IC₅₀	1.49 μM Compound: SAHA	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23547652]
Jurkat	IC₅₀	1.49 μM Compound: SAHA	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 24304348]
Jurkat	IC₅₀	1.49 μM Compound: SAHA	Cytotoxicity against human Jurkat cells Cytotoxicity against human Jurkat cells	[PMID: 25240614]
Jurkat	IC₅₀	10 nM Compound: 5; SAHA	Inhibition of HDAC1 in human Jurkat cells extract after 30 mins by immunoprecipitation assay Inhibition of HDAC1 in human Jurkat cells extract after 30 mins by immunoprecipitation assay	[PMID: 27177826]
Jurkat	IC₅₀	20 nM Compound: 5; SAHA	Inhibition of HDAC3 in human Jurkat cells extract after 30 mins by immunoprecipitation assay Inhibition of HDAC3 in human Jurkat cells extract after 30 mins by immunoprecipitation assay	[PMID: 27177826]
Jurkat	IC₅₀	3.62 μM Compound: SAHA	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 37079967]
Jurkat	IC₅₀	32 μM Compound: 1; SAHA	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 24 hrs MTT assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 24 hrs MTT assay	[PMID: 33668008]
Jurkat	IC₅₀	702 nM Compound: 1; SAHA	Antiproliferative activity against human Jurkat cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Jurkat cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
Jurkat	IC₅₀	9.33 μM Compound: SAHA	Antiproliferative activity against human Jurkat cells incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human Jurkat cells incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 39145486]
Jurkat	IC₅₀	> 10 μM Compound: 4, SAHA	Inhibition of HDAC4 in human Jurkat E6.1 cells using Boc-Lys-TFA as substrate incubated for 2 hrs prior to substrate addition measured after 3 hrs by fluorescence assay Inhibition of HDAC4 in human Jurkat E6.1 cells using Boc-Lys-TFA as substrate incubated for 2 hrs prior to substrate addition measured after 3 hrs by fluorescence assay	[PMID: 24261862]
Jurkat	IC₅₀	> 30 μM Compound: 3; SAHA	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36449947]
K562	EC₅₀	2.2 μM Compound: 1a, SAHA	Antiproliferative activity against human K562 cells after 48 hrs by cell titer-glo assay Antiproliferative activity against human K562 cells after 48 hrs by cell titer-glo assay	[PMID: 20218673]
K562	ED₅₀	0.45791 μM Compound: 5; SAHA	Potentiation of (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as (-)-lomaiviticin A ED50 at compound to (-)-lomaiviticin A ratio of 5000:1 after 48 hrs by cell titer-glo luminescence assay (Rvb = 0.23776 nM) Potentiation of (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as (-)-lomaiviticin A ED50 at compound to (-)-lomaiviticin A ratio of 5000:1 after 48 hrs by cell titer-glo luminescence assay (Rvb = 0.23776 nM)	[PMID: 27177826]
K562	ED₅₀	1.24803 μM Compound: 5; SAHA	Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by cell titer-glo luminescence assay Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by cell titer-glo luminescence assay	[PMID: 27177826]
K562	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human K562 cells after 72 hrs by MTS assay Growth inhibition of human K562 cells after 72 hrs by MTS assay	[PMID: 22435669]
K562	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human K562 cells after 72 hrs by MTS assay Growth inhibition of human K562 cells after 72 hrs by MTS assay	[PMID: 22435669]
K562	GI₅₀	0.52 μM Compound: SAHA	Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay	[PMID: 25800646]
K562	GI₅₀	0.9 μM Compound: SAHA	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	[PMID: 34500130]
K562	GI₅₀	1.97 μM Compound: vorinostat, SAHA	Antiproliferative activity against human K562 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
K562	GI₅₀	3.66 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28629630]
K562	IC₅₀	0.11 μM Compound: SAHA	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35152694]
K562	IC₅₀	0.14 μM Compound: SAHA	Inhibition of HDAC in human K562 cell extract using Fluor-de-Lys deacetylase as substrate preincubated for 45 mins measured after 15 mins by fluorescence assay Inhibition of HDAC in human K562 cell extract using Fluor-de-Lys deacetylase as substrate preincubated for 45 mins measured after 15 mins by fluorescence assay	[PMID: 24328302]
K562	IC₅₀	0.17 μM Compound: 1; SAHA	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay	[PMID: 27142751]
K562	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
K562	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
K562	IC₅₀	0.21 nM Compound: 1; SAHA	Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay	[PMID: 36622852]
K562	IC₅₀	0.35 μM Compound: SAHA	Antiproliferative activity against human K562 cells incubated for 48 hrs by resazurin based microplate reader analysis Antiproliferative activity against human K562 cells incubated for 48 hrs by resazurin based microplate reader analysis	[PMID: 37647727]
K562	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human K562 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
K562	IC₅₀	0.52 μM Compound: 1	Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
K562	IC₅₀	0.54 μM Compound: SAHA	Antiproliferative activity against human K562 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human K562 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
K562	IC₅₀	0.55 μM Compound: 1; SAHA	Antiproliferative activity against human K562 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human K562 cells incubated for 48 hrs by CCK8 assay	[PMID: 37037787]
K562	IC₅₀	0.56 μM Compound: SAHA	Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
K562	IC₅₀	0.64 μM Compound: SAHA, Vorinostat	Antiproliferative activity against human K562 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human K562 cells after 72 hrs by CellTiter-Glo assay	[PMID: 23792316]
K562	IC₅₀	0.645 μM Compound: SAHA	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 23644210]
K562	IC₅₀	0.645 μM Compound: vorinostat	Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay	[PMID: 26629860]
K562	IC₅₀	0.65 μM Compound: SAHA	Cytotoxicity against human K562 cells after 72 hrs by CellTiter-Glo assay Cytotoxicity against human K562 cells after 72 hrs by CellTiter-Glo assay	[PMID: 30245394]
K562	IC₅₀	0.67 μM Compound: 2	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 17691763]
K562	IC₅₀	0.67 μM Compound: 6, SAHA	Cytotoxicity against human K562 cells after 72 hrs by alamar-blue cell viability assay Cytotoxicity against human K562 cells after 72 hrs by alamar-blue cell viability assay	[PMID: 19301902]
K562	IC₅₀	0.68 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 29533873]
K562	IC₅₀	0.68 μM Compound: SAHA	Antiproliferative activity against human K562 cells measured after 72 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
K562	IC₅₀	0.75 μM Compound: 3, SAHA	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 18038969]
K562	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
K562	IC₅₀	0.9 μM Compound: SAHA	Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 34624191]
K562	IC₅₀	0.98 μM Compound: SAHA	Anti-proliferative activity against human K562 cells after 48 hrs by MTT assay Anti-proliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28947154]
K562	IC₅₀	1 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by trypan blue dye exclusion method Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by trypan blue dye exclusion method	[PMID: 25221651]
K562	IC₅₀	1.02 μM Compound: Vor; SAHA	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
K562	IC₅₀	1.03 μM Compound: 3; SAHA	Synergistic antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs in presence of ruxolitinib by MTT assay Synergistic antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs in presence of ruxolitinib by MTT assay	[PMID: 30901208]
K562	IC₅₀	1.11 μM Compound: 3; SAHA	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30901208]
K562	IC₅₀	1.17 μM Compound: SAHA	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 36272186]
K562	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human K562 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
K562	IC₅₀	1.29 μM Compound: SAHA	Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK-8 assay	[PMID: 37057760]
K562	IC₅₀	1.35 μM Compound: SAHA	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 33132117]
K562	IC₅₀	1.35 μM Compound: Vorinostat	Cytotoxicity against human K562 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
K562	IC₅₀	1.391 μM Compound: SAHA	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 35926141]
K562	IC₅₀	1.41 μM Compound: Vorinostat	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 37875056]
K562	IC₅₀	1.44 μM Compound: SAHA, Zolinza	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 26100440]
K562	IC₅₀	1.45 μM Compound: SAHA	Antiproliferative activity against human K562 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells incubated for 48 hrs by MTT assay	[PMID: 31413795]
K562	IC₅₀	1.49 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28336407]
K562	IC₅₀	1.49 μM Compound: Vorinostat	Cytotoxicity against human K562 cells assessed as cell growth inhibition Cytotoxicity against human K562 cells assessed as cell growth inhibition	[PMID: 38107170]
K562	IC₅₀	1.51 μM Compound: SAHA	Antiproliferative activity against human K562 cells incubated for 24 hrs by CCK8 assay Antiproliferative activity against human K562 cells incubated for 24 hrs by CCK8 assay	[PMID: 32247729]
K562	IC₅₀	1.52 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 29787262]
K562	IC₅₀	1.61 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 25311567]
K562	IC₅₀	1.8 μM Compound: 1; SAHA	Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay	[PMID: 36622852]
K562	IC₅₀	1.91 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 28419930]
K562	IC₅₀	1.91 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 28601509]
K562	IC₅₀	1.95 μM Compound: Vorinostat	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28371677]
K562	IC₅₀	10 nM Compound: SAHA	Inhibition of human histone deacetylase (mixture of HDAC1 and HDAC2) prepared from K562 erythroleukemia cells. Inhibition of human histone deacetylase (mixture of HDAC1 and HDAC2) prepared from K562 erythroleukemia cells.	[PMID: 12419380]
K562	IC₅₀	10 μM Compound: 5; SAHA	Antiproliferative activity against human K562 cells after 96 hrs by MTT assay Antiproliferative activity against human K562 cells after 96 hrs by MTT assay	[PMID: 31117517]
K562	IC₅₀	120 nM Compound: 1	Concentration required to inhibit Histone Deacetylase (HDAC) from K562 erythroleukemia cells Concentration required to inhibit Histone Deacetylase (HDAC) from K562 erythroleukemia cells	[PMID: 12270175]
K562	IC₅₀	140 nM Compound: 1	Inhibitory activity against histone deacetylase (HDAC1 and HDAC2) isolated from K562 erythroleukemia cells Inhibitory activity against histone deacetylase (HDAC1 and HDAC2) isolated from K562 erythroleukemia cells	[PMID: 14552787]
K562	IC₅₀	140 nM Compound: 1; SAHA	Inhibition of HDAC in human K562 nuclear extract Inhibition of HDAC in human K562 nuclear extract	[PMID: 31655430]
K562	IC₅₀	140 nM Compound: SAHA	Inhibition of HDAC from human K562 cells Inhibition of HDAC from human K562 cells	[PMID: 18247554]
K562	IC₅₀	143 nM Compound: 24; SAHA	Inhibition of HDAC in human K562 cell extracts using (QSY-7)-RGGRGLGK(Ac)-GGARRHRK(TAMRA)NH2 as substrate preincubated for 30 mins followed by addition of endoproteinase Lys-C and measured after 2 hrs by fluorescence assay Inhibition of HDAC in human K562 cell extracts using (QSY-7)-RGGRGLGK(Ac)-GGARRHRK(TAMRA)NH2 as substrate preincubated for 30 mins followed by addition of endoproteinase Lys-C and measured after 2 hrs by fluorescence assay	[PMID: 31536895]
K562	IC₅₀	2 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay	[PMID: 35939996]
K562	IC₅₀	2.24 μM Compound: 3; SAHA	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36449947]
K562	IC₅₀	2.26 μM Compound: SAHA	Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
K562	IC₅₀	2.9 μM Compound: SAHA	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
K562	IC₅₀	2.93 μM Compound: XII; SAHA	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
K562	IC₅₀	3.24 μM Compound: SA, SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 24694055]
K562	IC₅₀	3.24 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 25462271]
K562	IC₅₀	3.32 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 21476600]
K562	IC₅₀	3.77 μM Compound: 1, SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 24525003]
K562	IC₅₀	3.88 μM Compound: SAHA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 30879863]
K562	IC₅₀	3.89 μM Compound: SAHA	Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26349626]
K562	IC₅₀	3.94 μM Compound: SAHA	Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26149591]
K562	IC₅₀	370 nM Compound: 1; SAHA	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin staining based assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin staining based assay	[PMID: 39047608]
K562	IC₅₀	38 μM Compound: SAHA, Vorinostat	Cytotoxicity against human K562 cells assessed as reduction in cell viability Cytotoxicity against human K562 cells assessed as reduction in cell viability	[PMID: 26264503]
K562	IC₅₀	4.95 μM Compound: SAHA	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 31546197]
K562	IC₅₀	444 nM Compound: SAHA	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 26443078]
K562	IC₅₀	7.7 μM Compound: 2; SAHA	Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay	[PMID: 29940115]
K562	IC₅₀	828 nM Compound: 1; SAHA	Antiproliferative activity against human K562 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
K562/A02	IC₅₀	3.13 μM Compound: SAHA	Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay	[PMID: 33132117]
KB	IC₅₀	0.75 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 24766560]
KB	IC₅₀	1.8 μM Compound: SAHA	Cytotoxicity against human KB cells after 72 hrs by MTS assay Cytotoxicity against human KB cells after 72 hrs by MTS assay	[PMID: 25899338]
KB-V1	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human KB-V1 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human KB-V1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
KB-V1	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human vinblastine resistant KB-V1 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human vinblastine resistant KB-V1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
KG-1	IC₅₀	0.07 μM Compound: SAHA	Antiproliferative activity against human KG-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human KG-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35152694]
KG-1	IC₅₀	0.21 μM Compound: Vorinostat	Antiproliferative activity against human KG-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human KG-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
KG-1	IC₅₀	0.59 μM Compound: 1; SAHA	Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
KG-1	IC₅₀	0.64 μM Compound: SAHA, Zolinza	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	[PMID: 26100440]
KG-1	IC₅₀	0.68 μM Compound: 1, SAHA	Cytotoxicity against human KG1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human KG1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26122774]
KG-1	IC₅₀	0.68 μM Compound: 6, SAHA	Cytotoxicity against human KG1 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human KG1 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25906087]
KG-1	IC₅₀	0.79 μM Compound: SAHA; 6	Antiproliferative activity against human KG-1 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human KG-1 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
KG-1	IC₅₀	0.9 μM Compound: SAHA	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	[PMID: 26907204]
KG-1	IC₅₀	1.11 μM Compound: SAHA	Cytotoxicity against human KG1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human KG1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C4MD00203B
KG-1	IC₅₀	1.15 μM Compound: 1, SAHA	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	[PMID: 24525003]
KG-1	IC₅₀	1.52 μM Compound: SAHA	Antiproliferative activity against human KG1 cells after 72 hrs by MTT assay Antiproliferative activity against human KG1 cells after 72 hrs by MTT assay	[PMID: 29787262]
KG-1	IC₅₀	1.59 μM Compound: SA, SAHA	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	[PMID: 24694055]
KG-1	IC₅₀	1.59 μM Compound: SAHA	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	[PMID: 25462271]
KG-1	IC₅₀	1.59 μM Compound: SAHA	Antiproliferative activity against human KG-1 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human KG-1 cells incubated for 72 hrs by MTT assay	[PMID: 32961382]
KG-1	IC₅₀	2.75 μM Compound: SAHA	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	[PMID: 26216016]
KM-H2	IC₅₀	1.54 μM Compound: SAHA	Antiproliferative activity against human KM-H2 cells after 72 hrs by MTT assay Antiproliferative activity against human KM-H2 cells after 72 hrs by MTT assay	[PMID: 29150335]
KM12	GI₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human KM12 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human KM12 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
KM12	GI₅₀	1.88 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human KM12 cells after 48 hrs by SRB assay Cytotoxicity against human KM12 cells after 48 hrs by SRB assay	[PMID: 24015327]
KM12	GI₅₀	2 μM Compound: SAHA, Zolinza	Growth inhibition of human KM12 cells after 72 hrs by MTS assay Growth inhibition of human KM12 cells after 72 hrs by MTS assay	[PMID: 22435669]
KM3/BTZ	IC₅₀	78.2 nM Compound: SAHA	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells in presence of bortezomib incubated for 48 hrs by MTT assay Antiproliferative activity against bortezomib resistant human KM3/BTZ cells in presence of bortezomib incubated for 48 hrs by MTT assay	[PMID: 32267687]
KM3/BTZ	IC₅₀	860 nM Compound: SAHA	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
KMS-12-BM	EC₅₀	0.94 μM Compound: 3; SAHA	Antiproliferative activity against human KMS-12-BM cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human KMS-12-BM cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31627059]
KMS-12-BM	IC₅₀	0.94 μM Compound: 1; SAHA	Antiproliferative activity against human KMS-12-BM cells after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human KMS-12-BM cells after 48 hrs by CellTiter-Glo assay	[PMID: 27541357]
KMS-12-BM	IC₅₀	0.94 μM Compound: 2	Antiproliferative activity against human KMS-12-BM cells after 48 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human KMS-12-BM cells after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 28953386]
KMS-12-BM	IC₅₀	0.94 μM Compound: 4	Antiproliferative activity against human KMS-12-BM cells after 72 hrs by MTT assay Antiproliferative activity against human KMS-12-BM cells after 72 hrs by MTT assay	[PMID: 30243158]
KYSE-30	IC₅₀	3 μM Compound: Vorinostat	Antiproliferative activity against human KYSE-30 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human KYSE-30 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
KYSE-450	IC₅₀	6.478 μM Compound: Vorinostat	Antiproliferative activity against human KYSE-450 cells Antiproliferative activity against human KYSE-450 cells	[PMID: 37875056]
KYSE-510	IC₅₀	0.59 μM Compound: SAHA, vorinostat	Inhibition of HDAC in cisplatin resistant human KYSE-510 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human KYSE-510 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
KYSE-510	IC₅₀	0.7 μM Compound: SAHA, vorinostat	Inhibition of HDAC in cisplatin sensitive human KYSE-510 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin sensitive human KYSE-510 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
KYSE-510	IC₅₀	4.62 μM Compound: SAHA, vorinostat	Cytotoxicity against cisplatin sensitive human KYSE-510 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin sensitive human KYSE-510 cells after 72 hrs by MTT assay	[PMID: 23252603]
KYSE-510	IC₅₀	4.66 μM Compound: SAHA, vorinostat	Cytotoxicity against cisplatin resistant human KYSE-510 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human KYSE-510 cells after 72 hrs by MTT assay	[PMID: 23252603]
Kasumi 1	IC₅₀	0.38 μM Compound: SAHA	Inhibition of cell viability in human Kasumi 1 cells incubated for 4 days in presence of GSK5032 by CCK8 assay Inhibition of cell viability in human Kasumi 1 cells incubated for 4 days in presence of GSK5032 by CCK8 assay	[PMID: 39264152]
Kasumi 1	IC₅₀	0.65 μM Compound: SAHA	Inhibition of cell viability in human Kasumi 1 cells incubated for 4 days by CCK8 assay Inhibition of cell viability in human Kasumi 1 cells incubated for 4 days by CCK8 assay	[PMID: 39264152]
Kasumi 1	IC₅₀	620 nM Compound: Vorinostat	Cytotoxicity against human Kasumi 1 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human Kasumi 1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
L-363	IC₅₀	0.48 μM Compound: 4; SAHA	Antiproliferative activity against human L-363 cells Antiproliferative activity against human L-363 cells	[PMID: 37652098]
L-428	IC₅₀	0.87 μM Compound: SAHA	Antiproliferative activity against human L428 cells after 72 hrs by MTT assay Antiproliferative activity against human L428 cells after 72 hrs by MTT assay	[PMID: 29150335]
L-428	IC₅₀	2.3 μM Compound: SAHA	Antiproliferative activity against human L-428 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human L-428 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
L02	IC₅₀	0.948 μM Compound: SAHA	Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
L02	IC₅₀	1.35 μM Compound: SAHA	Cytotoxicity against human HL7702 cells measured after 72 hrs by MTT assay Cytotoxicity against human HL7702 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
L02	IC₅₀	27.4 μM Compound: SAHA	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33021789]
L02	IC₅₀	5.45 μM Compound: Vorinostat	cytotoxicity against human HL-7702 cells assessed as reduction of cell viability incubated for 72 hrs by MTT assay cytotoxicity against human HL-7702 cells assessed as reduction of cell viability incubated for 72 hrs by MTT assay	[PMID: 33493830]
L02	IC₅₀	7.23 μM Compound: SAHA	Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
L02	IC₅₀	> 10 μM Compound: SAHA	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
L02	IC₅₀	> 100 μM Compound: SAHA	Cytotoxicity against human HL7702 cells incubated for 48 hrs by resazurin based microplate reader analysis Cytotoxicity against human HL7702 cells incubated for 48 hrs by resazurin based microplate reader analysis	[PMID: 37647727]
L02	IC₅₀	> 50 μM Compound: SAHA	Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34509167]
L02	IC₅₀	> 50000 nM Compound: SAHA	Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
L1210	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against mouse L1210 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse L1210 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
L1210	IC₅₀	1.5 μM Compound: SAHA	Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
L6	IC₅₀	266 nM Compound: 1, SAHA	Cytotoxicity against rat L6 cells Cytotoxicity against rat L6 cells	[PMID: 25563890]
LNCaP	GI₅₀	1.3 μM Compound: SAHA	Antiproliferative activity against human LNCaP cells assessed as growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human LNCaP cells assessed as growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37633202]
LNCaP	IC₅₀	0.58 μM Compound: SAHA	Antiproliferative activity against human LNCAP cells Antiproliferative activity against human LNCAP cells	[PMID: 20143778]
LNCaP	IC₅₀	0.69 μM Compound: SAHA	Antiproliferative activity against human LNCAP cells incubated for 96 hrs by resazurin assay Antiproliferative activity against human LNCAP cells incubated for 96 hrs by resazurin assay	[PMID: 32435375]
LNCaP	IC₅₀	1 μM Compound: 5, SAHA	Antiproliferative activity against human LNCap by MTT assay Antiproliferative activity against human LNCap by MTT assay	[PMID: 18166465]
LNCaP	IC₅₀	1 μM Compound: SAHA	Concentration required to inhibit human LNCaP prostate carcinoma cells Concentration required to inhibit human LNCaP prostate carcinoma cells	[PMID: 16033284]
LNCaP	IC₅₀	1.22 μM Compound: SAHA	Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
LNCaP	IC₅₀	1.34 μM Compound: 1; SAHA	Antiproliferative activity against human LNCaP cells incubated for 96 hrs by MTT assay Antiproliferative activity against human LNCaP cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
LNCaP	IC₅₀	1.8 μM Compound: SAHA	Cytotoxicity against human LNCAP cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human LNCAP cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 28131715]
LNCaP	IC₅₀	2.31 μM Compound: SAHA	Cytotoxicity against human LNCAP cells assessed as growth inhibition by MTS assay Cytotoxicity against human LNCAP cells assessed as growth inhibition by MTS assay	[PMID: 23547652]
LNCaP	IC₅₀	2.31 μM Compound: SAHA	Cytotoxicity against androgen-dependent human LNCAP cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against androgen-dependent human LNCAP cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 24304348]
LNCaP	IC₅₀	2.31 μM Compound: SAHA	Cytotoxicity against human LNCAP cells Cytotoxicity against human LNCAP cells	[PMID: 25240614]
LNCaP	IC₅₀	2.31 μM Compound: SAHA	Inhibition of HDAC6 in human LNCAP cells assessed as tubulin acetylation by Western blot analysis Inhibition of HDAC6 in human LNCAP cells assessed as tubulin acetylation by Western blot analysis	[PMID: 25240614]
LOX IMVI	EC₅₀	1.3 μM Compound: SAHA	Inhibition of human LOX-IMVI cells Inhibition of human LOX-IMVI cells	[PMID: 18247554]
LOX IMVI	EC₅₀	1.3 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human LOX-IMVI cells Effective Concentration of compound to inhibit the growth of human LOX-IMVI cells	[PMID: 15715470]
LOX IMVI	GI₅₀	1 μM Compound: SAHA, Zolinza	Growth inhibition of human LOXIMVI cells after 72 hrs by MTS assay Growth inhibition of human LOXIMVI cells after 72 hrs by MTS assay	[PMID: 22435669]
LOX IMVI	GI₅₀	1.2 μM Compound: SAHA	Antiproliferative activity against human LOXIMVI cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human LOXIMVI cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
LOX IMVI	GI₅₀	1.3 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human LOXIMVI cells after 48 hrs by sulforhodamine B assay Growth inhibition of human LOXIMVI cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
LOX IMVI	GI₅₀	1.39 μM Compound: 1, SAHA	Growth inhibition of LOX-IMVI cells by SRB assay Growth inhibition of LOX-IMVI cells by SRB assay	[PMID: 17477518]
LOX IMVI	GI₅₀	1.39 μM Compound: 2, SAHA	Antiproliferative activity against human LOX-IMVI cells by SRB assay Antiproliferative activity against human LOX-IMVI cells by SRB assay	[PMID: 16723227]
LOX IMVI	GI₅₀	1.6 μM Compound: SAHA	Growth inhibition of human LOX-IMVI cells after 21 hrs by MTT assay Growth inhibition of human LOX-IMVI cells after 21 hrs by MTT assay	[PMID: 17662606]
LP-1	IC₅₀	1.39 μM Compound: SAHA	Antiproliferative activity against human LP-1 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay Antiproliferative activity against human LP-1 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	[PMID: 26890114]
LoVo	GI₅₀	1700 nM Compound: SAHA, vorinostat	Antiproliferative activity against human LoVo cells after 72 hrs by WST-1 assay Antiproliferative activity against human LoVo cells after 72 hrs by WST-1 assay	[PMID: 21080647]
LoVo	IC₅₀	2.15 μM Compound: SAHA	Antiproliferative activity against human LoVo cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
LoVo	IC₅₀	3.7 μM Compound: SAHA	Antiproliferative activity against human LoVo cells assessed as reduction in cell number after 72 hrs by cell counter analysis Antiproliferative activity against human LoVo cells assessed as reduction in cell number after 72 hrs by cell counter analysis	[PMID: 26890116]
LoVo	IC₅₀	4.95 μM Compound: SAHA	Antiproliferative activity against human LoVo cells by MTT assay Antiproliferative activity against human LoVo cells by MTT assay	[PMID: 31546197]
LoVo	IC₅₀	6.75 μM Compound: SAHA	Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
LoVo	IC₅₀	6.75 μM Compound: SAHA	Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay	[PMID: 30108831]
M14	GI₅₀	1.3 μM Compound: SAHA	Antiproliferative activity against human M14 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human M14 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
M14	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human M14 cells after 72 hrs by MTS assay Growth inhibition of human M14 cells after 72 hrs by MTS assay	[PMID: 22435669]
MC-38	GI₅₀	2.4 μM Compound: 7; SAHA	Antiproliferative activity against mouse MC38 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against mouse MC38 cells measured after 72 hrs by CCK8 assay	[PMID: 34783558]
MC-38	GI₅₀	2.74 μM Compound: 3; SAHA	Antiproliferative activity against mouse MC38 cells after 72 hrs by CCK-8 assay Antiproliferative activity against mouse MC38 cells after 72 hrs by CCK-8 assay	[PMID: 35390714]
MC-38	IC₅₀	1.26 μM Compound: SAHA	Antiproliferative activity against mouse MC38 cells after 48 hrs by CCK-8 assay Antiproliferative activity against mouse MC38 cells after 48 hrs by CCK-8 assay	[PMID: 35939996]
MC-38	IC₅₀	2.22 μM Compound: 1; SAHA	Antiproliferative activity against mouse MC38 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse MC38 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
MCF-10A	GI₅₀	9.6 μM Compound: SAHA, Zolinza	Growth inhibition of human MCF10A cells after 48 hrs by MTT assay Growth inhibition of human MCF10A cells after 48 hrs by MTT assay	[PMID: 22435669]
MCF-10A	IC₅₀	0.42 μM Compound: 6; SAHA	Cytotoxicity against ER negative human MCF10A cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay Cytotoxicity against ER negative human MCF10A cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay	[PMID: 30078609]
MCF-10A	IC₅₀	1.1 μM Compound: 6; SAHA	Cytotoxicity against ER negative human MCF10A cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay Cytotoxicity against ER negative human MCF10A cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay	[PMID: 30078609]
MCF-10A	IC₅₀	2.11 μM Compound: SAHA	Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay	[PMID: 28601509]
MCF-10A	IC₅₀	28 μM Compound: SAHA	Cytotoxicity against human MCF10A cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF10A cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
MCF-10A	IC₅₀	31 μM Compound: 3, SAHA	Cytotoxicity against human MCF10A cells after 96 hrs by MTA reduction assay Cytotoxicity against human MCF10A cells after 96 hrs by MTA reduction assay	[PMID: 23293738]
MCF-10A	IC₅₀	31 μM Compound: 81, SAHA	Antitumor activity against human MCF10A cells Antitumor activity against human MCF10A cells	[PMID: 19534534]
MCF-10A	IC₅₀	> 50 μM Compound: 1; SAHA	Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 32180916]
MCF7	CC₅₀	3000 nM Compound: 1	Antiproliferative activity against human MCF7 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human MCF7 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
MCF7	EC₅₀	0.01 μM Compound: 25a	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by SRB assay	[PMID: 34591488]
MCF7	EC₅₀	0.65 μM Compound: 3; SAHA	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31627059]
MCF7	GI₅₀	0.45 μM Compound: 1, SAHA	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 24119555]
MCF7	GI₅₀	0.61 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 25800646]
MCF7	GI₅₀	0.689 μM Compound: SAHA	Cytotoxicity against human MCF7 cells after 48 hrs by Sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by Sulforhodamine B assay	[PMID: 23639537]
MCF7	GI₅₀	1.25 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured after 6 days by WST8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured after 6 days by WST8 assay	[PMID: 34610548]
MCF7	GI₅₀	1.34 μM Compound: 1, SAHA	Growth inhibition of human MCF7 cells after 96 hrs by MTT assay Growth inhibition of human MCF7 cells after 96 hrs by MTT assay	[PMID: 26814680]
MCF7	GI₅₀	17.9 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28629630]
MCF7	GI₅₀	2 μM Compound: SAHA, Zolinza	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 22435669]
MCF7	GI₅₀	2.19 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 24015327]
MCF7	GI₅₀	2.2 μM Compound: vorinostat, SAHA	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
MCF7	GI₅₀	2.6 μM Compound: SAHA	Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	[PMID: 34500130]
MCF7	GI₅₀	29.1 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay	[PMID: 27614919]
MCF7	GI₅₀	3.02 μM Compound: 1; SAHA	Anticancer activity against human MCF7 cells overexpressing HDAC1 and HDAC2 assessed as inhibition of cell growth incubated for 48 hrs by sulforhodamine B assay Anticancer activity against human MCF7 cells overexpressing HDAC1 and HDAC2 assessed as inhibition of cell growth incubated for 48 hrs by sulforhodamine B assay	[PMID: 37847303]
MCF7	GI₅₀	8.6 μM Compound: 1, SAHA	Growth inhibition of human MCF7 cells after 72 hrs by XTT assay Growth inhibition of human MCF7 cells after 72 hrs by XTT assay	[PMID: 24900500]
MCF7	IC₅₀	0.13 μg/mL Compound: SAHA	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 22036991]
MCF7	IC₅₀	0.16 μM Compound: 1	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
MCF7	IC₅₀	0.18 μg/mL Compound: Vorinostat	Anticancer activity against human MCF7 cells Anticancer activity against human MCF7 cells	[PMID: 31945642]
MCF7	IC₅₀	0.21 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
MCF7	IC₅₀	0.294 μM Compound: SAHA	Inhibition of cell viability in human MCF7 cells incubated for 12 days with every 3 day treatment by Alamar blue staining based analysis Inhibition of cell viability in human MCF7 cells incubated for 12 days with every 3 day treatment by Alamar blue staining based analysis	[PMID: 38838548]
MCF7	IC₅₀	0.32 μM Compound: 6; SAHA	Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay	[PMID: 26613635]
MCF7	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
MCF7	IC₅₀	0.45 μM Compound: 6; SAHA	Cytotoxicity against ER positive human MCF7 cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay Cytotoxicity against ER positive human MCF7 cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay	[PMID: 30078609]
MCF7	IC₅₀	0.493 μM Compound: Vorinostat	Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 37875056]
MCF7	IC₅₀	0.58 μM Compound: SAHA, Zolinza	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26100440]
MCF7	IC₅₀	0.65 μM Compound: 1; SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27541357]
MCF7	IC₅₀	0.65 μM Compound: 2	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28953386]
MCF7	IC₅₀	0.65 μM Compound: 4	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 29945795]
MCF7	IC₅₀	0.68 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay	[PMID: 37875056]
MCF7	IC₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32151834]
MCF7	IC₅₀	0.81 μM Compound: 4	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30243158]
MCF7	IC₅₀	0.9 μM Compound: SAHA	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
MCF7	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
MCF7	IC₅₀	0.91 μM Compound: 1; SAHA	Antiproliferative activity against human MCF7 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
MCF7	IC₅₀	0.95 μM Compound: 6; SAHA	Cytotoxicity against ER positive human MCF7 cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay Cytotoxicity against ER positive human MCF7 cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay	[PMID: 30078609]
MCF7	IC₅₀	1.03 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 37875056]
MCF7	IC₅₀	1.04 μM Compound: SAHA	Antiproliferative against human MCF-7 cells assessed as reduction in cell viability by MTT assay Antiproliferative against human MCF-7 cells assessed as reduction in cell viability by MTT assay	[PMID: 33045329]
MCF7	IC₅₀	1.1 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 24766560]
MCF7	IC₅₀	1.11 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
MCF7	IC₅₀	1.15 μM Compound: SAHA, Vorinostat	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21924799]
MCF7	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
MCF7	IC₅₀	1.26 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells incubated for 96 hrs by resazurin assay Antiproliferative activity against human MCF7 cells incubated for 96 hrs by resazurin assay	[PMID: 32435375]
MCF7	IC₅₀	1.31 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by CCK-8 assay	[PMID: 37057760]
MCF7	IC₅₀	1.5 μM Compound: SAHA	Inhibition of MCF7 cell proliferation (mean of two experiments) Inhibition of MCF7 cell proliferation (mean of two experiments)	[PMID: 17095213]
MCF7	IC₅₀	1.5 μM Compound: SAHA	Inhibition of MCF7 cell proliferation (mean of two experiments) Inhibition of MCF7 cell proliferation (mean of two experiments)	[PMID: 17107790]
MCF7	IC₅₀	1.6 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 24296013]
MCF7	IC₅₀	1.6 μM Compound: Vor; SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay	[PMID: 29360358]
MCF7	IC₅₀	1.7 μM Compound: SAHA; 112	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation by CCK-8 assay	[PMID: 31881454]
MCF7	IC₅₀	1.7 μM Compound: Vorinostat	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability Cytotoxicity against human MCF7 cells assessed as reduction in cell viability	[PMID: 30660827]
MCF7	IC₅₀	2 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32738414]
MCF7	IC₅₀	2.18 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 29396364]
MCF7	IC₅₀	2.29 μM Compound: Vorinostat	Cytotoxicity against human MCF7 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay Cytotoxicity against human MCF7 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay	[PMID: 23829483]
MCF7	IC₅₀	2.36 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 35043615]
MCF7	IC₅₀	2.43 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
MCF7	IC₅₀	2.5 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 22260166]
MCF7	IC₅₀	2.5 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 25993269]
MCF7	IC₅₀	2.5 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33965842]
MCF7	IC₅₀	2.5 μM Compound: SAHA; vorinostat	Cytotoxicity against human MCF7 cells after 72 hrs by CCK8 assay Cytotoxicity against human MCF7 cells after 72 hrs by CCK8 assay	[PMID: 26725029]
MCF7	IC₅₀	2.5 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells measured after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells measured after 24 hrs by MTT assay	[PMID: 37875056]
MCF7	IC₅₀	2.6 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 34624191]
MCF7	IC₅₀	2.7 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 29317150]
MCF7	IC₅₀	2.7 μM Compound: SAHA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability in presence of erlotinib by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability in presence of erlotinib by MTT assay	[PMID: 32320239]
MCF7	IC₅₀	2.8 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after hrs by ATP content assay Antiproliferative activity against human MCF7 cells after hrs by ATP content assay	[PMID: 20143778]
MCF7	IC₅₀	2.8 μM Compound: Vorinostat	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 32791404]
MCF7	IC₅₀	2.81 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21714538]
MCF7	IC₅₀	2.9 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells by CCK8 assay Antiproliferative activity against human MCF7 cells by CCK8 assay	[PMID: 30660827]
MCF7	IC₅₀	2.92 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37875056]
MCF7	IC₅₀	2.98 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
MCF7	IC₅₀	28.66 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	10.1039/C5MD00247H
MCF7	IC₅₀	3.13 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay	[PMID: 37875056]
MCF7	IC₅₀	3.26 μM Compound: SAHA	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C4MD00203B
MCF7	IC₅₀	3.27 μM Compound: SAHA	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
MCF7	IC₅₀	3.27 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 31546197]
MCF7	IC₅₀	3.47 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28601509]
MCF7	IC₅₀	3.49 μM Compound: SAHA	Antiproliferative activity in human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTS assay Antiproliferative activity in human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	[PMID: 32061484]
MCF7	IC₅₀	3.56 μM Compound: 4; SAHA	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 37652098]
MCF7	IC₅₀	3.57 μM Compound: SAHA	Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 38452727]
MCF7	IC₅₀	3.78 μM Compound: SA, SAHA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24694055]
MCF7	IC₅₀	3.78 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25462271]
MCF7	IC₅₀	354 nM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30629434]
MCF7	IC₅₀	38.2 μM Compound: SAHA	Cytotoxic activity against human MCF7 cells after 24 hrs by MTT assay Cytotoxic activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 29496367]
MCF7	IC₅₀	4.1 μM Compound: 5; SAHA	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 31117517]
MCF7	IC₅₀	4.17 μM Compound: SAHA	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
MCF7	IC₅₀	4.2 μM Compound: 1; SAHA	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 33077264]
MCF7	IC₅₀	4.2 μM Compound: SAHA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 32320239]
MCF7	IC₅₀	4.2 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26741358]
MCF7	IC₅₀	4.22 μM Compound: SAHA	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 30245394]
MCF7	IC₅₀	4.339 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by SRB assay	[PMID: 34454126]
MCF7	IC₅₀	4.4 μM Compound: SAHA, vorinostat	Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
MCF7	IC₅₀	4.48 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29288941]
MCF7	IC₅₀	4.5 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26475519]
MCF7	IC₅₀	4.69 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 28987602]
MCF7	IC₅₀	4.78 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay	[PMID: 37116762]
MCF7	IC₅₀	4.83 μM Compound: 1; SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
MCF7	IC₅₀	5.15 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 35272009]
MCF7	IC₅₀	5.15 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells measured after 72 hrs Antiproliferative activity against human MCF7 cells measured after 72 hrs	[PMID: 35697181]
MCF7	IC₅₀	5.43 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
MCF7	IC₅₀	500 nM Compound: SAHA	Growth inhibition of MCF7 cells Growth inhibition of MCF7 cells	[PMID: 17958342]
MCF7	IC₅₀	54.55 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	10.1039/C5MD00247H
MCF7	IC₅₀	6 μM Compound: 1; SAHA	Antiproliferative activity against human MCF7 cells up to 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells up to 72 hrs by MTT assay	[PMID: 27541357]
MCF7	IC₅₀	6.17 μM Compound: 1; SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 32180916]
MCF7	IC₅₀	6.23 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36996717]
MCF7	IC₅₀	6.42 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 24185378]
MCF7	IC₅₀	6.5 μM Compound: Vorinostat	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 35608269]
MCF7	IC₅₀	6.7 μM Compound: 2	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 17691763]
MCF7	IC₅₀	60.2 μM Compound: SAHA, Vorinostat	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 24095016]
MCF7	IC₅₀	637.2 nM Compound: SAHA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 31177073]
MCF7	IC₅₀	7.11 μM Compound: 1; SAHA	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
MCF7	IC₅₀	8.5 μM Compound: 3, SAHA	Cytotoxicity against human MCF7 cells after 96 hrs by MTA reduction assay Cytotoxicity against human MCF7 cells after 96 hrs by MTA reduction assay	[PMID: 23293738]
MCF7	IC₅₀	8.5 μM Compound: 81, SAHA	Antitumor activity against human MCF7 cells Antitumor activity against human MCF7 cells	[PMID: 19534534]
MCF7	IC₅₀	9.59 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	10.1039/C5MD00247H
MCF7	IC₅₀	9.798 μM Compound: SAHA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
MCF7	IC₅₀	939.97 nM Compound: SAHA	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 30819618]
MCF7	IC₅₀	> 10 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34116381]
MCF7	IC₅₀	> 100 μM Compound: SAHA	Inhibition of human MCF7 cells Inhibition of human MCF7 cells	[PMID: 18247554]
MCF7	IC₅₀	> 150 μM Compound: SAHA	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
MCF7	IC₅₀	> 50 μM Compound: 1; SAHA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33668008]
MCF7	IC₅₀	> 50 μM Compound: Vorinostat	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay	[PMID: 37989057]
MDA-MB-231	EC₅₀	1.2 μM Compound: 3; SAHA	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 31627059]
MDA-MB-231	EC₅₀	1.5 μM Compound: SAHA	Inhibition of human MDA-MB-231 cells Inhibition of human MDA-MB-231 cells	[PMID: 18247554]
MDA-MB-231	EC₅₀	1.5 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human MDA-MB-231 cells Effective Concentration of compound to inhibit the growth of human MDA-MB-231 cells	[PMID: 15715470]
MDA-MB-231	GI₅₀	0.66 μM Compound: 1, SAHA	Growth inhibition of human MDA-MB-231 cells by SRB assay Growth inhibition of human MDA-MB-231 cells by SRB assay	[PMID: 17477518]
MDA-MB-231	GI₅₀	0.66 μM Compound: 2, SAHA	Antiproliferative activity against human MDA-MB-231 cells by SRB assay Antiproliferative activity against human MDA-MB-231 cells by SRB assay	[PMID: 16723227]
MDA-MB-231	GI₅₀	0.89 μM Compound: SAHA	Growth inhibition of human MDA-MB-231 cells after 21 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 21 hrs by MTT assay	[PMID: 17662606]
MDA-MB-231	GI₅₀	0.97 μM Compound: 1, SAHA	Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 22439863]
MDA-MB-231	GI₅₀	1 μM Compound: SAHA, Zolinza	Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 22435669]
MDA-MB-231	GI₅₀	1.81 μM Compound: 1, SAHA	Growth inhibition of human MDA-MB-231 cells after 96 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 96 hrs by MTT assay	[PMID: 26814680]
MDA-MB-231	GI₅₀	2 μM Compound: 1, SAHA, Zolinza, Vorinostat	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by SRB assay	[PMID: 23163332]
MDA-MB-231	GI₅₀	2 μM Compound: 2, SAHA	Growth inhibition of human MDA-MB-231 cells by SRB assay Growth inhibition of human MDA-MB-231 cells by SRB assay	[PMID: 17904843]
MDA-MB-231	GI₅₀	2 μM Compound: SAHA	Growth inhibition of human MDA-MB-231 cells after 5 days by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells after 5 days by sulforhodamine B assay	[PMID: 25811792]
MDA-MB-231	GI₅₀	2 μM Compound: SAHA	Growth inhibition of human MDA-MB-231 cells measured after 5 days by sulforhodamine-B assay Growth inhibition of human MDA-MB-231 cells measured after 5 days by sulforhodamine-B assay	[PMID: 28011426]
MDA-MB-231	GI₅₀	2.32 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 24015327]
MDA-MB-231	GI₅₀	2.5 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
MDA-MB-231	GI₅₀	2.5 μM Compound: SAHA, Zolinza	Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTS assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTS assay	[PMID: 22435669]
MDA-MB-231	GI₅₀	2.67 μM Compound: 1; SAHA	Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
MDA-MB-231	GI₅₀	2.73 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay	[PMID: 36262394]
MDA-MB-231	IC₅₀	0.16 μM Compound: SAHA, Vorinostat	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24095016]
MDA-MB-231	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
MDA-MB-231	IC₅₀	0.201 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by resazurin dye based fluorescence assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by resazurin dye based fluorescence assay	[PMID: 29456804]
MDA-MB-231	IC₅₀	0.21 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
MDA-MB-231	IC₅₀	0.43 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 5 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 5 days by MTT assay	[PMID: 28601509]
MDA-MB-231	IC₅₀	0.46 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of fedratinib by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of fedratinib by MTT assay	[PMID: 37796543]
MDA-MB-231	IC₅₀	0.61 μM Compound: 6; SAHA	Cytotoxicity against ER negative human MDA-MB-231 cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay Cytotoxicity against ER negative human MDA-MB-231 cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay	[PMID: 30078609]
MDA-MB-231	IC₅₀	0.61 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34237620]
MDA-MB-231	IC₅₀	0.61 μM Compound: SAHA, vorinostat	Inhibition of HDAC in cisplatin resistant human MDA-MB-231 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human MDA-MB-231 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
MDA-MB-231	IC₅₀	0.61 μM Compound: SAHA, vorinostat	Inhibition of HDAC in cisplatin sensitive human MDA-MB-231 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin sensitive human MDA-MB-231 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
MDA-MB-231	IC₅₀	0.61 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 37875056]
MDA-MB-231	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
MDA-MB-231	IC₅₀	0.9 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
MDA-MB-231	IC₅₀	0.96 μM Compound: 6; SAHA	Antiproliferative activity against human MDA-MB-231 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay Antiproliferative activity against human MDA-MB-231 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay	[PMID: 26613635]
MDA-MB-231	IC₅₀	0.97 μM Compound: 6; SAHA	Cytotoxicity against ER negative human MDA-MB-231 cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay Cytotoxicity against ER negative human MDA-MB-231 cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay	[PMID: 30078609]
MDA-MB-231	IC₅₀	1.09 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33586434]
MDA-MB-231	IC₅₀	1.11 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C4MD00203B
MDA-MB-231	IC₅₀	1.18 μM Compound: SAHA, Zolinza	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 21733698]
MDA-MB-231	IC₅₀	1.19 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27541357]
MDA-MB-231	IC₅₀	1.19 μM Compound: 2	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28953386]
MDA-MB-231	IC₅₀	1.19 μM Compound: 4	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 29945795]
MDA-MB-231	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
MDA-MB-231	IC₅₀	1.29 μM Compound: SAHA	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24702857]
MDA-MB-231	IC₅₀	1.3 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 23906422]
MDA-MB-231	IC₅₀	1.31 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 21476600]
MDA-MB-231	IC₅₀	1.35 μM Compound: Vorinostat	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
MDA-MB-231	IC₅₀	1.45 μM Compound: 1; SAHA	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 33077264]
MDA-MB-231	IC₅₀	1.49 μM Compound: 4	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30243158]
MDA-MB-231	IC₅₀	1.54 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
MDA-MB-231	IC₅₀	1.6 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs in presence of CF53 by CCK-8 assay	[PMID: 36622852]
MDA-MB-231	IC₅₀	1.66 μM Compound: SAHA, vorinostat	Cytotoxicity against cisplatin sensitive human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin sensitive human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 23252603]
MDA-MB-231	IC₅₀	1.72 μM Compound: SA, SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24694055]
MDA-MB-231	IC₅₀	1.72 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 25462271]
MDA-MB-231	IC₅₀	1.73 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 26907204]
MDA-MB-231	IC₅₀	1.77 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34043359]
MDA-MB-231	IC₅₀	1.8 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	10.1039/C4MD00211C
MDA-MB-231	IC₅₀	1.91 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 38452727]
MDA-MB-231	IC₅₀	1.91 μM Compound: SAHA, Vorinostat	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 21924799]
MDA-MB-231	IC₅₀	1.98 μM Compound: SAHA	Anti-proliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Anti-proliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28947154]
MDA-MB-231	IC₅₀	1.98 μM Compound: XII; SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
MDA-MB-231	IC₅₀	12.3 μM Compound: SAHA	Inhibition of MDA-MB-231 cell proliferation (mean of two experiments) Inhibition of MDA-MB-231 cell proliferation (mean of two experiments)	[PMID: 17095213]
MDA-MB-231	IC₅₀	12.3 μM Compound: SAHA	Inhibition of MDA-MB-231 cell proliferation (mean of two experiments) Inhibition of MDA-MB-231 cell proliferation (mean of two experiments)	[PMID: 17107790]
MDA-MB-231	IC₅₀	13.48 μM Compound: SAHA, Zolinza	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 26100440]
MDA-MB-231	IC₅₀	1480 nM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
MDA-MB-231	IC₅₀	1710 nM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 31177073]
MDA-MB-231	IC₅₀	2 μM Compound: 1, SAHA	Growth inhibition of human MDA-MB-231 cells Growth inhibition of human MDA-MB-231 cells	[PMID: 20850971]
MDA-MB-231	IC₅₀	2.02 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26149591]
MDA-MB-231	IC₅₀	2.03 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
MDA-MB-231	IC₅₀	2.11 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after hrs by ATP content assay Antiproliferative activity against human MDA-MB-231 cells after hrs by ATP content assay	[PMID: 20143778]
MDA-MB-231	IC₅₀	2.14 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 30245394]
MDA-MB-231	IC₅₀	2.2 μM Compound: 2	Cytotoxicity against human MDA-MB-231cells Cytotoxicity against human MDA-MB-231cells	[PMID: 17691763]
MDA-MB-231	IC₅₀	2.23 μM Compound: SAHA	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay	[PMID: 36244186]
MDA-MB-231	IC₅₀	2.29 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 25311567]
MDA-MB-231	IC₅₀	2.36 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
MDA-MB-231	IC₅₀	2.5 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by CCK-8 assay	[PMID: 36622852]
MDA-MB-231	IC₅₀	2.59 μM Compound: Vorinostat	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
MDA-MB-231	IC₅₀	2.69 μM Compound: SAHA, vorinostat	Cytotoxicity against cisplatin resistant human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 23252603]
MDA-MB-231	IC₅₀	2.8 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by CellTiter blue-reagent based assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by CellTiter blue-reagent based assay	[PMID: 30645113]
MDA-MB-231	IC₅₀	2.9 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by Celltiter-glo assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by Celltiter-glo assay	[PMID: 38141287]
MDA-MB-231	IC₅₀	2.92 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37875056]
MDA-MB-231	IC₅₀	3 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 7 days Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 7 days	[PMID: 35643262]
MDA-MB-231	IC₅₀	3.02 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 29787262]
MDA-MB-231	IC₅₀	3.07 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
MDA-MB-231	IC₅₀	3.26 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 39145486]
MDA-MB-231	IC₅₀	3.3 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28601509]
MDA-MB-231	IC₅₀	3.3 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells harboring wild type BRCA1 and wild BRCA2 assessed as reduction in cell viability Cytotoxicity against human MDA-MB-231 cells harboring wild type BRCA1 and wild BRCA2 assessed as reduction in cell viability	[PMID: 36053318]
MDA-MB-231	IC₅₀	3.31 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
MDA-MB-231	IC₅₀	3.4 μM Compound: SAHA	Antiproliferative activity in human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTS assay Antiproliferative activity in human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	[PMID: 32061484]
MDA-MB-231	IC₅₀	3.4 μM Compound: SAHA, vorinostat	Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
MDA-MB-231	IC₅₀	3.52 μM Compound: SAHA	Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation	[PMID: 35944852]
MDA-MB-231	IC₅₀	3.52 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method	[PMID: 33261898]
MDA-MB-231	IC₅₀	3.52 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay	[PMID: 35255412]
MDA-MB-231	IC₅₀	3.96 μM Compound: SAHA, Zolinza	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
MDA-MB-231	IC₅₀	4.5 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells up to 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells up to 72 hrs by MTT assay	[PMID: 27541357]
MDA-MB-231	IC₅₀	4.53 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28757101]
MDA-MB-231	IC₅₀	4.585 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
MDA-MB-231	IC₅₀	4.61 μM Compound: 1, SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24525003]
MDA-MB-231	IC₅₀	4.61 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 26216016]
MDA-MB-231	IC₅₀	4.66 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 32180916]
MDA-MB-231	IC₅₀	4.93 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29954683]
MDA-MB-231	IC₅₀	5.52 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 35477142]
MDA-MB-231	IC₅₀	5.6 μM Compound: 1, SAHA	Inhibition of human MDA-MB-231 cell proliferation after 48 hrs by MTT assay Inhibition of human MDA-MB-231 cell proliferation after 48 hrs by MTT assay	[PMID: 23493449]
MDA-MB-231	IC₅₀	5.8 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human MDA-MB-231 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
MDA-MB-231	IC₅₀	6.04 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth measured after 2 days by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth measured after 2 days by CCK8 assay	[PMID: 34610548]
MDA-MB-231	IC₅₀	6000 nM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 27665180]
MDA-MB-231	IC₅₀	7.4 μM Compound: SAHA	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25815139]
MDA-MB-231	IC₅₀	8.14 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay	[PMID: 32791401]
MDA-MB-231	IC₅₀	8.25 μM Compound: 1; SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	[PMID: 34656899]
MDA-MB-231	IC₅₀	9.2 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37796543]
MDA-MB-231	IC₅₀	> 100 μM Compound: 1; SAHA	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28885834]
MDA-MB-231	IC₅₀	> 411 nM Compound: Vorinostat	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
MDA-MB-238	IC₅₀	4.92 μM Compound: 1; SAHA	Anticancer activity against human MDA-MB-238 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis Anticancer activity against human MDA-MB-238 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis	[PMID: 36215854]
MDA-MB-435	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human MDA-MB-435 cells after 72 hrs by MTS assay Growth inhibition of human MDA-MB-435 cells after 72 hrs by MTS assay	[PMID: 22435669]
MDA-MB-435	GI₅₀	0.88 μM Compound: 1, SAHA	Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay	[PMID: 24119555]
MDA-MB-435	GI₅₀	1.18 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 25800646]
MDA-MB-435	IC₅₀	1.9 μM Compound: 3 (SAHA)	Antiproliferative activity against MDA-435 (human breast carcinoma) cell line. Antiproliferative activity against MDA-435 (human breast carcinoma) cell line.	[PMID: 12749893]
MDA-MB-435	IC₅₀	1900 nM Compound: 1 (SAHA)	Inhibitory concentration against MDA-435 cells proliferation Inhibitory concentration against MDA-435 cells proliferation	[PMID: 14613312]
MDA-MB-436	IC₅₀	3.9 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-436 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human MDA-MB-436 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
MDA-MB-453	IC₅₀	0.37 μM Compound: 5; SAHA	Antiproliferative activity against human MDA-MB-453 cells after 96 hrs by MTT assay Antiproliferative activity against human MDA-MB-453 cells after 96 hrs by MTT assay	[PMID: 31117517]
MDA-MB-468	GI₅₀	0.63 μM Compound: SAHA, Zolinza	Growth inhibition of human MDA-MB-468 cells after 72 hrs by MTS assay Growth inhibition of human MDA-MB-468 cells after 72 hrs by MTS assay	[PMID: 22435669]
MDA-MB-468	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
MDA-MB-468	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
MDA-MB-468	IC₅₀	0.95 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-468 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells incubated for 72 hrs by MTT assay	[PMID: 32961382]
MDA-MB-468	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human MDA-MB-468 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-468 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
MDA-MB-468	IC₅₀	1.3 μM Compound: 2	Cytotoxicity against human MDA-MB-468 cells Cytotoxicity against human MDA-MB-468 cells	[PMID: 17691763]
MDA-MB-468	IC₅₀	10.03 μM Compound: SAHA	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
MDA-MB-468	IC₅₀	2.3 μM Compound: SAHA	Cytotoxicity against human MDA-MB-468 cells harboring wild type BRCA1 and BRCA2 mutant reduction in assessed as cell viability Cytotoxicity against human MDA-MB-468 cells harboring wild type BRCA1 and BRCA2 mutant reduction in assessed as cell viability	[PMID: 36053318]
MDA-MB-468	IC₅₀	2.69 μM Compound: Vorinostat	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
MDA-MB-468	IC₅₀	2.75 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 33586434]
MDA-MB-468	IC₅₀	2.85 μM Compound: SAHA	Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay	[PMID: 36244186]
MDA-MB-468	IC₅₀	5 μM Compound: SAHA	Antiproliferative activity against human MDA-MB-468 cells Antiproliferative activity against human MDA-MB-468 cells	[PMID: 20143778]
MEF	IC₅₀	4.4 μM Compound: SAHA	Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay	[PMID: 23570542]
MG-63	GI₅₀	> 10 μM Compound: SAHA, vorinostat	Antiproliferative activity against human MG63 cells after 72 hrs by WST-1 assay Antiproliferative activity against human MG63 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
MGC-803	IC₅₀	1.54 μM Compound: SAHA	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 33957387]
MGC-803	IC₅₀	1.58 μM Compound: SAHA	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36996717]
MGC-803	IC₅₀	1.7 μM Compound: SAHA; 112	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell proliferation by CCK-8 assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell proliferation by CCK-8 assay	[PMID: 31881454]
MGC-803	IC₅₀	1.7 μM Compound: Vorinostat	Cytotoxicity against human MGC803 cells assessed as reduction in cell viability Cytotoxicity against human MGC803 cells assessed as reduction in cell viability	[PMID: 30660827]
MGC-803	IC₅₀	2.678 μM Compound: SAHA	Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition after 72 hrs by SRB assay Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition after 72 hrs by SRB assay	[PMID: 34454126]
MGC-803	IC₅₀	2.82 μM Compound: SAHA	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay	[PMID: 37086699]
MGC-803	IC₅₀	3.51 μM Compound: SAHA	Antiproliferative activity against human MGC803 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
MGC-803	IC₅₀	8.06 μM Compound: SAHA	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
MGC-803	IC₅₀	8.67 μM Compound: Vorinostat	Antiproliferative activity against human MGC803 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells incubated for 72 hrs by MTT assay	[PMID: 33831778]
MGC-803	IC₅₀	8.75 μM Compound: SAHA	Antiproliferative activity against human MGC803 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells incubated for 72 hrs by MTT assay	[PMID: 28987602]
MGC-803	IC₅₀	9.74 μM Compound: SAHA	Cytotoxicity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
MIA PaCa-2	GI₅₀	3500 nM Compound: SAHA, vorinostat	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by WST-1 assay Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
MIA PaCa-2	GI₅₀	790 nM Compound: SAHA	Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay	[PMID: 24999749]
MIA PaCa-2	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human MiaPaca2 cells after 72 hrs by MTT assay Antiproliferative activity against human MiaPaca2 cells after 72 hrs by MTT assay	[PMID: 18642892]
MIA PaCa-2	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human MIAPaCa2 cells by MTT assay Antiproliferative activity against human MIAPaCa2 cells by MTT assay	[PMID: 19419863]
MIA PaCa-2	IC₅₀	1.1 μM Compound: 1a, SAHA	Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTS assay Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTS assay	[PMID: 20055418]
MIA PaCa-2	IC₅₀	1.1 μM Compound: SAHA	Cytotoxicity against human Mia Paca2 cells after 72 hrs by MTT assay Cytotoxicity against human Mia Paca2 cells after 72 hrs by MTT assay	[PMID: 18494463]
MIA PaCa-2	IC₅₀	2.2 μM Compound: SAHA	Cytotoxicity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
MIA PaCa-2	IC₅₀	996 nM Compound: 1; SAHA	Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
MKN-45	GI₅₀	7.3 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human MKN45 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MKN45 cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
MKN-45	IC₅₀	1.25 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human MKN45 cells by MTT assay Cytotoxicity against human MKN45 cells by MTT assay	[PMID: 24766560]
MKN-45	IC₅₀	> 10 μM Compound: SAHA	Antiproliferative activity against human MKN-45 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MKN-45 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
MM1.S	IC₅₀	0.73 μM Compound: SAHA	Antiproliferative activity against human MM.1S cells assessed as inhibition of cell growth incubated for 72 hrs by microplate photometer analysis Antiproliferative activity against human MM.1S cells assessed as inhibition of cell growth incubated for 72 hrs by microplate photometer analysis	[PMID: 38116436]
MM1.S	IC₅₀	0.82 μM Compound: SAHA	Antiproliferative activity against human MM1S cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay Antiproliferative activity against human MM1S cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	[PMID: 26890114]
MM1.S	IC₅₀	1.54 μM Compound: SAHA	Cytotoxicity against human MM1.S cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis Cytotoxicity against human MM1.S cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis	[PMID: 35119267]
MM1.S	IC₅₀	2844 nM Compound: SAHA	Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay	[PMID: 29795767]
MM1.S	IC₅₀	573 nM Compound: SAHA	Antiproliferative activity against human MM1S cells after 72 hrs by MTT assay Antiproliferative activity against human MM1S cells after 72 hrs by MTT assay	[PMID: 30629434]
MM1.S	IC₅₀	590.3 nM Compound: SAHA	Antiproliferative activity against human MM1S cells after 72 hrs by MTT assay Antiproliferative activity against human MM1S cells after 72 hrs by MTT assay	[PMID: 31177073]
MM473	IC₅₀	8.2 μM Compound: SAHA	Antiproliferative activity against human MM473 cells at 10 uM after 72 hrs by MTT assay relative to control Antiproliferative activity against human MM473 cells at 10 uM after 72 hrs by MTT assay relative to control	[PMID: 29150335]
MM473	IC₅₀	> 10 μM Compound: SAHA	Antiproliferative activity against human MM473 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human MM473 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
MM96L	EC₅₀	0.01 μM Compound: 25a	Antiproliferative activity against human MM96L cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human MM96L cells assessed as cell growth inhibition by SRB assay	[PMID: 34591488]
MOLM-13	EC₅₀	1.2 μM Compound: SAHA	Growth inhibition of human MOLM13 cells after 44 hrs by MTT assay Growth inhibition of human MOLM13 cells after 44 hrs by MTT assay	[PMID: 28337317]
MOLM-13	IC₅₀	0.345 μM Compound: 1; SAHA	Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay	[PMID: 31938464]
MOLM-13	IC₅₀	984.9 nM Compound: SAHA	Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs by MTT assay Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs by MTT assay	[PMID: 27505848]
MOLM-14	EC₅₀	0.54 μM Compound: 3; SAHA	Antiproliferative activity against human MOLM14 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MOLM14 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31627059]
MOLT-4	GI₅₀	0.4 μM Compound: SAHA, Zolinza	Growth inhibition of human MOLT4 cells after 72 hrs by MTS assay Growth inhibition of human MOLT4 cells after 72 hrs by MTS assay	[PMID: 22435669]
MOLT-4	GI₅₀	0.68 μM Compound: vorinostat, SAHA	Antiproliferative activity against human MOLT4 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human MOLT4 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
MOLT-4	GI₅₀	3.3 μM Compound: 1	Growth inhibition of human MOLT-4 cells measured after 24 hrs by MTT assay Growth inhibition of human MOLT-4 cells measured after 24 hrs by MTT assay	[PMID: 37429084]
MOLT-4	GI₅₀	542 nM Compound: SAHA	Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay	[PMID: 26331334]
MOLT-4	GI₅₀	670 nM Compound: SAHA, vorinostat	Antiproliferative activity against human MOLT4 cells after 72 hrs by WST-1 assay Antiproliferative activity against human MOLT4 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
MOLT-4	IC₅₀	0.21 μM Compound: Vorinostat	Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
MOLT-4	IC₅₀	0.33 μM Compound: SAHA	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 28336407]
MOLT-4	IC₅₀	0.33 μM Compound: Vorinostat	Cytotoxicity against human MOLT-4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MOLT-4 cells assessed as reduction in cell viability by MTT assay	[PMID: 38107170]
MOLT-4	IC₅₀	0.36 μM Compound: SAHA	Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay	[PMID: 29787262]
MOLT-4	IC₅₀	0.38 μM Compound: SAHA	Antiproliferative activity against human MOLT4 cells incubated for 24 hrs by CCK8 assay Antiproliferative activity against human MOLT4 cells incubated for 24 hrs by CCK8 assay	[PMID: 32247729]
MOLT-4	IC₅₀	0.4 μM Compound: 3; SAHA	Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30901208]
MOLT-4	IC₅₀	0.41 μM Compound: SAHA	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 29533873]
MOLT-4	IC₅₀	0.41 μM Compound: SAHA	Antiproliferative activity against human MOLT-4 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MOLT-4 cells after 48 hrs by CCK-8 assay	[PMID: 35939996]
MOLT-4	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
MOLT-4	IC₅₀	0.52 μM Compound: Vor; SAHA	Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
MOLT-4	IC₅₀	0.56 μM Compound: Vorinostat	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 28371677]
MOLT-4	IC₅₀	0.57 μM Compound: SAHA	Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay	[PMID: 37086699]
MOLT-4	IC₅₀	0.7 μM Compound: SAHA	Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
MOLT-4	IC₅₀	1.08 μM Compound: SAHA	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 29500131]
MOLT-4	IC₅₀	3.09 μM Compound: XII; SAHA	Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
MRC5	IC₅₀	68.7 μM Compound: SAHA	Anti-proliferative activity against human MRC5 cells after 48 hrs by MTT assay Anti-proliferative activity against human MRC5 cells after 48 hrs by MTT assay	[PMID: 28947154]
MV4-11	EC₅₀	0.53 μM Compound: Vor; SAHA	Induction of cell death in human MV4-11 cells measured at 48 hrs by fluorescence based microplate reader analysis Induction of cell death in human MV4-11 cells measured at 48 hrs by fluorescence based microplate reader analysis	[PMID: 29360358]
MV4-11	EC₅₀	0.9 μM Compound: Vor; SAHA	Induction of apoptosis in human MV4-11 cells assessed as increase in caspase 3/7 activity measured at 24 hrs in presence of Z-DEVD-R110 or (Z-Asp-Glu-Val-Asp)2-rhodamine110 by fluorescence based microplate reader analysis Induction of apoptosis in human MV4-11 cells assessed as increase in caspase 3/7 activity measured at 24 hrs in presence of Z-DEVD-R110 or (Z-Asp-Glu-Val-Asp)2-rhodamine110 by fluorescence based microplate reader analysis	[PMID: 29360358]
MV4-11	EC₅₀	418.1 nM Compound: SAHA; Vor	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Blue dye based spectrophotometric analysis Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Blue dye based spectrophotometric analysis	[PMID: 32321249]
MV4-11	EC₅₀	< 30 nM Compound: Vorinostat	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 48 hrs by Cell-titer-blue cell viability assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 48 hrs by Cell-titer-blue cell viability assay	[PMID: 27754681]
MV4-11	GI₅₀	0.59 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human MV4-11 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay	[PMID: 25800646]
MV4-11	IC₅₀	0.22 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
MV4-11	IC₅₀	0.24 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs in presence of SHP099 by CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs in presence of SHP099 by CCK-8 assay	[PMID: 36097406]
MV4-11	IC₅₀	0.26 μM Compound: 10; SAHA	Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 33077265]
MV4-11	IC₅₀	0.29 μM Compound: SAHA	Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis	[PMID: 35119267]
MV4-11	IC₅₀	0.31 μM Compound: 1; SAHA	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay	[PMID: 31938464]
MV4-11	IC₅₀	0.37 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay	[PMID: 37086699]
MV4-11	IC₅₀	0.38 μM Compound: SAHA	Cytotoxicity against human MV4-11 cells assessed as cell viability incubated for 72 hrs by Cell titer-blue assay Cytotoxicity against human MV4-11 cells assessed as cell viability incubated for 72 hrs by Cell titer-blue assay	[PMID: 34101461]
MV4-11	IC₅₀	0.4 μM Compound: SAHA	Inhibition of cell viability in human MV4-11 cells incubated for 4 days in presence of GSK5032 by CCK8 assay Inhibition of cell viability in human MV4-11 cells incubated for 4 days in presence of GSK5032 by CCK8 assay	[PMID: 39264152]
MV4-11	IC₅₀	0.421 μM Compound: Vorinostat	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by CellTiterGlo assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by CellTiterGlo assay	[PMID: 37659198]
MV4-11	IC₅₀	0.43 μM Compound: Vor; SAHA	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay	[PMID: 29360358]
MV4-11	IC₅₀	0.47 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells incubated for 48 hrs by resazurin based microplate reader analysis Antiproliferative activity against human MV4-11 cells incubated for 48 hrs by resazurin based microplate reader analysis	[PMID: 37647727]
MV4-11	IC₅₀	0.493 μM Compound: Vorinostat	Cytotoxicity against human MV4-11 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 37875056]
MV4-11	IC₅₀	0.5 μM Compound: SAHA	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30034592]
MV4-11	IC₅₀	0.5 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36097406]
MV4-11	IC₅₀	0.51 μM Compound: 1; SAHA	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 3 days in presence of atamparib by celltiter-glo luminescent assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 3 days in presence of atamparib by celltiter-glo luminescent assay	[PMID: 38456618]
MV4-11	IC₅₀	0.55 μM Compound: 1; SAHA	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 3 days by celltiter-glo luminescent assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 3 days by celltiter-glo luminescent assay	[PMID: 38456618]
MV4-11	IC₅₀	0.68 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 36272186]
MV4-11	IC₅₀	0.7 μM Compound: 2; SAHA	Cytotoxicity against human MV411 cells Cytotoxicity against human MV411 cells	[PMID: 26005563]
MV4-11	IC₅₀	0.7 μM Compound: SAHA	Antiproliferative activity against human MV4-11 cells incubated for 96 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells incubated for 96 hrs by CCK8 assay	[PMID: 39264152]
MV4-11	IC₅₀	0.7 μM Compound: SAHA	Inhibition of cell viability in human MV4-11 cells incubated for 4 days by CCK8 assay Inhibition of cell viability in human MV4-11 cells incubated for 4 days by CCK8 assay	[PMID: 39264152]
MV4-11	IC₅₀	0.72 μM Compound: 1; SAHA	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay	[PMID: 27142751]
MV4-11	IC₅₀	0.85 μM Compound: 1; SAHA	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
MV4-11	IC₅₀	0.88 μM Compound: SAHA; 6	Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
MV4-11	IC₅₀	0.98 μM Compound: 5; SAHA	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 28765013]
MV4-11	IC₅₀	2.41 μM Compound: SAHA	Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
MV4-11	IC₅₀	220 nM Compound: SAHA	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 30629434]
MV4-11	IC₅₀	230 nM Compound: SAHA	Cytotoxicity against human MV4-11 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 27186676]
MV4-11	IC₅₀	439 nM Compound: SAHA	Growth inhibition of human MV4-11 cells assessed as ATP level after 72 hrs by CellTiterGlo assay Growth inhibition of human MV4-11 cells assessed as ATP level after 72 hrs by CellTiterGlo assay	10.1039/C3MD00285C
MV4-11	IC₅₀	471.4 nM Compound: SAHA	Antiproliferative activity against human MV4-11 cells Antiproliferative activity against human MV4-11 cells	[PMID: 35580726]
MV4-11	IC₅₀	483 nM Compound: 1; SAHA	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin staining based assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin staining based assay	[PMID: 39047608]
MV4-11	IC₅₀	496.1 nM Compound: SAHA	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 27505848]
MV4-11	IC₅₀	537 nM Compound: 1; SAHA	Antiproliferative activity against human MV4-11 cells harboring wild type p53 assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based fluorescence analysis Antiproliferative activity against human MV4-11 cells harboring wild type p53 assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based fluorescence analysis	[PMID: 38224650]
MV4-11	IC₅₀	8.44 μM Compound: 4; SAHA	Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant assessed as reduction in cell viability Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant assessed as reduction in cell viability	[PMID: 34314844]
MV4-11	IC₅₀	85 nM Compound: SAHA	Cytotoxicity against human MV4-11 cells after 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 26443078]
Malme-3M	GI₅₀	0.32 μM Compound: SAHA, Zolinza	Growth inhibition of human MALME-3M cells after 72 hrs by MTS assay Growth inhibition of human MALME-3M cells after 72 hrs by MTS assay	[PMID: 22435669]
Malme-3M	GI₅₀	0.37 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay	[PMID: 24015327]
N2a	IC₅₀	1.45 μM Compound: SAHA	Cytotoxicity against mouse Neuro2a cells assessed as reduction in cell viability incubated for 24 hrs by Cell Titer-Glo 2.0 Luminescent cell assay Cytotoxicity against mouse Neuro2a cells assessed as reduction in cell viability incubated for 24 hrs by Cell Titer-Glo 2.0 Luminescent cell assay	[PMID: 33845233]
NALM-6	IC₅₀	1.2 μM Compound: SAHA	Antiproliferative activity against human NALM-6 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human NALM-6 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36395680]
NAMALVA	IC₅₀	0.11 μM Compound: 1; SAHA	Cytotoxicity against human NAMALVA cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human NAMALVA cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33668008]
NAMALVA	IC₅₀	0.11 μM Compound: Vorinostat	Cytotoxicity against human NAMALVA cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay Cytotoxicity against human NAMALVA cells assessed as cell growth inhibition incubated for 24 to 72 hrs by MTT assay	[PMID: 37989057]
NB-4	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against human NB4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NB4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
NB-4	IC₅₀	0.6 μM Compound: SAHA, vorinostat	Antiproliferative activity against human NB4 cells after 48 hrs Antiproliferative activity against human NB4 cells after 48 hrs	[PMID: 18723349]
NB-4	IC₅₀	0.7 μM Compound: SAHA	Antiproliferative activity against human NB4 cells after 72 hrs Antiproliferative activity against human NB4 cells after 72 hrs	[PMID: 19084294]
NB-4	IC₅₀	0.7 μM Compound: SAHA	Growth inhibition of human NB4 cells after 72 hrs Growth inhibition of human NB4 cells after 72 hrs	[PMID: 26376355]
NB-4	IC₅₀	0.7 μM Compound: SAHA, vorinostat	Growth inhibition of human NB4 cells by SRB assay Growth inhibition of human NB4 cells by SRB assay	[PMID: 17892933]
NB-4	IC₅₀	0.71 μM Compound: SAHA	Antiproliferative activity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
NB-4	IC₅₀	0.98 μM Compound: SAHA, Vorinostat	Induction of apoptosis in human NB4 cells after 48 hrs by Annexin V test Induction of apoptosis in human NB4 cells after 48 hrs by Annexin V test	[PMID: 23792316]
NB-4	IC₅₀	1.2 μM Compound: SAHA	Antiproliferative activity against human NB-4 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human NB-4 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
NB-4	IC₅₀	1.52 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human NB4 cells after 48 hrs by MTT assay Cytotoxicity against human NB4 cells after 48 hrs by MTT assay	[PMID: 21476600]
NB-4	IC₅₀	3.3 μM Compound: SAHA	Antiproliferative activity against human NB4 cells after 72 hrs by MTT assay Antiproliferative activity against human NB4 cells after 72 hrs by MTT assay	[PMID: 29150335]
NB-4	IC₅₀	880 nM Compound: Vorinostat	Cytotoxicity against human NB-4 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human NB-4 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
NB1	IC₅₀	2.71 μM Compound: Vorinostat	Antiproliferative activity against human NB-1 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay Antiproliferative activity against human NB-1 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay	[PMID: 31391882]
NCI-H1299	IC₅₀	0.55 μM Compound: SAHA	Cytotoxicity against human NCI-H1299 by SRB assay Cytotoxicity against human NCI-H1299 by SRB assay	[PMID: 20855208]
NCI-H1299	IC₅₀	3.46 μM Compound: Vorinostat	Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
NCI-H1299	IC₅₀	4.92 μM Compound: 1; SAHA	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay	[PMID: 30045621]
NCI-H1299	IC₅₀	5.1 μM Compound: 5; SAHA	Antiproliferative activity against human NCI-H1299 cells after 96 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells after 96 hrs by MTT assay	[PMID: 31117517]
NCI-H1299	IC₅₀	5.53 μM Compound: Vorinostat	Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
NCI-H1299	IC₅₀	7.02 μM Compound: SAHA	Antiproliferative activity against human H1299 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human H1299 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
NCI-H1299	IC₅₀	7.24 μM Compound: 3, SAHA	Antiproliferative activity against H1299 cells Antiproliferative activity against H1299 cells	[PMID: 16904890]
NCI-H1299	IC₅₀	7240 nM Compound: SAHA (1)	Inhibitory activity against H1299 human lung carcinoma cell growth Inhibitory activity against H1299 human lung carcinoma cell growth	[PMID: 14521422]
NCI-H1299	IC₅₀	8200 nM Compound: 1, SAHA	Antiproliferative activity against human H1299 cells Antiproliferative activity against human H1299 cells	[PMID: 21650221]
NCI-H1373	IC₅₀	0.13 μM Compound: 1; SAHA	Antiproliferative activity against human NCI-H1373 cells assessed as inhibition of cell growth incubated for 6 days in presence of atamparib by celltiter-glo luminescent assay Antiproliferative activity against human NCI-H1373 cells assessed as inhibition of cell growth incubated for 6 days in presence of atamparib by celltiter-glo luminescent assay	[PMID: 38456618]
NCI-H1373	IC₅₀	1.46 μM Compound: 1; SAHA	Antiproliferative activity against human NCI-H1373 cells assessed as inhibition of cell growth incubated for 6 days by celltiter-glo luminescent assay Antiproliferative activity against human NCI-H1373 cells assessed as inhibition of cell growth incubated for 6 days by celltiter-glo luminescent assay	[PMID: 38456618]
NCI-H157	IC₅₀	1.33 μM Compound: Vorinostat	Antiproliferative activity against human NCI-H157 cells Antiproliferative activity against human NCI-H157 cells	[PMID: 37875056]
NCI-H1581	IC₅₀	2.501 μM Compound: SAHA	Cytotoxicity against human NCI-1581 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human NCI-1581 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
NCI-H1650	IC₅₀	5.5 μM Compound: 1; SAHA	Antiproliferative activity against human NCI-H1650 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human NCI-H1650 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
NCI-H1975	GI₅₀	0.98 μM Compound: 1; SAHA	Growth inhibition of human NCI-H1975 cells incubated for 48 hrs by SRB assay Growth inhibition of human NCI-H1975 cells incubated for 48 hrs by SRB assay	[PMID: 32058238]
NCI-H1975	GI₅₀	1.41 μM Compound: SAHA; 1	Antiproliferative activity against human NCI-H1975 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H1975 cells after 48 hrs by sulforhodamine B assay	[PMID: 29567459]
NCI-H1975	GI₅₀	2.61 μM Compound: 1; SAHA	Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31655430]
NCI-H1975	IC₅₀	1.7 μM Compound: SAHA	Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 48 hrs by Celltiter-glo assay Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 48 hrs by Celltiter-glo assay	[PMID: 38141287]
NCI-H1975	IC₅₀	1.9 μM Compound: 8	Antiproliferative activity against human NCI-H1975 expressing EGFR T790M/L858R mutant assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1975 expressing EGFR T790M/L858R mutant assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27769671]
NCI-H1975	IC₅₀	2.04 μM Compound: Vorinostat	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	[PMID: 33493830]
NCI-H1975	IC₅₀	2.08 μM Compound: SAHA	Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
NCI-H2122	IC₅₀	7.5 μM Compound: SAHA	Antiproliferative activity against human NCI-H2122 cells Antiproliferative activity against human NCI-H2122 cells	[PMID: 20143778]
NCI-H2126	IC₅₀	1.319 μM Compound: SAHA	Cytotoxicity against human NCI-H2126 by SRB assay Cytotoxicity against human NCI-H2126 by SRB assay	[PMID: 20855208]
NCI-H226	EC₅₀	2.6 μM Compound: SAHA	Inhibition of human NCI-H226 cells Inhibition of human NCI-H226 cells	[PMID: 18247554]
NCI-H226	EC₅₀	2.6 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human NCI-H226 cells Effective Concentration of compound to inhibit the growth of human NCI-H226 cells	[PMID: 15715470]
NCI-H226	GI₅₀	4 μM Compound: SAHA, Zolinza	Growth inhibition of human NCI-H226 cells after 72 hrs by MTS assay Growth inhibition of human NCI-H226 cells after 72 hrs by MTS assay	[PMID: 22435669]
NCI-H226	IC₅₀	3.48 μM Compound: SAHA	Cytotoxicity against human NCI-H226 by SRB assay Cytotoxicity against human NCI-H226 by SRB assay	[PMID: 20855208]
NCI-H226	IC₅₀	8.33 μM Compound: SAHA	Antiproliferative activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
NCI-H23	GI₅₀	0.92 μM Compound: 1, SAHA	Growth inhibition of NCI-H23 cells by SRB assay Growth inhibition of NCI-H23 cells by SRB assay	[PMID: 17477518]
NCI-H23	GI₅₀	0.92 μM Compound: 2, SAHA	Antiproliferative activity against human NCI-H23 cells by SRB assay Antiproliferative activity against human NCI-H23 cells by SRB assay	[PMID: 16723227]
NCI-H23	GI₅₀	1 μM Compound: SAHA, Zolinza	Growth inhibition of human NCI-H23 cells after 72 hrs by MTS assay Growth inhibition of human NCI-H23 cells after 72 hrs by MTS assay	[PMID: 22435669]
NCI-H23	GI₅₀	1.34 μM Compound: SAHA	Growth inhibition of human NCI-H23 cells after 21 hrs by MTT assay Growth inhibition of human NCI-H23 cells after 21 hrs by MTT assay	[PMID: 17662606]
NCI-H23	GI₅₀	2 μM Compound: SAHA; NSC759852	Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition at 10 uM incubated for 24 hrs by MTT assay Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition at 10 uM incubated for 24 hrs by MTT assay	[PMID: 36306372]
NCI-H23	GI₅₀	2.34 μM Compound: 1, SAHA	Growth inhibition of human NCI-H23 cells Growth inhibition of human NCI-H23 cells	[PMID: 20850971]
NCI-H23	GI₅₀	2.34 μM Compound: 1, SAHA, Zolinza, Vorinostat	Cytotoxicity against human NCI-H23 cells assessed as growth inhibition by SRB assay Cytotoxicity against human NCI-H23 cells assessed as growth inhibition by SRB assay	[PMID: 23163332]
NCI-H23	GI₅₀	2.34 μM Compound: SAHA	Growth inhibition of human NCI-H23 cells after 5 days by sulforhodamine B assay Growth inhibition of human NCI-H23 cells after 5 days by sulforhodamine B assay	[PMID: 25811792]
NCI-H23	GI₅₀	2.34 μM Compound: SAHA	Growth inhibition of human NCI-H23 cells measured after 5 days by sulforhodamine-B assay Growth inhibition of human NCI-H23 cells measured after 5 days by sulforhodamine-B assay	[PMID: 28011426]
NCI-H23	IC₅₀	0.383 μM Compound: SAHA	Cytotoxicity against human NCI-H23 by SRB assay Cytotoxicity against human NCI-H23 by SRB assay	[PMID: 20855208]
NCI-H23	IC₅₀	1.12 μM Compound: Vorinostat	Antiproliferative activity against human NCI-H23 cells incubated for 72 hrs by colorimetric method Antiproliferative activity against human NCI-H23 cells incubated for 72 hrs by colorimetric method	[PMID: 37875056]
NCI-H23	IC₅₀	1.44 μM Compound: SAHA	Cytotoxicity against human NCI-H23 cells by colorimetric method Cytotoxicity against human NCI-H23 cells by colorimetric method	[PMID: 32916298]
NCI-H23	IC₅₀	1.44 μM Compound: Vorinostat	Antiproliferative activity against human NCI-H23 cells incubated for 48 hrs by colorimetric method Antiproliferative activity against human NCI-H23 cells incubated for 48 hrs by colorimetric method	[PMID: 37875056]
NCI-H23	IC₅₀	2.8 μM Compound: Vorinostat	Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
NCI-H23	IC₅₀	3.2 μM Compound: SAHA	Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
NCI-H292	IC₅₀	1.11 μM Compound: SAHA	Growth inhibition of human NCI-H292 cells after 72 hrs by MTT assay Growth inhibition of human NCI-H292 cells after 72 hrs by MTT assay	[PMID: 28108250]
NCI-H292	IC₅₀	2.01 μM Compound: SAHA	Growth inhibition of human NCI-H292 cells in LDL depleted FBS containing medium after 72 hrs using compound after sonication in presence of LDL by MTT assay Growth inhibition of human NCI-H292 cells in LDL depleted FBS containing medium after 72 hrs using compound after sonication in presence of LDL by MTT assay	[PMID: 28108250]
NCI-H292	IC₅₀	4.61 μM Compound: SAHA	Growth inhibition of human NCI-H292 cells in FBS containing medium after 72 hrs using compound after sonication in presence of LDL by MTT assay Growth inhibition of human NCI-H292 cells in FBS containing medium after 72 hrs using compound after sonication in presence of LDL by MTT assay	[PMID: 28108250]
NCI-H292	IC₅₀	5.15 μM Compound: SAHA	Growth inhibition of human NCI-H292 cells after 72 hrs in presence of LDL by MTT assay Growth inhibition of human NCI-H292 cells after 72 hrs in presence of LDL by MTT assay	[PMID: 28108250]
NCI-H322M	GI₅₀	0.79 μM Compound: SAHA, Zolinza	Growth inhibition of human NCI-H322M cells after 72 hrs by MTS assay Growth inhibition of human NCI-H322M cells after 72 hrs by MTS assay	[PMID: 22435669]
NCI-H358	IC₅₀	2.5 μM Compound: SAHA	Antiproliferative activity against human NCI-H358 cells after hrs by ATP content assay Antiproliferative activity against human NCI-H358 cells after hrs by ATP content assay	[PMID: 20143778]
NCI-H441	IC₅₀	0.686 μM Compound: SAHA	Cytotoxicity against human H441 by SRB assay Cytotoxicity against human H441 by SRB assay	[PMID: 20855208]
NCI-H446	IC₅₀	0.34 μM Compound: 1; SAHA	Antiproliferative activity against human NCI-H446 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human NCI-H446 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
NCI-H460	GI₅₀	0.79 μM Compound: SAHA, Zolinza	Growth inhibition of human NCI-H460 cells after 72 hrs by MTS assay Growth inhibition of human NCI-H460 cells after 72 hrs by MTS assay	[PMID: 22435669]
NCI-H460	GI₅₀	0.85 μM Compound: 1, SAHA	Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 24119555]
NCI-H460	GI₅₀	0.85 μM Compound: SAHA	Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 25800646]
NCI-H460	GI₅₀	1 μM Compound: SAHA	Cytotoxicity against human NCI-H460 cells by MTT assay Cytotoxicity against human NCI-H460 cells by MTT assay	[PMID: 23538115]
NCI-H460	GI₅₀	8 μM Compound: SAHA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 20605448]
NCI-H460	IC₅₀	0.425 μM Compound: 1; SAHA	Antiproliferative activity against human NCI-H460 cells after 72 hrs by resazurin dye based fluorescence assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by resazurin dye based fluorescence assay	[PMID: 29456804]
NCI-H460	IC₅₀	0.68 μg/mL Compound: SAHA	Cytotoxicity against human NCI-H460 cells Cytotoxicity against human NCI-H460 cells	[PMID: 22036991]
NCI-H460	IC₅₀	0.82 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human H460 cells by MTT assay Cytotoxicity against human H460 cells by MTT assay	[PMID: 24766560]
NCI-H460	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human NCI-H460 cells after 72 hrs by SRB assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by SRB assay	[PMID: 29150335]
NCI-H460	IC₅₀	1 μM Compound: Vorinostat	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability by SRB assay	[PMID: 30660827]
NCI-H460	IC₅₀	1.2 μM Compound: 2	Cytotoxicity against human NCI H460 cells Cytotoxicity against human NCI H460 cells	[PMID: 17691763]
NCI-H460	IC₅₀	1.7 μM Compound: SAHA	Antiproliferative activity against human H460 cells after hrs by ATP content assay Antiproliferative activity against human H460 cells after hrs by ATP content assay	[PMID: 20143778]
NCI-H460	IC₅₀	1.7 μM Compound: SAHA; 112	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation by CCK-8 assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation by CCK-8 assay	[PMID: 31881454]
NCI-H460	IC₅₀	1.7 μM Compound: Vorinostat	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability	[PMID: 30660827]
NCI-H460	IC₅₀	100 μM Compound: 5; SAHA	Antiproliferative activity against human NCI-H460 cells after 96 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 96 hrs by MTT assay	[PMID: 31117517]
NCI-H460	IC₅₀	11.92 μM Compound: SAHA	Antiproliferative activity against human H460 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human H460 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
NCI-H460	IC₅₀	2.77 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human NCI-H460 cells after 48 hrs by SRB assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 24185378]
NCI-H460	IC₅₀	3.04 μM Compound: SAHA	Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
NCI-H460	IC₅₀	3.4 μM Compound: 2, SAHA	Growth inhibition of human H460 cells after 48 hrs by SRB assay Growth inhibition of human H460 cells after 48 hrs by SRB assay	[PMID: 21073160]
NCI-H460	IC₅₀	3.4 μM Compound: SAHA	Antiproliferative activity against human H460 cells after 72 hrs Antiproliferative activity against human H460 cells after 72 hrs	[PMID: 19084294]
NCI-H460	IC₅₀	3.4 μM Compound: SAHA	Cytotoxicity against human H460 cells after 24 hrs by sulforhodamine B assay Cytotoxicity against human H460 cells after 24 hrs by sulforhodamine B assay	[PMID: 19359173]
NCI-H460	IC₅₀	3.4 μM Compound: SAHA	Antiproliferative activity against human H460 cells assessed as growth inhibition after 72 hrs Antiproliferative activity against human H460 cells assessed as growth inhibition after 72 hrs	[PMID: 24742384]
NCI-H460	IC₅₀	3.4 μM Compound: SAHA	Growth inhibition of human H460 cells after 72 hrs Growth inhibition of human H460 cells after 72 hrs	[PMID: 26376355]
NCI-H460	IC₅₀	3.4 μM Compound: SAHA	Antiproliferative activity against human H460 cells assessed as reduction in cell number after 72 hrs by cell counter analysis Antiproliferative activity against human H460 cells assessed as reduction in cell number after 72 hrs by cell counter analysis	[PMID: 26890116]
NCI-H460	IC₅₀	3.4 μM Compound: SAHA, Vorinostat	Cytotoxicity against human H460 cells Cytotoxicity against human H460 cells	[PMID: 24345446]
NCI-H460	IC₅₀	3.4 μM Compound: SAHA, vorinostat	Growth inhibition of human H460 cells by SRB assay Growth inhibition of human H460 cells by SRB assay	[PMID: 17892933]
NCI-H460	IC₅₀	3.448 μM Compound: SAHA	Cytotoxicity against human NCI-H460 by SRB assay Cytotoxicity against human NCI-H460 by SRB assay	[PMID: 20855208]
NCI-H460	IC₅₀	3400 nM Compound: 1, SAHA	Cytotoxicity against human NCI-H460 cells Cytotoxicity against human NCI-H460 cells	[PMID: 25563890]
NCI-H460	IC₅₀	4.136 μM Compound: SAHA	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
NCI-H460	IC₅₀	4.2 μM Compound: SAHA	Antiproliferative activity against human NCI-H460 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human NCI-H460 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
NCI-H460	IC₅₀	5.46 μM Compound: Vorinostat	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
NCI-H460	IC₅₀	6.29 μM Compound: Vorinostat	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
NCI-H460	IC₅₀	> 10 μM Compound: SAHA	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
NCI-H460	IC₅₀	> 1000 nM Compound: SAHA	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 26443078]
NCI-H522	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human NCI-H522 cells after 72 hrs by MTS assay Growth inhibition of human NCI-H522 cells after 72 hrs by MTS assay	[PMID: 22435669]
NCI-H522	IC₅₀	0.832 μM Compound: SAHA	Cytotoxicity against human NCI-H522 by SRB assay Cytotoxicity against human NCI-H522 by SRB assay	[PMID: 20855208]
NCI-H522	IC₅₀	1.72 μM Compound: SAHA	Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	[PMID: 35984756]
NCI-H522	IC₅₀	2.38 μM Compound: SAHA	Anticancer activity against human NCI-H522 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay Anticancer activity against human NCI-H522 cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay	[PMID: 36244186]
NCI-H526	GI₅₀	0.481 μM Compound: Vorinostat	Antiproliferative activity against human NCI-H526 cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay Antiproliferative activity against human NCI-H526 cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay	[PMID: 36262394]
NCI-H661	IC₅₀	0.13 μM Compound: SAHA, Zolinza	Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
NCI-H661	IC₅₀	0.13 μM Compound: Vorinostat	Antiproliferative activity against human NCI-H661 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H661 cells incubated for 72 hrs by MTT assay	[PMID: 25953722]
NCI-H661	IC₅₀	1 μM Compound: 1	Antiproliferative activity against human H661 cells after 48 hrs Antiproliferative activity against human H661 cells after 48 hrs	[PMID: 17157009]
NCI-H661	IC₅₀	5 μM Compound: SAHA	Antiproliferative activity against H661 cells after 48 hrs Antiproliferative activity against H661 cells after 48 hrs	[PMID: 17897824]
NCI-H661	IC₅₀	> 5 μM Compound: 3, SAHA	Antiproliferative activity against H661 cells Antiproliferative activity against H661 cells	[PMID: 16904890]
NCI-H69	EC₅₀	2.06 μM Compound: SAHA	Cytotoxicity against human NCI-H69 cells after 72 hrs by trypan blue exclusion assay Cytotoxicity against human NCI-H69 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19093884]
NCI-H69	IC₅₀	0.6 μM Compound: SAHA	Cytotoxicity against human H69 cells Cytotoxicity against human H69 cells	[PMID: 23906422]
NCI-H727	IC₅₀	1.37 μM Compound: SAHA	Cytotoxicity against human NCI-H727 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H727 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 35858522]
NCI-H838	IC₅₀	5.18 μM Compound: Vorinostat	Antiproliferation activity against human NCI-H838 cells incubated for 72 hrs by MTT assay Antiproliferation activity against human NCI-H838 cells incubated for 72 hrs by MTT assay	[PMID: 33493830]
NCI-H929	EC₅₀	1.4 μM Compound: 3; SAHA	Antiproliferative activity against human NCI-H929 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human NCI-H929 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31627059]
NCI-H929	IC₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human NCI-H929 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H929 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25238284]
NCI-H929	IC₅₀	2.83 μM Compound: SAHA	Antiproliferative activity against human NCI-H929 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay Antiproliferative activity against human NCI-H929 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	[PMID: 26890114]
NCI-N87	IC₅₀	1027 nM Compound: 1; SAHA	Antiproliferative activity against human NCI-N87 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-N87 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
NCI/ADR-RES	GI₅₀	0.16 μM Compound: SAHA, Zolinza	Growth inhibition of human NCI-ADR-RES cells after 72 hrs by MTS assay Growth inhibition of human NCI-ADR-RES cells after 72 hrs by MTS assay	[PMID: 22435669]
NCI/ADR-RES	IC₅₀	1413.4 nM Compound: SAHA	Cytotoxicity against human MCF7/ADR cells after 72 hrs by SRB assay Cytotoxicity against human MCF7/ADR cells after 72 hrs by SRB assay	[PMID: 30819618]
NFF	IC₅₀	5.5 μM Compound: SAHA	Cytotoxicity against human NFF cells incubated for 72 hrs by SRB assay Cytotoxicity against human NFF cells incubated for 72 hrs by SRB assay	[PMID: 39208744]
NFF	IC₅₀	5170 nM Compound: SAHA	Cytotoxicity against human NFF cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human NFF cells after 72 hrs by sulforhodamine B assay	[PMID: 30245402]
NIH3T3	EC₅₀	4.8 μM Compound: SAHA	Cytotoxicity against mouse NIH/3T3 cells assessed as cell proliferation after 70 hrs by MTS assay Cytotoxicity against mouse NIH/3T3 cells assessed as cell proliferation after 70 hrs by MTS assay	[PMID: 25974739]
NIH3T3	IC₅₀	16.6 μM Compound: SAHA	Antiproliferative activity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 3 days by CCK-8 assay Antiproliferative activity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 3 days by CCK-8 assay	[PMID: 37463500]
NSC	IC₅₀	4 μM Compound: Chemical Probe: Vorinostat	Cytotoxicity against human fetal NSC assessed as reduction in cell vaibility incubated for 48 hrs by alamar blue assay Cytotoxicity against human fetal NSC assessed as reduction in cell vaibility incubated for 48 hrs by alamar blue assay	[PMID: 30559935]
NUGC-3	GI₅₀	2.79 μM Compound: 2, SAHA	Growth inhibition of human NUGC3 cells by SRB assay Growth inhibition of human NUGC3 cells by SRB assay	[PMID: 17904843]
NUGC-3	GI₅₀	2.94 μM Compound: 1, SAHA	Growth inhibition of human NUGC3 cells Growth inhibition of human NUGC3 cells	[PMID: 20850971]
NUGC-3	GI₅₀	2.94 μM Compound: 1, SAHA, Zolinza, Vorinostat	Cytotoxicity against human NUGC3 cells assessed as growth inhibition by SRB assay Cytotoxicity against human NUGC3 cells assessed as growth inhibition by SRB assay	[PMID: 23163332]
NUGC-3	GI₅₀	2.94 μM Compound: SAHA	Growth inhibition of human NUGC3 cells after 5 days by sulforhodamine B assay Growth inhibition of human NUGC3 cells after 5 days by sulforhodamine B assay	[PMID: 25811792]
NUGC-3	GI₅₀	2.94 μM Compound: SAHA	Growth inhibition of human NUGC3 cells measured after 5 days by sulforhodamine-B assay Growth inhibition of human NUGC3 cells measured after 5 days by sulforhodamine-B assay	[PMID: 28011426]
Non-small cell lung cancer cell line	IC₅₀	> 1 μM Compound: 1; SAHA	Antiproliferative activity against non-small cell lung cancer cell line (unknown origin) Antiproliferative activity against non-small cell lung cancer cell line (unknown origin)	[PMID: 33077264]
OCI-AML-3	IC₅₀	0.85 μM Compound: 5; SAHA	Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay	[PMID: 28765013]
OCI-AML-3	IC₅₀	1365 nM Compound: SAHA	Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay	[PMID: 27505848]
OCI-AML-3	IC₅₀	300 nM Compound: SAHA	Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay	[PMID: 30629434]
OCI-AML2	IC₅₀	0.78 μM Compound: 5; SAHA	Antiproliferative activity against human OCI-AML2 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-AML2 cells after 72 hrs by MTT assay	[PMID: 28765013]
OCI-AML2	IC₅₀	390 nM Compound: SAHA	Antiproliferative activity against human OCI-AML2 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-AML2 cells after 72 hrs by MTT assay	[PMID: 30629434]
OCI-Ly3	IC₅₀	2.2 μM Compound: SAHA	Antiproliferative activity against human OCI-LY3 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-LY3 cells after 72 hrs by MTT assay	[PMID: 29150335]
OE19	GI₅₀	1.42 μM Compound: Vorinostat	Antiproliferative activity against human OE19 cells assessed as reduction in cell viability incubated for 72 hrs by presto blue assay Antiproliferative activity against human OE19 cells assessed as reduction in cell viability incubated for 72 hrs by presto blue assay	[PMID: 31420257]
OE33	GI₅₀	1.12 μM Compound: Vorinostat	Antiproliferative activity against human OE33 cells assessed as reduction in cell viability incubated for 72 hrs by presto blue assay Antiproliferative activity against human OE33 cells assessed as reduction in cell viability incubated for 72 hrs by presto blue assay	[PMID: 31420257]
ONS-76	IC₅₀	2.04 μM Compound: Vorinostat	Antiproliferative activity against human ONS76 cells after 72 hrs by Celltiter-Glo assay Antiproliferative activity against human ONS76 cells after 72 hrs by Celltiter-Glo assay	[PMID: 28581289]
OPM-2	EC₅₀	2.9 μM Compound: 3; SAHA	Antiproliferative activity against human OPM2 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human OPM2 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31627059]
OPM-2	IC₅₀	2.91 μM Compound: 1; SAHA	Antiproliferative activity against human OPM2 cells after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human OPM2 cells after 48 hrs by CellTiter-Glo assay	[PMID: 27541357]
OPM-2	IC₅₀	2.91 μM Compound: 2	Antiproliferative activity against human OPM2 cells after 48 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human OPM2 cells after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 28953386]
OVCAR-3	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human OVCAR3 cells after 72 hrs by MTS assay Growth inhibition of human OVCAR3 cells after 72 hrs by MTS assay	[PMID: 22435669]
OVCAR-3	GI₅₀	1.4 μM Compound: SAHA	Antiproliferative activity against human OVCAR3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human OVCAR3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
OVCAR-3	GI₅₀	2 μM Compound: SAHA, Zolinza	Growth inhibition of human OVCAR3 cells after 72 hrs by MTS assay Growth inhibition of human OVCAR3 cells after 72 hrs by MTS assay	[PMID: 22435669]
OVCAR-4	GI₅₀	4 μM Compound: SAHA, Zolinza	Growth inhibition of human OVCAR4 cells after 72 hrs by MTS assay Growth inhibition of human OVCAR4 cells after 72 hrs by MTS assay	[PMID: 22435669]
OVCAR-5	GI₅₀	0.79 μM Compound: SAHA, Zolinza	Growth inhibition of human OVCAR5 cells after 72 hrs by MTS assay Growth inhibition of human OVCAR5 cells after 72 hrs by MTS assay	[PMID: 22435669]
OVCAR-5	GI₅₀	1.78 μM Compound: 1, SAHA	Antiproliferative activity against human OVCAR5 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human OVCAR5 cells after 48 hrs by sulforhodamine B assay	[PMID: 24119555]
OVCAR-5	GI₅₀	1.78 μM Compound: SAHA	Antiproliferative activity against human OVCAR5 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human OVCAR5 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 25800646]
OVCAR-8	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human OVCAR8 cells after 72 hrs by MTS assay Growth inhibition of human OVCAR8 cells after 72 hrs by MTS assay	[PMID: 22435669]
Osteoclast-like	EC₅₀	150 μM Compound: SAHA	Compound was tested for anti-proliferative activity in human bone marrow cells Compound was tested for anti-proliferative activity in human bone marrow cells	[PMID: 14698179]
PANC-1	GI₅₀	678 nM Compound: SAHA	Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay	[PMID: 24999749]
PANC-1	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
PANC-1	IC₅₀	0.9 μM Compound: Vorinostat	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
PANC-1	IC₅₀	2.43 μM Compound: SAHA	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
PANC-1	IC₅₀	2.52 μM Compound: SAHA	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
PANC-1	IC₅₀	3.14 μM Compound: SAHA	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 37116762]
PANC-1	IC₅₀	450 nM Compound: 5, Zolinza	Antiproliferative activity against human PANC1 cells Antiproliferative activity against human PANC1 cells	[PMID: 17588744]
PANC-1	IC₅₀	> 10 μM Compound: SAHA	Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
PBL	IC₅₀	3.4 μM Compound: Vorinostat	Cytotoxicity against human PBL cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human PBL cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 30004697]
PBMC	IC₅₀	229 nM Compound: SAHA	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-stimulated TNF-alpha production incubated for 30 mins prior to LPS-challenge measured after overnight incubation Antiinflammatory activity in human PBMC assessed as inhibition of LPS-stimulated TNF-alpha production incubated for 30 mins prior to LPS-challenge measured after overnight incubation	10.1039/C3MD00285C
PBMC	IC₅₀	955 nM Compound: SAHA	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-stimulated IL-6 production incubated for 30 mins prior to LPS-challenge measured after overnight incubation Antiinflammatory activity in human PBMC assessed as inhibition of LPS-stimulated IL-6 production incubated for 30 mins prior to LPS-challenge measured after overnight incubation	10.1039/C3MD00285C
PBMC	IC₅₀	< 3.5 μM Compound: Vorinostat	Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30365892]
PC-3	EC₅₀	> 166.67 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 23820574]
PC-3	GI₅₀	0.6 μM Compound: 1; SAHA	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
PC-3	GI₅₀	0.71 μM Compound: SAHA	Growth inhibition of human PC3 cells after 21 hrs by MTT assay Growth inhibition of human PC3 cells after 21 hrs by MTT assay	[PMID: 17662606]
PC-3	GI₅₀	0.73 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay	[PMID: 27344487]
PC-3	GI₅₀	0.89 μM Compound: 1, SAHA	Growth inhibition of PC3 cells by SRB assay Growth inhibition of PC3 cells by SRB assay	[PMID: 17477518]
PC-3	GI₅₀	0.89 μM Compound: 2, SAHA	Antiproliferative activity against human PC3 cells by SRB assay Antiproliferative activity against human PC3 cells by SRB assay	[PMID: 16723227]
PC-3	GI₅₀	0.96 μM Compound: Vorinostat	Growth inhibition of human PC3 cells after 72 hrs by CellTiter Glo assay Growth inhibition of human PC3 cells after 72 hrs by CellTiter Glo assay	[PMID: 25182565]
PC-3	GI₅₀	1.02 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay	[PMID: 21712146]
PC-3	GI₅₀	1.21 μM Compound: 1, SAHA	Growth inhibition of human PC3 cells after 48 hrs by SRB assay Growth inhibition of human PC3 cells after 48 hrs by SRB assay	[PMID: 22439863]
PC-3	GI₅₀	1.6 μM Compound: SAHA, Zolinza	Growth inhibition of human PC3 cells after 72 hrs by MTS assay Growth inhibition of human PC3 cells after 72 hrs by MTS assay	[PMID: 22435669]
PC-3	GI₅₀	1.7 μM Compound: Vorinostat	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay	[PMID: 37875056]
PC-3	GI₅₀	1.77 μM Compound: 1, SAHA	Growth inhibition of human PC3 cells after 96 hrs by MTT assay Growth inhibition of human PC3 cells after 96 hrs by MTT assay	[PMID: 26814680]
PC-3	GI₅₀	18.83 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28629630]
PC-3	GI₅₀	2 μM Compound: SAHA, Zolinza	Growth inhibition of human PC3 cells after 72 hrs by MTS assay Growth inhibition of human PC3 cells after 72 hrs by MTS assay	[PMID: 22435669]
PC-3	GI₅₀	2.69 μM Compound: 1, SAHA, Zolinza, Vorinostat	Cytotoxicity against human PC3 cells assessed as growth inhibition by SRB assay Cytotoxicity against human PC3 cells assessed as growth inhibition by SRB assay	[PMID: 23163332]
PC-3	GI₅₀	2.69 μM Compound: 2, SAHA	Growth inhibition of human PC3 cells by SRB assay Growth inhibition of human PC3 cells by SRB assay	[PMID: 17904843]
PC-3	GI₅₀	2.69 μM Compound: SAHA	Growth inhibition of human PC3 cells after 5 days by sulforhodamine B assay Growth inhibition of human PC3 cells after 5 days by sulforhodamine B assay	[PMID: 25811792]
PC-3	GI₅₀	2.69 μM Compound: SAHA	Growth inhibition of human PC3 cells measured after 5 days by sulforhodamine-B assay Growth inhibition of human PC3 cells measured after 5 days by sulforhodamine-B assay	[PMID: 28011426]
PC-3	GI₅₀	2000 nM Compound: SAHA, vorinostat	Antiproliferative activity against human PC3 cells after 72 hrs by WST-1 assay Antiproliferative activity against human PC3 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
PC-3	GI₅₀	4.6 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
PC-3	GI₅₀	5 μM Compound: Vorinostat	Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay	[PMID: 30802730]
PC-3	GI₅₀	8.17 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 19822426]
PC-3	GI₅₀	> 410 nM Compound: Vorinostat	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
PC-3	IC₅₀	0.21 μM Compound: Vorinostat	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
PC-3	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
PC-3	IC₅₀	0.85 μM Compound: 1; SAHA	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 27541357]
PC-3	IC₅₀	0.85 μM Compound: 2	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 28953386]
PC-3	IC₅₀	0.85 μM Compound: 4	Antiproliferative activity against human PC3 cells Antiproliferative activity against human PC3 cells	[PMID: 29945795]
PC-3	IC₅₀	0.94 μg/mL Compound: SAHA	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 22036991]
PC-3	IC₅₀	1 μM Compound: 4	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 30243158]
PC-3	IC₅₀	1.12 μM Compound: Vorinostat	Antiproliferative activity against human PC-3 cells incubated for 72 hrs by colorimetric method Antiproliferative activity against human PC-3 cells incubated for 72 hrs by colorimetric method	[PMID: 37875056]
PC-3	IC₅₀	1.14 μM Compound: SAHA	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
PC-3	IC₅₀	1.21 μM Compound: SAHA	Antiproliferative activity against human PC3 cells Antiproliferative activity against human PC3 cells	[PMID: 20451378]
PC-3	IC₅₀	1.21 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human PC3 cells after 96 hrs by celltiter 96 assay Antiproliferative activity against human PC3 cells after 96 hrs by celltiter 96 assay	[PMID: 21634430]
PC-3	IC₅₀	1.33 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 21714538]
PC-3	IC₅₀	1.34 μM Compound: 1; SAHA	Antiproliferative activity against human PC-3 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human PC-3 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
PC-3	IC₅₀	1.35 μM Compound: Vorinostat	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
PC-3	IC₅₀	1.41 μM Compound: SAHA	Antiproliferative activity against human PC-3 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human PC-3 cells incubated for 72 hrs by CCK-8 assay	[PMID: 37057760]
PC-3	IC₅₀	1.42 μM Compound: SAHA	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C4MD00203B
PC-3	IC₅₀	1.44 μM Compound: Vorinostat	Antiproliferative activity against human PC-3 cells incubated for 48 hrs by colorimetric method Antiproliferative activity against human PC-3 cells incubated for 48 hrs by colorimetric method	[PMID: 37875056]
PC-3	IC₅₀	1.5 μM Compound: SAHA	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 29223096]
PC-3	IC₅₀	1.56 μM Compound: 1; SAHA	Antiproliferative activity against human PC-3 cells incubated for 48 hrs by Sulforhodamine B staining method Antiproliferative activity against human PC-3 cells incubated for 48 hrs by Sulforhodamine B staining method	[PMID: 33077264]
PC-3	IC₅₀	1.7 μM Compound: SAHA; 112	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell proliferation by CCK-8 assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell proliferation by CCK-8 assay	[PMID: 31881454]
PC-3	IC₅₀	1.7 μM Compound: Vorinostat	Cytotoxicity against human PC3 cells assessed as reduction in cell viability Cytotoxicity against human PC3 cells assessed as reduction in cell viability	[PMID: 30660827]
PC-3	IC₅₀	1.74 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human PC3 cells by MTT assay Cytotoxicity against human PC3 cells by MTT assay	[PMID: 24766560]
PC-3	IC₅₀	1.81 μM Compound: SAHA	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 31883490]
PC-3	IC₅₀	1.82 μM Compound: SAHA	Cytotoxicity against human PC3 cells by colorimetric method Cytotoxicity against human PC3 cells by colorimetric method	[PMID: 32916298]
PC-3	IC₅₀	1.86 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 30879863]
PC-3	IC₅₀	1.9 μM Compound: 2	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 17691763]
PC-3	IC₅₀	1.9 μM Compound: SAHA	Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 35152694]
PC-3	IC₅₀	1.92 μM Compound: SAHA, Zolinza	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 26100440]
PC-3	IC₅₀	1.98 μM Compound: SAHA, Vorinostat	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 21924799]
PC-3	IC₅₀	10.4 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 26216016]
PC-3	IC₅₀	13.91 μM Compound: Vorinostat	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28371677]
PC-3	IC₅₀	16.28 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28336407]
PC-3	IC₅₀	16.28 μM Compound: Vorinostat	Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition	[PMID: 38107170]
PC-3	IC₅₀	1791 nM Compound: 1; SAHA	Antiproliferative activity against human PC-3 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human PC-3 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
PC-3	IC₅₀	2.03 μM Compound: SAHA	Antiproliferative activity against human PC3 cells incubated for 96 hrs by resazurin assay Antiproliferative activity against human PC3 cells incubated for 96 hrs by resazurin assay	[PMID: 32435375]
PC-3	IC₅₀	2.38 μM Compound: SAHA	Cytotoxicity against human PC-3 cells incubated for 72 hrs by MTT assay Cytotoxicity against human PC-3 cells incubated for 72 hrs by MTT assay	[PMID: 38452727]
PC-3	IC₅₀	2.459 μM Compound: SAHA	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
PC-3	IC₅₀	2.58 μM Compound: SAHA	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 30245394]
PC-3	IC₅₀	2.69 μM Compound: 1, SAHA	Growth inhibition of human PC3 cells Growth inhibition of human PC3 cells	[PMID: 20850971]
PC-3	IC₅₀	2.78 μM Compound: 1, SAHA	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26122774]
PC-3	IC₅₀	2.9 μM Compound: Vorinostat	Antiproliferative activity against human PC3 cells by CCK8 assay Antiproliferative activity against human PC3 cells by CCK8 assay	[PMID: 30660827]
PC-3	IC₅₀	2.92 μM Compound: SAHA	Anti-proliferative activity against human PC3 cells after 48 hrs by MTT assay Anti-proliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28947154]
PC-3	IC₅₀	3 μM Compound: 2; SAHA	Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34634618]
PC-3	IC₅₀	3 μM Compound: SAHA	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
PC-3	IC₅₀	3.02 μM Compound: XII; SAHA	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
PC-3	IC₅₀	3.07 μM Compound: Vor; SAHA	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay	[PMID: 29360358]
PC-3	IC₅₀	3.11 μM Compound: SAHA	Inhibition of PC3 cell proliferation (mean of two experiments) Inhibition of PC3 cell proliferation (mean of two experiments)	[PMID: 17095213]
PC-3	IC₅₀	3.2 μM Compound: SAHA	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
PC-3	IC₅₀	3.22 μM Compound: SAHA	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 37079967]
PC-3	IC₅₀	3.31 μM Compound: 1; SAHA	Cytotoxicity against human PC-3 cells Cytotoxicity against human PC-3 cells	[PMID: 33077264]
PC-3	IC₅₀	3.46 μM Compound: SAHA	Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 28987602]
PC-3	IC₅₀	3.57 μM Compound: SA, SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 24694055]
PC-3	IC₅₀	3.57 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 25462271]
PC-3	IC₅₀	3.6 μM Compound: 1; SAHA	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
PC-3	IC₅₀	3052.4 nM Compound: SAHA	Inhibition of Class 2a histone deacetylase in human PC3 cells using Boc-Lys (triflouroacetyl)-AMC as substrate preincubated for 3 hrs followed by substrate addition measured after 3 hrs by fluorescence assay Inhibition of Class 2a histone deacetylase in human PC3 cells using Boc-Lys (triflouroacetyl)-AMC as substrate preincubated for 3 hrs followed by substrate addition measured after 3 hrs by fluorescence assay	[PMID: 26349626]
PC-3	IC₅₀	4.31 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay	[PMID: 24185378]
PC-3	IC₅₀	403 nM Compound: Vorinostat	Antiproliferative activity against human PC-3 cells Antiproliferative activity against human PC-3 cells	[PMID: 37875056]
PC-3	IC₅₀	447.6 nM Compound: SAHA	Inhibition of Class 1 histone deacetylase in human PC3 cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 3 hrs followed by substrate addition measured after 3 hrs by fluorescence assay Inhibition of Class 1 histone deacetylase in human PC3 cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 3 hrs followed by substrate addition measured after 3 hrs by fluorescence assay	[PMID: 26349626]
PC-3	IC₅₀	5.36 μM Compound: SAHA	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26349626]
PC-3	IC₅₀	5.79 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 25311567]
PC-3	IC₅₀	6.5 μM Compound: SAHA	Concentration required to inhibit human PC-3 prostate carcinoma cells Concentration required to inhibit human PC-3 prostate carcinoma cells	[PMID: 16033284]
PC-3	IC₅₀	6.5 μM Compound: vorinostat	Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 20403695]
PC-3	IC₅₀	6.7 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 29533873]
PC-3	IC₅₀	60.8 μM Compound: SAHA	Antiproliferative activity against human PC3 cells incubated for 24 hrs by CCK8 assay Antiproliferative activity against human PC3 cells incubated for 24 hrs by CCK8 assay	[PMID: 32247729]
PC-3	IC₅₀	7.26 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 26907204]
PC-3	IC₅₀	7.3 μM Compound: SAHA	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26149591]
PC-3	IC₅₀	873.26 nM Compound: 1; SAHA	Antiproliferative activity against human PC3 cells measured after 48 hrs by sulforhodamine-B assay Antiproliferative activity against human PC3 cells measured after 48 hrs by sulforhodamine-B assay	[PMID: 27886544]
PC-3	IC₅₀	9.79 μM Compound: 1, SAHA	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 24525003]
PC-3	IC₅₀	9.9 μM Compound: 1, SAHA	Inhibition of human PC3 cell proliferation after 48 hrs by MTT assay Inhibition of human PC3 cell proliferation after 48 hrs by MTT assay	[PMID: 23493449]
PC-3	IC₅₀	> 10 μM Compound: SAHA	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
PC-3	IC₅₀	> 5 μM Compound: SAHA	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 29787262]
PC-9	IC₅₀	1.1 μM Compound: SAHA; 6	Antiproliferative activity against human PC-9 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human PC-9 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
PC-9	IC₅₀	1.15 μM Compound: SAHA	Antiproliferative activity against human PC-9 cells incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human PC-9 cells incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 39145486]
PC-9	IC₅₀	1181 nM Compound: 1; SAHA	Antiproliferative activity against human PC-9 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human PC-9 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
PLC	IC₅₀	1.534 μM Compound: SAHA	Cytotoxicity against human PLC cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human PLC cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
PLC-PRF-5	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human PLC-PRF-5 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human PLC-PRF-5 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
PLC-PRF-5	IC₅₀	1.87 μM Compound: Vor; SAHA	Antiproliferative activity against human PLC-PRF-5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human PLC-PRF-5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
PLC-PRF-5	IC₅₀	2.22 μM Compound: SAHA	Antiproliferative activity against human PLC-PRF-5 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human PLC-PRF-5 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
PT-45	IC₅₀	4000 nM Compound: 5, Zolinza	Antiproliferative activity against human drug-resistant PT45 cells Antiproliferative activity against human drug-resistant PT45 cells	[PMID: 17588744]
RAW264.7	IC₅₀	0.76 μM Compound: 1, SAHA	Inhibition of LPS-stimulated TNFalpha production in RAW264.7 cells after 24 hrs by ELISA Inhibition of LPS-stimulated TNFalpha production in RAW264.7 cells after 24 hrs by ELISA	[PMID: 17477518]
RAW264.7	IC₅₀	1.88 μM Compound: 1, SAHA	Inhibition of LPS-stimulated NO production in RAW264.7 cells after 24 hrs by ELISA Inhibition of LPS-stimulated NO production in RAW264.7 cells after 24 hrs by ELISA	[PMID: 17477518]
RAW264.7	IC₅₀	110 nM Compound: SAHA, WR-308364	Antimalarial activity against Plasmodium falciparum infected in mouse RAW264.7 cells Antimalarial activity against Plasmodium falciparum infected in mouse RAW264.7 cells	[PMID: 18644969]
RPMI-8226	GI₅₀	1.5 μM Compound: SAHA; NSC759852	Cytotoxicity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Cytotoxicity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 36306372]
RPMI-8226	IC₅₀	0.43 μM Compound: SAHA	Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 72 hrs by alamar blue dye based assay Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 72 hrs by alamar blue dye based assay	[PMID: 37660484]
RPMI-8226	IC₅₀	0.57 μM Compound: SAHA	Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay	[PMID: 31413795]
RPMI-8226	IC₅₀	0.66 μM Compound: SAHA	Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 29534936]
RPMI-8226	IC₅₀	0.684 μM Compound: SAHA	Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay	[PMID: 31865013]
RPMI-8226	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human RPMI8226 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	[PMID: 26890114]
RPMI-8226	IC₅₀	1.25 μM Compound: SAHA	Antiproliferative activity against human RPMI8226 cells after 72 hrs by CellTiter 96 AQueous Non-Radioactive assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by CellTiter 96 AQueous Non-Radioactive assay	[PMID: 28213282]
RPMI-8226	IC₅₀	10.6 μM Compound: SAHA	Growth inhibition of human RPMI8226 cells after 72 hrs by MTT assay Growth inhibition of human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 30594434]
RPMI-8226	IC₅₀	2.39 μM Compound: SAHA	Antiproliferative activity against human RPMI8226 cells after 72 hrs by WST8 assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by WST8 assay	[PMID: 25261927]
RPMI-8226	IC₅₀	2.39 μM Compound: SAHA	Cytotoxicity against human RPMI8226 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human RPMI8226 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 26211462]
RPMI-8226	IC₅₀	2.4 μM Compound: SAHA	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay	[PMID: 25490132]
RPMI-8226	IC₅₀	423 nM Compound: SAHA	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 26443078]
RPMI-8226	IC₅₀	585.8 nM Compound: SAHA	Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 31177073]
RPMI-8226	IC₅₀	870 nM Compound: SAHA	Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
RS4-11	IC₅₀	3.98 μM Compound: SAHA	Antiproliferative activity against human RS4-11 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human RS4-11 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34954595]
RWPE-1	GI₅₀	1.6 μM Compound: SAHA	Antiproliferative activity against human RWPE-1 cells assessed as growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human RWPE-1 cells assessed as growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37633202]
RWPE-1	IC₅₀	0.48 μM Compound: 1; SAHA	Cytotoxicity against human RWPE-1 cells Cytotoxicity against human RWPE-1 cells	[PMID: 33077264]
RWPE-1	IC₅₀	3.64 μM Compound: SAHA	Cytotoxicity against human RWPE1 cells Cytotoxicity against human RWPE1 cells	[PMID: 30245394]
RXF 393	GI₅₀	1.3 μM Compound: SAHA	Antiproliferative activity against human RXF393 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human RXF393 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
RXF 393	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human RXF393 cells after 72 hrs by MTS assay Growth inhibition of human RXF393 cells after 72 hrs by MTS assay	[PMID: 22435669]
RXF 631	GI₅₀	2 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human RXF631L cells after 48 hrs by sulforhodamine B assay Growth inhibition of human RXF631L cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
Raji	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human Raji cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human Raji cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
Raji	IC₅₀	0.97 nM Compound: SAHA	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	[PMID: 28325601]
Raji	IC₅₀	0.97 μM Compound: SAHA	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	[PMID: 29534936]
Raji	IC₅₀	1.11 μM Compound: Vor; SAHA	Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
Raji	IC₅₀	196 nM Compound: SAHA	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	[PMID: 30629434]
Raji	IC₅₀	2 μM Compound: SAHA	Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
Raji	IC₅₀	3 μM Compound: Vorinostat	Antiproliferative activity against human Raji cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Raji cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
Raji	IC₅₀	867.4 nM Compound: SAHA	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	[PMID: 31177073]
Raji	IC₅₀	9.44 μM Compound: SAHA	Antiproliferative activity against human Raji cells after 3 days by MTT assay Antiproliferative activity against human Raji cells after 3 days by MTT assay	[PMID: 28601509]
Ramos	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against human Ramos cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human Ramos cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
Ramos	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human Ramos cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human Ramos cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
Ramos	IC₅₀	0.52 nM Compound: SAHA	Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay	[PMID: 28325601]
Ramos	IC₅₀	0.52 μM Compound: SAHA	Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay	[PMID: 29534936]
Ramos	IC₅₀	0.62 μM Compound: Vor; SAHA	Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
Ramos	IC₅₀	3.9 μM Compound: SAHA	Antiproliferative activity against human Ramos cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human Ramos cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
Ramos	IC₅₀	5.3 μM Compound: SAHA	Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38048697]
Ramos	IC₅₀	514.6 nM Compound: SAHA	Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay	[PMID: 31177073]
Ramos	IC₅₀	> 1000 nM Compound: SAHA	Cytotoxicity against human Ramos cells after 72 hrs by MTT assay Cytotoxicity against human Ramos cells after 72 hrs by MTT assay	[PMID: 26443078]
Rec1	IC₅₀	0.35 μM Compound: SAHA; 6	Antiproliferative activity against human REC1 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human REC1 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]
S2	IC₅₀	59 nM Compound: 4, SAHA	Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells	[PMID: 19317450]
S9	IC₅₀	120.5 nM Compound: 6, SAHA	Inhibition of full length human recombinant HDAC2 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Ac)-AMC as substrate after 30 mins by fluorescence assay Inhibition of full length human recombinant HDAC2 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Ac)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 25906087]
S9	IC₅₀	21.5 nM Compound: 6, SAHA	Inhibition of full length human recombinant HDAC6 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay Inhibition of full length human recombinant HDAC6 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 25906087]
S9	IC₅₀	34.5 nM Compound: 6, SAHA	Inhibition of full length human recombinant HDAC11 expressed in baculovirus infected insect S9 cells after 30 mins by fluorescence assay Inhibition of full length human recombinant HDAC11 expressed in baculovirus infected insect S9 cells after 30 mins by fluorescence assay	[PMID: 25906087]
S9	IC₅₀	5.5 nM Compound: 6, SAHA	Inhibition of full length human recombinant HDAC8 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay Inhibition of full length human recombinant HDAC8 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 25906087]
S9	IC₅₀	58.5 nM Compound: 6, SAHA	Inhibition of full length human recombinant HDAC3 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Ac)-AMC as substrate after 30 mins by fluorescence assay Inhibition of full length human recombinant HDAC3 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Ac)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 25906087]
S9	IC₅₀	> 100 nM Compound: 6, SAHA	Inhibition of human recombinant HDAC4 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay Inhibition of human recombinant HDAC4 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 25906087]
SAOS-2	IC₅₀	2.3 μM Compound: 2	Cytotoxicity against human Saos2 cells Cytotoxicity against human Saos2 cells	[PMID: 17691763]
SCC-15	IC₅₀	2.49 μM Compound: SAHA	Antiproliferative activity against human SCC15 cells Antiproliferative activity against human SCC15 cells	[PMID: 20143778]
SCC-25	IC₅₀	1.93 μM Compound: SAHA	Antiproliferative activity against human SCC25 cells Antiproliferative activity against human SCC25 cells	[PMID: 20143778]
SF-268	GI₅₀	1.6 μM Compound: SAHA, Zolinza	Growth inhibition of human SF268 cells after 72 hrs by MTS assay Growth inhibition of human SF268 cells after 72 hrs by MTS assay	[PMID: 22435669]
SF-295	GI₅₀	1.6 μM Compound: SAHA, Zolinza	Growth inhibition of human SF295 cells after 72 hrs by MTS assay Growth inhibition of human SF295 cells after 72 hrs by MTS assay	[PMID: 22435669]
SF-539	GI₅₀	2 μM Compound: SAHA, Zolinza	Growth inhibition of human SF539 cells after 72 hrs by MTS assay Growth inhibition of human SF539 cells after 72 hrs by MTS assay	[PMID: 22435669]
SF-539	GI₅₀	2 μM Compound: SAHA; NSC759852	Cytotoxicity against human SF-539 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Cytotoxicity against human SF-539 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 36306372]
SGC-7901	IC₅₀	0.64 μM Compound: 1; SAHA	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	[PMID: 34656899]
SGC-7901	IC₅₀	1.03 μM Compound: SAHA	Antiproliferative activity against human SGC7901 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human SGC7901 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 31400938]
SGC-7901	IC₅₀	1.4 μM Compound: Vorinostat	Antiproliferative activity against human SGC-7901 cells Antiproliferative activity against human SGC-7901 cells	[PMID: 37875056]
SGC-7901	IC₅₀	135.71 μM Compound: SAHA	Cytotoxicity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
SGC-7901	IC₅₀	2.12 μM Compound: SAHA	Antiproliferative activity against human SGC-7901 cells measured after 48 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
SGC-7901	IC₅₀	2.89 μM Compound: SAHA	Cytotoxicity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38261411]
SGC-7901	IC₅₀	3.3 μM Compound: Vorinostat	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 35608269]
SGC-7901	IC₅₀	9.73 μM Compound: SAHA	Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
SH-SY5Y	EC₅₀	17.4 μM Compound: SAHA	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by XTT assay Antiproliferative activity against human SH-SY5Y cells after 72 hrs by XTT assay	[PMID: 21548582]
SH-SY5Y	EC₅₀	25.6 μM Compound: SAHA	Antiproliferative activity against human SH-SY5Y cells after 48 hrs by XTT assay Antiproliferative activity against human SH-SY5Y cells after 48 hrs by XTT assay	[PMID: 21548582]
SH-SY5Y	EC₅₀	> 50 μM Compound: SAHA	Antiproliferative activity against human SH-SY5Y cells after 24 hrs by XTT assay Antiproliferative activity against human SH-SY5Y cells after 24 hrs by XTT assay	[PMID: 21548582]
SH-SY5Y	IC₅₀	0.5 μM Compound: SAHA	Inhibition of HDAC in human SHSY5Y cells by fluorimetric cellular activity assay Inhibition of HDAC in human SHSY5Y cells by fluorimetric cellular activity assay	[PMID: 19344175]
SH-SY5Y	IC₅₀	0.73 μM Compound: SAHA	Antiproliferative activity against human SH-SY5Y cells harboring ALK F1174L mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against human SH-SY5Y cells harboring ALK F1174L mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34237620]
SH-SY5Y	IC₅₀	2 μM Compound: SAHA	Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 19344175]
SH-SY5Y	IC₅₀	3.59 μM Compound: Vorinostat	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MUH reagent based spectrophotometric analysis Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MUH reagent based spectrophotometric analysis	[PMID: 38911150]
SH-SY5Y	IC₅₀	32.2 μM Compound: Vorinostat	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by MUH reagent based spectrophotometric analysis Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by MUH reagent based spectrophotometric analysis	[PMID: 38911150]
SH-SY5Y	IC₅₀	5.43 μM Compound: Vorinostat	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by MUH reagent based spectrophotometric analysis Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by MUH reagent based spectrophotometric analysis	[PMID: 38911150]
SH-SY5Y	IC₅₀	7.87 μM Compound: SAHA	Cytotoxicity against human SH-SY5Y cells assessed as cell viability measured after 36 hrs by CCK8 assay Cytotoxicity against human SH-SY5Y cells assessed as cell viability measured after 36 hrs by CCK8 assay	[PMID: 36645952]
SK-BR-3	EC₅₀	2.1 μM Compound: 1a, SAHA	Antiproliferative activity against human SK-BR-3 cells after 48 hrs by cell titer-glo assay Antiproliferative activity against human SK-BR-3 cells after 48 hrs by cell titer-glo assay	[PMID: 20218673]
SK-BR-3	GI₅₀	1.2 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human SK-BR-3 cells after 72 hrs by WST1 assay Cytotoxicity against human SK-BR-3 cells after 72 hrs by WST1 assay	[PMID: 24015327]
SK-BR-3	IC₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human SKBR3 cells Antiproliferative activity against human SKBR3 cells	[PMID: 18247554]
SK-BR-3	IC₅₀	1.19 μM Compound: SAHA	Antiproliferative activity against human SK-BR-3 cells after hrs by ATP content assay Antiproliferative activity against human SK-BR-3 cells after hrs by ATP content assay	[PMID: 20143778]
SK-BR-3	IC₅₀	2.13 μM Compound: Vorinostat	Antiproliferation activity against human SK-BR-3 cells incubated for 72 hrs by MTT assay Antiproliferation activity against human SK-BR-3 cells incubated for 72 hrs by MTT assay	[PMID: 33493830]
SK-BR-3	IC₅₀	2.58 μM Compound: 8	Antiproliferative activity against human SK-BR-3 cells expressing HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human SK-BR-3 cells expressing HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27769671]
SK-BR-3	IC₅₀	2.6 μM Compound: 2	Cytotoxicity against human SKBR3 cells Cytotoxicity against human SKBR3 cells	[PMID: 17691763]
SK-BR-3	IC₅₀	2.6 μM Compound: 2a	Cytotoxicity against human SKBR3 cells overexpressing HER2 by resazurin dye reduction assay Cytotoxicity against human SKBR3 cells overexpressing HER2 by resazurin dye reduction assay	[PMID: 21080629]
SK-BR-3	IC₅₀	> 1000 nM Compound: SAHA	Cytotoxicity against human SKBR3 cells after 72 hrs by MTT assay Cytotoxicity against human SKBR3 cells after 72 hrs by MTT assay	[PMID: 26443078]
SK-HEP1	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human SK-HEP1 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SK-HEP1 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
SK-HEP1	IC₅₀	1.85 μM Compound: Vor; SAHA	Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
SK-HEP1	IC₅₀	3.3 μM Compound: 2; SAHA	Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 34634618]
SK-HEP1	IC₅₀	3.46 μM Compound: SAHA	Antiproliferative activity against human SKHEP1 cells after hrs by ATP content assay Antiproliferative activity against human SKHEP1 cells after hrs by ATP content assay	[PMID: 20143778]
SK-HEP1	IC₅₀	36.93 μM Compound: SAHA	Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
SK-MEL-2	GI₅₀	1.3 μM Compound: SAHA, Zolinza	Growth inhibition of human SK-MEL-2 cells after 72 hrs by MTS assay Growth inhibition of human SK-MEL-2 cells after 72 hrs by MTS assay	[PMID: 22435669]
SK-MEL-28	GI₅₀	1 μM Compound: SAHA, Zolinza	Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTS assay Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTS assay	[PMID: 22435669]
SK-MEL-28	IC₅₀	0.482 μM Compound: 1; SAHA	Antiproliferative activity against human SK-MEL-28 cells after 72 hrs by resazurin dye based fluorescence assay Antiproliferative activity against human SK-MEL-28 cells after 72 hrs by resazurin dye based fluorescence assay	[PMID: 29456804]
SK-MEL-5	GI₅₀	0.63 μM Compound: SAHA, Zolinza	Growth inhibition of human SK-MEL-5 cells after 72 hrs by MTS assay Growth inhibition of human SK-MEL-5 cells after 72 hrs by MTS assay	[PMID: 22435669]
SK-MES-1	EC₅₀	2.42 μM Compound: SAHA	Cytotoxicity against human SKMES1 cells after 72 hrs by trypan blue exclusion assay Cytotoxicity against human SKMES1 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19093884]
SK-MES-1	IC₅₀	2.42 μM Compound: SAHA	Antiproliferative activity against human SKMES1 cells after 72 hrs by MTS assay Antiproliferative activity against human SKMES1 cells after 72 hrs by MTS assay	[PMID: 22260166]
SK-N-AS	IC₅₀	0.7 μM Compound: Vorinostat	Antiproliferative activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay Antiproliferative activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay	[PMID: 31391882]
SK-N-BE(2)	IC₅₀	0.21 μM Compound: Vorinostat	Antiproliferative activity against human SK-N-BE(2) cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-N-BE(2) cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
SK-N-BE(2)	IC₅₀	4.58 μM Compound: SAHA	Antiproliferative activity against human SK-N-BE(2) cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human SK-N-BE(2) cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 37079967]
SK-OV-3	EC₅₀	2.5 μM Compound: SAHA	Inhibition of human SKOV3 cells Inhibition of human SKOV3 cells	[PMID: 18247554]
SK-OV-3	EC₅₀	2.5 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human SK-OV-3 cells Effective Concentration of compound to inhibit the growth of human SK-OV-3 cells	[PMID: 15715470]
SK-OV-3	GI₅₀	1 μM Compound: SAHA, Zolinza	Growth inhibition of human SKOV3 cells after 72 hrs by MTS assay Growth inhibition of human SKOV3 cells after 72 hrs by MTS assay	[PMID: 22435669]
SK-OV-3	GI₅₀	2.5 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
SK-OV-3	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
SK-OV-3	IC₅₀	1.66 mM Compound: vorinostat, SAHA	Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 20171895]
SK-OV-3	IC₅₀	1130 nM Compound: SAHA	Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 31177073]
SK-OV-3	IC₅₀	2.2 μM Compound: 2	Cytotoxicity against human SK-OV-3 cells Cytotoxicity against human SK-OV-3 cells	[PMID: 17691763]
SK-OV-3	IC₅₀	2.2 μM Compound: 2a	Cytotoxicity against human SKOV3 cells overexpressing HER2 by resazurin dye reduction assay Cytotoxicity against human SKOV3 cells overexpressing HER2 by resazurin dye reduction assay	[PMID: 21080629]
SK-OV-3	IC₅₀	2.3 μM Compound: SAHA	Cytotoxicity against human SKOV3 cells Cytotoxicity against human SKOV3 cells	[PMID: 23906422]
SK-OV-3	IC₅₀	> 1000 nM Compound: SAHA	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 26443078]
SMMC-7721	IC₅₀	1.99 μM Compound: SAHA	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
SMMC-7721	IC₅₀	5.2 μM Compound: SAHA	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 31120744]
SMMC-7721	IC₅₀	5.23 μM Compound: SAHA	Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
SMMC-7721	IC₅₀	5.274 μM Compound: SAHA	Antiproliferative activity against human SMMC7721 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31991336]
SMMC-7721	IC₅₀	5.46 μM Compound: 1; CTCL	Cytotoxicity against human SMMC-7721 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 33143937]
SMMC-7721	IC₅₀	5.46 μM Compound: 1; SAHA	Cytotoxicity against human SMMC-7721 cells Cytotoxicity against human SMMC-7721 cells	[PMID: 33077264]
SMMC-7721	IC₅₀	5.46 μM Compound: Vorinostat	Cytotoxicity against human SMMC-7721 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
SMMC-7721	IC₅₀	5.61 μM Compound: SAHA	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 29288941]
SMMC-7721	IC₅₀	5.61 μM Compound: SAHA	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 30108831]
SMMC-7721	IC₅₀	> 10 μM Compound: SAHA	Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
SN12C	GI₅₀	2 μM Compound: SAHA, Zolinza	Growth inhibition of human SN12C cells after 72 hrs by MTS assay Growth inhibition of human SN12C cells after 72 hrs by MTS assay	[PMID: 22435669]
SNB-19	GI₅₀	0.63 μM Compound: SAHA, Zolinza	Growth inhibition of human SNB19 cells after 72 hrs by MTS assay Growth inhibition of human SNB19 cells after 72 hrs by MTS assay	[PMID: 22435669]
SNB-75	GI₅₀	0.79 μM Compound: SAHA, Zolinza	Growth inhibition of human SNB75 cells after 72 hrs by MTS assay Growth inhibition of human SNB75 cells after 72 hrs by MTS assay	[PMID: 22435669]
SNB-75	GI₅₀	0.8 μM Compound: SAHA	Antiproliferative activity against human SNB75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human SNB75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
SNB-78	EC₅₀	16 μM Compound: SAHA	Inhibition of human SNB78 cells Inhibition of human SNB78 cells	[PMID: 18247554]
SNB-78	EC₅₀	16 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human SNB-78 cells Effective Concentration of compound to inhibit the growth of human SNB-78 cells	[PMID: 15715470]
SNB-78	GI₅₀	16 μM Compound: 2, (SAHA, vorinostat)	Growth inhibition of human SNB78 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SNB78 cells after 48 hrs by sulforhodamine B assay	[PMID: 19419205]
SNU-16	IC₅₀	0.29 μM Compound: 3; SAHA	Antiproliferative activity against human SNU-16 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SNU-16 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36449947]
SNU-387	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human SNU-387 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SNU-387 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
SNU-387	IC₅₀	2.45 μM Compound: Vor; SAHA	Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
SNU-398	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human SNU-398 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SNU-398 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
SNU-398	IC₅₀	1.39 μM Compound: Vor; SAHA	Antiproliferative activity against human SNU-398 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human SNU-398 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
SNU-423	IC₅₀	0.079 μM Compound: SAHA	Antiproliferative activity against human SNU-423 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human SNU-423 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34509167]
SQ20B	IC₅₀	3 μM Compound: SAHA	Inhibition of human SQ20B cells Inhibition of human SQ20B cells	[PMID: 18247554]
SR	GI₅₀	0.4 μM Compound: SAHA	Antiproliferative activity against human SR cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human SR cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
SR	GI₅₀	0.4 μM Compound: SAHA, Zolinza	Growth inhibition of human SR cells after 72 hrs by MTS assay Growth inhibition of human SR cells after 72 hrs by MTS assay	[PMID: 22435669]
SU-DHL-6	IC₅₀	0.43 μM Compound: Vorinostat	Cytotoxicity against human SU-DHL-6 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SU-DHL-6 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
SU-DHL-6	IC₅₀	0.58 μM Compound: Vor; SAHA	Antiproliferative activity against human SU-DHL-6 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay Antiproliferative activity against human SU-DHL-6 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	[PMID: 29360358]
SU-DHL10	IC₅₀	0.47 μM Compound: 1; SAHA	Antiproliferative activity against human SU-DHL-10 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SU-DHL-10 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36153841]
SU.86.86	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human SU.86.86 cells after 72 hrs by MTT assay Antiproliferative activity against human SU.86.86 cells after 72 hrs by MTT assay	[PMID: 18642892]
SU.86.86	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human SU-8686 cells by MTT assay Antiproliferative activity against human SU-8686 cells by MTT assay	[PMID: 19419863]
SU.86.86	IC₅₀	1.3 μM Compound: 1a, SAHA	Growth inhibition of human SU-8686 cells after 72 hrs by MTS assay Growth inhibition of human SU-8686 cells after 72 hrs by MTS assay	[PMID: 20055418]
SU.86.86	IC₅₀	1.3 μM Compound: SAHA	Cytotoxicity against human SU 86.86 cells after 72 hrs by MTT assay Cytotoxicity against human SU 86.86 cells after 72 hrs by MTT assay	[PMID: 18494463]
SUM-159-PT	IC₅₀	1.381 μM Compound: SAHA	Cytotoxicity against human SUM159PT cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SUM159PT cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
SUM-159-PT	IC₅₀	3 μM Compound: SAHA	Cytotoxicity against human SUM159PT cells harboring wild type BRCA1 and wild type BRCA2 assessed as reduction in cell viability Cytotoxicity against human SUM159PT cells harboring wild type BRCA1 and wild type BRCA2 assessed as reduction in cell viability	[PMID: 36053318]
SW-620	GI₅₀	0.54 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human SW620 cells after 48 hrs by SRB assay Cytotoxicity against human SW620 cells after 48 hrs by SRB assay	[PMID: 24015327]
SW-620	GI₅₀	0.63 μM Compound: SAHA, Zolinza	Growth inhibition of human SW620 cells after 72 hrs by MTS assay Growth inhibition of human SW620 cells after 72 hrs by MTS assay	[PMID: 22435669]
SW-620	GI₅₀	0.63 μM Compound: SAHA, Zolinza	Growth inhibition of human SW620 cells after 72 hrs by MTS assay Growth inhibition of human SW620 cells after 72 hrs by MTS assay	[PMID: 22435669]
SW-620	IC₅₀	0.5 μg/mL Compound: SAHA	Cytotoxicity against human SW620 cells Cytotoxicity against human SW620 cells	[PMID: 22036991]
SW-620	IC₅₀	0.6 μM Compound: SAHA	Inhibition of human SW620 cells Inhibition of human SW620 cells	[PMID: 18247554]
SW-620	IC₅₀	1.12 μM Compound: SAHA	Cytotoxicity against human SW620 cells by colorimetric method Cytotoxicity against human SW620 cells by colorimetric method	[PMID: 32916298]
SW-620	IC₅₀	1.12 μM Compound: Vorinostat	Antiproliferative activity against human SW620 cells incubated for 72 hrs by colorimetric method Antiproliferative activity against human SW620 cells incubated for 72 hrs by colorimetric method	[PMID: 37875056]
SW-620	IC₅₀	1.44 μM Compound: Vorinostat	Antiproliferative activity against human SW620 cells incubated for 48 hrs by colorimetric method Antiproliferative activity against human SW620 cells incubated for 48 hrs by colorimetric method	[PMID: 37875056]
SW-620	IC₅₀	1.7 μM Compound: SAHA; 112	Antiproliferative activity against human SW620 cells assessed as inhibition of cell proliferation by CCK-8 assay Antiproliferative activity against human SW620 cells assessed as inhibition of cell proliferation by CCK-8 assay	[PMID: 31881454]
SW-620	IC₅₀	1.7 μM Compound: Vorinostat	Cytotoxicity against human SW620 cells assessed as reduction in cell viability Cytotoxicity against human SW620 cells assessed as reduction in cell viability	[PMID: 30660827]
SW-620	IC₅₀	2.8 μM Compound: Vorinostat	Cytotoxicity against human SW620 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human SW620 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
SW-620	IC₅₀	3.2 μM Compound: SAHA	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
SW-620	IC₅₀	3.7 μM Compound: SAHA, Vorinostat, Zolinza	Antiproliferative activity against human SW620 cells after 48 hrs by SRB assay Antiproliferative activity against human SW620 cells after 48 hrs by SRB assay	[PMID: 24185378]
SW-620	IC₅₀	3.87 μM Compound: SAHA	Antiproliferative activity against human SW620 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human SW620 cells incubated for 72 hrs by MTT assay	[PMID: 28987602]
SW-620	IC₅₀	4.31 μM Compound: Vorinostat	Cytotoxicity against human SW620 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human SW620 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
SW-620	IC₅₀	4.32 μM Compound: SAHA	Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
SW-620	IC₅₀	403 nM Compound: Vorinostat	Antiproliferative activity against human SW620 cells Antiproliferative activity against human SW620 cells	[PMID: 37875056]
SW-620	IC₅₀	6.94 μM Compound: SAHA	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay	[PMID: 32153186]
SW1990	IC₅₀	3.8 μM Compound: 5; SAHA	Antiproliferative activity against human SW1990 cells after 96 hrs by MTT assay Antiproliferative activity against human SW1990 cells after 96 hrs by MTT assay	[PMID: 31117517]
SW1990	IC₅₀	5.72 μM Compound: SAHA	Antiproliferative activity against human SW1990 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SW1990 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36097406]
SW480	IC₅₀	1.89 μM Compound: SAHA	Antiproliferative activity against human SW480 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
SW480	IC₅₀	2.12 μM Compound: SAHA	Antiproliferative activity against human SW480 cells measured after 72 hrs Antiproliferative activity against human SW480 cells measured after 72 hrs	[PMID: 35697181]
SW480	IC₅₀	3.97 μM Compound: SAHA	Antiproliferative activity against human SW480 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
Sf21	IC₅₀	0.037 μM Compound: 2a	Inhibition of Flag tagged human recombinant HDAC3 expressed in Sf21 cells coexpressing SMRT DAD domain Inhibition of Flag tagged human recombinant HDAC3 expressed in Sf21 cells coexpressing SMRT DAD domain	[PMID: 21080629]
Sf21	IC₅₀	0.26 μM Compound: SAHA	Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 (1 to 482 residues) expressed in sf21 cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 (1 to 482 residues) expressed in sf21 cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	[PMID: 26890116]
Sf21	IC₅₀	0.306 μM Compound: 1; SAHA	Inhibition of full length human recombinant C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in sf21 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay Inhibition of full length human recombinant C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in sf21 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay	[PMID: 27541357]
Sf21	IC₅₀	1.2 μM Compound: 2a	Inhibition of Flag tagged human recombinant HDAC8 expressed in Sf21 cells Inhibition of Flag tagged human recombinant HDAC8 expressed in Sf21 cells	[PMID: 21080629]
Sf21	IC₅₀	1.6 μM Compound: SAHA	Inhibition of recombinant human N-terminal GST-tagged/C-terminal His-tagged HDAC4 (627 to 1084 residues) expressed in baculovirus infected Sf21 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay Inhibition of recombinant human N-terminal GST-tagged/C-terminal His-tagged HDAC4 (627 to 1084 residues) expressed in baculovirus infected Sf21 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	[PMID: 30245394]
Sf9	IC₅₀	0.0058 μM Compound: 1; SAHA	Inhibition of recombinant full length human HDAC6 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 5 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC6 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 5 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.00657 μM Compound: 1; SAHA	Inhibition of recombinant full length human HDAC3 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC3 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.0097 μM Compound: Vorinostat	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 90 mins by fluorescence assay Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 90 mins by fluorescence assay	[PMID: 31762274]
Sf9	IC₅₀	0.02 μM Compound: 1; SAHA	Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay	[PMID: 27541357]
Sf9	IC₅₀	0.029 μM Compound: SAHA	Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate incubated for 90 mins by fluorescence assay Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate incubated for 90 mins by fluorescence assay	[PMID: 26890116]
Sf9	IC₅₀	0.032 μM Compound: SAHA	Inhibition of recombinant full length human HDAC6 expressed in Baculovirus infected insect Sf9 cells incubated for 30 mins measured by fluorescence assay Inhibition of recombinant full length human HDAC6 expressed in Baculovirus infected insect Sf9 cells incubated for 30 mins measured by fluorescence assay	10.1039/C4MD00203B
Sf9	IC₅₀	0.038 μM Compound: Vorinostat	Inhibition of recombinant human full length C-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method Inhibition of recombinant human full length C-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method	[PMID: 31420257]
Sf9	IC₅₀	0.051 μM Compound: SAHA	Inhibition of recombinant full length human HDAC1 (1 to 482 amino acids) expressed in Baculovirus infected insect Sf9 cells incubated for 30 mins measured by fluorescence assay Inhibition of recombinant full length human HDAC1 (1 to 482 amino acids) expressed in Baculovirus infected insect Sf9 cells incubated for 30 mins measured by fluorescence assay	10.1039/C4MD00203B
Sf9	IC₅₀	0.081 μM Compound: SAHA	Inhibition of C-terminal GST-tagged human recombinant HDAC2 expressed in Sf9 cells after 30 mins by microtiter plate reader analysis Inhibition of C-terminal GST-tagged human recombinant HDAC2 expressed in Sf9 cells after 30 mins by microtiter plate reader analysis	[PMID: 26907204]
Sf9	IC₅₀	0.089 μM Compound: Vorinostat	Inhibition of recombinant human full length C-terminal Flag/His-tagged HDAC1 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method Inhibition of recombinant human full length C-terminal Flag/His-tagged HDAC1 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method	[PMID: 31420257]
Sf9	IC₅₀	0.102 μM Compound: Vorinostat	Inhibition of human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells ZMAL as substrate incubated for 90 mins by fluorescence assay Inhibition of human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells ZMAL as substrate incubated for 90 mins by fluorescence assay	[PMID: 31762274]
Sf9	IC₅₀	0.105 μM Compound: Vorinostat	Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method	[PMID: 31420257]
Sf9	IC₅₀	0.111 μM Compound: Vorinostat	Inhibition of recombinant human full length C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL as substrate incubated for 90 mins by fluorescence assay Inhibition of recombinant human full length C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL as substrate incubated for 90 mins by fluorescence assay	[PMID: 31762274]
Sf9	IC₅₀	0.146 μM Compound: Vorinostat	Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 90 mins by fluorescence assay Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 90 mins by fluorescence assay	[PMID: 31762274]
Sf9	IC₅₀	0.183 μM Compound: Vorinostat	Inhibition of recombinant human full length C-terminal Flag-tagged HDAC2 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method Inhibition of recombinant human full length C-terminal Flag-tagged HDAC2 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method	[PMID: 31420257]
Sf9	IC₅₀	0.23 μM Compound: SAHA	Inhibition of recombinant full length human HDAC8 expressed in Baculovirus infected insect Sf9 cells preincubated for 30 mins followed by substrate addition measured after 15 to 45 mins by luminescence assay Inhibition of recombinant full length human HDAC8 expressed in Baculovirus infected insect Sf9 cells preincubated for 30 mins followed by substrate addition measured after 15 to 45 mins by luminescence assay	10.1039/C4MD00203B
Sf9	IC₅₀	0.497 μM Compound: 1; SAHA	Inhibition of recombinant full length human HDAC8 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC8 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.78 μM Compound: SAHA	Inhibition of recombinant full-length human C-terminal HDAC8 expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay Inhibition of recombinant full-length human C-terminal HDAC8 expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	[PMID: 30245394]
Sf9	IC₅₀	0.8 μM Compound: SAHA	Inhibition of human N-terminal GST-tagged HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay Inhibition of human N-terminal GST-tagged HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	[PMID: 30245394]
Sf9	IC₅₀	101 nM Compound: Vorinostat	Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based assay Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based assay	[PMID: 31391882]
Sf9	IC₅₀	102 nM Compound: Zolinza	Inhibition of full length recombinant GST-tagged N-terminal human HDAC6 expressed in baculovirus infected Sf9 insect cells using ZMAL (Z-Lys(Ac)-AMC) as substrate incubated for 90 mins by fluorescence based assay Inhibition of full length recombinant GST-tagged N-terminal human HDAC6 expressed in baculovirus infected Sf9 insect cells using ZMAL (Z-Lys(Ac)-AMC) as substrate incubated for 90 mins by fluorescence based assay	[PMID: 31531206]
Sf9	IC₅₀	11 nM Compound: SAHA	Inhibition of full length C-terminal His/FLAG-tagged human recombinant HDAC1 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured after 1 hr by fluorescence assay Inhibition of full length C-terminal His/FLAG-tagged human recombinant HDAC1 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured after 1 hr by fluorescence assay	[PMID: 27186676]
Sf9	IC₅₀	13 nM Compound: SAHA	Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay	[PMID: 30594434]
Sf9	IC₅₀	144.7 nM Compound: SAHA; Vor	Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis	[PMID: 32321249]
Sf9	IC₅₀	170 nM Compound: SAHA	Inhibition of recombinant full length N-terminal FLAG-tagged human HDAC10 expressed in baculovirus infected sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay Inhibition of recombinant full length N-terminal FLAG-tagged human HDAC10 expressed in baculovirus infected sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay	[PMID: 30629434]
Sf9	IC₅₀	174 nM Compound: SAHA	Inhibition of recombinant C-terminal His-tagged full length human HDAC2 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay Inhibition of recombinant C-terminal His-tagged full length human HDAC2 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay	[PMID: 25815139]
Sf9	IC₅₀	19 nM Compound: SAHA	Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	[PMID: 31505452]
Sf9	IC₅₀	208 nM Compound: SAHA	Inhibition of recombinant N-terminal FLAG-tagged human HDAC10 (2 to 631 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant N-terminal FLAG-tagged human HDAC10 (2 to 631 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	23 nM Compound: SAHA	Inhibition of recombinant N-terminal GST-tagged full length human HDAC6 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay Inhibition of recombinant N-terminal GST-tagged full length human HDAC6 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay	[PMID: 25815139]
Sf9	IC₅₀	23 nM Compound: SAHA	Inhibition of recombinant full length human HDAC1 (1 to 482) expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay Inhibition of recombinant full length human HDAC1 (1 to 482) expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay	[PMID: 25815139]
Sf9	IC₅₀	29 nM Compound: SAHA	Inhibition of recombinant full length human HDAC2 expressed in sf9 insect cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant full length human HDAC2 expressed in sf9 insect cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	3.7 μM Compound: SAHA	Inhibition of C-terminal His-tagged human recombinant HDAC8 expressed in Sf9 cells after 30 mins by microtiter plate reader analysis Inhibition of C-terminal His-tagged human recombinant HDAC8 expressed in Sf9 cells after 30 mins by microtiter plate reader analysis	[PMID: 26907204]
Sf9	IC₅₀	32 nM Compound: 5; SAHA	Inhibition of recombinant C-terminal His/FLAG-tagged HDAC1 (unknown origin) expressed in baculovirus infected Sf9 insect cells using Ac-peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr Inhibition of recombinant C-terminal His/FLAG-tagged HDAC1 (unknown origin) expressed in baculovirus infected Sf9 insect cells using Ac-peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr	[PMID: 31117517]
Sf9	IC₅₀	328 nM Compound: SAHA	Inhibition of full length C-terminal His-tagged human HDAC8 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 240 mins by fluorescence based assay Inhibition of full length C-terminal His-tagged human HDAC8 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 240 mins by fluorescence based assay	[PMID: 31505452]
Sf9	IC₅₀	33 nM Compound: SAHA	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	34.3 nM Compound: Vorinostat	Inhibition of recombinant full length N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based assay Inhibition of recombinant full length N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based assay	[PMID: 31391882]
Sf9	IC₅₀	35 nM Compound: SAHA	Inhibition of full length recombinant human C-terminal FLAG-tagged HDAC1 expressed in sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay Inhibition of full length recombinant human C-terminal FLAG-tagged HDAC1 expressed in sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay	[PMID: 30594434]
Sf9	IC₅₀	370 nM Compound: SAHA	Inhibition of His-tagged human HDAC11 expressed in Sf9 cells using Ac-Arg-Gly-Lys(Ac)-AMC as substrate by fluorometric assay Inhibition of His-tagged human HDAC11 expressed in Sf9 cells using Ac-Arg-Gly-Lys(Ac)-AMC as substrate by fluorometric assay	[PMID: 27055940]
Sf9	IC₅₀	47 nM Compound: Zolinza	Inhibition of full length recombinant FLAG/His-tagged C-terminal human HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL (Z-Lys(Ac)-AMC) as substrate incubated for 90 mins by fluorescence based assay Inhibition of full length recombinant FLAG/His-tagged C-terminal human HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL (Z-Lys(Ac)-AMC) as substrate incubated for 90 mins by fluorescence based assay	[PMID: 31531206]
Sf9	IC₅₀	49 nM Compound: SAHA	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	[PMID: 31505452]
Sf9	IC₅₀	51 nM Compound: SAHA	Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	[PMID: 31505452]
Sf9	IC₅₀	56 nM Compound: SAHA	Inhibition of recombinant C-terminal His-tagged full length human HDAC3/NcoR2 complex expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay Inhibition of recombinant C-terminal His-tagged full length human HDAC3/NcoR2 complex expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay	[PMID: 25815139]
Sf9	IC₅₀	682 nM Compound: SAHA	Inhibition of recombinant full length C-terminal His-tagged human HDAC8 expressed in baculovirus infected in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant full length C-terminal His-tagged human HDAC8 expressed in baculovirus infected in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	8.7 μM Compound: SAHA	Inhibition of recombinant full-length human HDAC11 expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay Inhibition of recombinant full-length human HDAC11 expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	[PMID: 30245394]
Sf9	IC₅₀	8.8 nM Compound: SAHA	Inhibition of recombinant C-terminal His-tagged full length human HDAC8 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC class 2a substrate after 30 mins by fluorescence assay Inhibition of recombinant C-terminal His-tagged full length human HDAC8 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC class 2a substrate after 30 mins by fluorescence assay	[PMID: 25815139]
Sf9	IC₅₀	> 1 μM Compound: 1; SAHA	Inhibition of recombinant full length human HDAC11 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC11 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	> 1000 nM Compound: SAHA	Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay	[PMID: 30629434]
Sf9	IC₅₀	> 10000 nM Compound: SAHA	Inhibition of recombinant C-terminal His-tagged human HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant C-terminal His-tagged human HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	> 10000 nM Compound: SAHA	Inhibition of recombinant N-terminal GST-tagged human HDAC7 (518 to end residues) expressed in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant N-terminal GST-tagged human HDAC7 (518 to end residues) expressed in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	> 10000 nM Compound: SAHA	Inhibition of recombinant full length N-terminal GST-tagged human HDAC5 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant full length N-terminal GST-tagged human HDAC5 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	> 10000 nM Compound: SAHA	Inhibition of recombinant full length human HDAC11 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant full length human HDAC11 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
Sf9	IC₅₀	> 10000 nM Compound: SAHA	Inhibition of recombinant full length human HDAC4 expressed in sf9 insect cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay Inhibition of recombinant full length human HDAC4 expressed in sf9 insect cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	[PMID: 31177073]
SiHa	IC₅₀	4.34 μM Compound: XII; SAHA	Antiproliferative activity against human SiHa cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human SiHa cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
St-4	EC₅₀	5.2 μM Compound: SAHA	Inhibition of human St4 cells Inhibition of human St4 cells	[PMID: 18247554]
St-4	EC₅₀	5.2 μM Compound: Suberoylanilide hydroxamic acid (SAHA)	Effective Concentration of compound to inhibit the growth of human St-4 cells Effective Concentration of compound to inhibit the growth of human St-4 cells	[PMID: 15715470]
T-24	EC₅₀	0.12 μM Compound: SAHA, Zolinza	Induction of histone H3 acetylation in human T24 cells after 3 hrs by ELISA Induction of histone H3 acetylation in human T24 cells after 3 hrs by ELISA	[PMID: 19084395]
T-24	EC₅₀	0.25 μM Compound: SAHA, Zolinza	Induction of alpha tubulin acetylation in human T24 cells after 3 hrs by ELISA Induction of alpha tubulin acetylation in human T24 cells after 3 hrs by ELISA	[PMID: 19084395]
T-24	IC₅₀	2.4 μM Compound: SAHA	Antiproliferative activity against human T24 cells after 72 hrs by CellTiter blue-reagent based assay Antiproliferative activity against human T24 cells after 72 hrs by CellTiter blue-reagent based assay	[PMID: 30645113]
T-cell	EC₅₀	0.6 μM Compound: SAHA, Vorinostat	Reactivation of latent HIV1 NL4-3-Luc expression in human naive CD4+ T cells treated 7 days post-infection measured after 48 hrs by luminescence plate reader analysis Reactivation of latent HIV1 NL4-3-Luc expression in human naive CD4+ T cells treated 7 days post-infection measured after 48 hrs by luminescence plate reader analysis	[PMID: 24495105]
T47D	GI₅₀	0.5 μM Compound: SAHA	Antiproliferative activity against human T47D cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human T47D cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
T47D	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human T47D cells after 72 hrs by MTS assay Growth inhibition of human T47D cells after 72 hrs by MTS assay	[PMID: 22435669]
T47D	IC₅₀	1.25 μM Compound: SAHA	Antiproliferative activity against human T47D cells after 72 hrs by MTT assay Antiproliferative activity against human T47D cells after 72 hrs by MTT assay	[PMID: 28601509]
T47D	IC₅₀	1.5 μM Compound: 4; SAHA	Antiproliferative activity against human T47D cells Antiproliferative activity against human T47D cells	[PMID: 37652098]
T47D	IC₅₀	2.243 μM Compound: SAHA	Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32823005]
T47D	IC₅₀	3.01 μM Compound: Vorinostat	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human T47D cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 29518312]
T47D	IC₅₀	3.21 μM Compound: SAHA	Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
TAMH	IC₅₀	7.86 μM Compound: 1; SAHA	Antiproliferative activity against mouse TAMH cells after 24 hrs by CellTiter-Glo assay Antiproliferative activity against mouse TAMH cells after 24 hrs by CellTiter-Glo assay	[PMID: 27541357]
TAMH	IC₅₀	7.86 μM Compound: 2	Cytotoxicity against TAMH cells assessed as cell viability after 24 hrs by CellTiter-Glo assay Cytotoxicity against TAMH cells assessed as cell viability after 24 hrs by CellTiter-Glo assay	[PMID: 28953386]
TE-1	IC₅₀	2.25 μM Compound: SAHA	Antiproliferative activity against human TE-1 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human TE-1 cells assessed as inhibition of cell growth by MTT assay	[PMID: 39102466]
THP-1	GI₅₀	15.4 μM Compound: 1	Growth inhibition of human THP-1 cells Growth inhibition of human THP-1 cells	[PMID: 37429084]
THP-1	GI₅₀	15.5 μM Compound: SAHA	Growth inhibition of human THP-1 cells Growth inhibition of human THP-1 cells	[PMID: 32320239]
THP-1	IC₅₀	0.18 μM Compound: Vorinostat	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37979441]
THP-1	IC₅₀	0.5 μg/mL Compound: SAHA	Antileishmanial activity against amastigote stage of Leishmania donovani infected in human THP1 cells after 48 hrs by Alamar blue assay Antileishmanial activity against amastigote stage of Leishmania donovani infected in human THP1 cells after 48 hrs by Alamar blue assay	[PMID: 25240614]
THP-1	IC₅₀	0.62 μM Compound: SAHA	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
THP-1	IC₅₀	1.03 μM Compound: SAHA	Antiproliferative activity against human THP-1 cells incubated for 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human THP-1 cells incubated for 24 to 48 hrs by CCK-8 assay	[PMID: 39145486]
THP-1	IC₅₀	1.1 μM Compound: SAHA	Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28368585]
THP-1	IC₅₀	18 μM Compound: SAHA, Vorinostat	Cytotoxicity against human THP1 cells assessed as reduction in cell viability Cytotoxicity against human THP1 cells assessed as reduction in cell viability	[PMID: 26264503]
THP-1	IC₅₀	2.9 μM Compound: SAHA	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo assay	[PMID: 37086699]
THP-1	IC₅₀	3.9 μM Compound: SAHA	Antiproliferative activity against human THP-1 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human THP-1 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
THP-1	IC₅₀	9.5 μM Compound: 5; SAHA	Antiproliferative activity against human THP1 cells after 96 hrs by MTT assay Antiproliferative activity against human THP1 cells after 96 hrs by MTT assay	[PMID: 31117517]
THP-1	IC₅₀	> 10 μg/mL Compound: SAHA	Cytotoxicity against human THP1 cells after 48 hrs by Alamar blue assay Cytotoxicity against human THP1 cells after 48 hrs by Alamar blue assay	[PMID: 25240614]
TK-10	GI₅₀	0.63 μM Compound: SAHA, Zolinza	Growth inhibition of human TK10 cells after 72 hrs by MTS assay Growth inhibition of human TK10 cells after 72 hrs by MTS assay	[PMID: 22435669]
TPC1	IC₅₀	3 μM Compound: Vorinostat	Antiproliferative activity against human TPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human TPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37875056]
TSGH	IC₅₀	2.09 μM Compound: 1, SAHA, Vorinostat	Cytotoxicity against human TSGH cells by MTT assay Cytotoxicity against human TSGH cells by MTT assay	[PMID: 24766560]
U-251	GI₅₀	1.53 μM Compound: Zolinza, NSC 701852	Cytotoxicity against human U251 cells after 48 hrs by SRB assay Cytotoxicity against human U251 cells after 48 hrs by SRB assay	[PMID: 24015327]
U-251	GI₅₀	1.6 μM Compound: SAHA	Antiproliferative activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Antiproliferative activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 32212730]
U-251	GI₅₀	1.6 μM Compound: SAHA, Zolinza	Growth inhibition of human U251 cells after 72 hrs by MTS assay Growth inhibition of human U251 cells after 72 hrs by MTS assay	[PMID: 22435669]
U-251	GI₅₀	2 μM Compound: SAHA	Cytotoxicity against human U251 cells by MTT assay Cytotoxicity against human U251 cells by MTT assay	[PMID: 23538115]
U-251	GI₅₀	6.5 μM Compound: SAHA	Cytotoxicity against human U251 cells after 48 hrs by MTT assay Cytotoxicity against human U251 cells after 48 hrs by MTT assay	[PMID: 20605448]
U-251	IC₅₀	1 μM Compound: Vorinostat	Cytotoxicity against human U251 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human U251 cells assessed as reduction in cell viability by SRB assay	[PMID: 30660827]
U-251	IC₅₀	17.87 μM Compound: 1; SAHA	Cytotoxicity against human TMZ-sensitive U251 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human TMZ-sensitive U251 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35005974]
U-251	IC₅₀	2.58 μM Compound: SAHA	Cytotoxicity against human U-251 cells incubated for 72 hrs by MTT assay Cytotoxicity against human U-251 cells incubated for 72 hrs by MTT assay	[PMID: 38452727]
U-251	IC₅₀	8.94 μM Compound: SAHA	Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37399711]
U-266	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
U-266	IC₅₀	0.59 μM Compound: SAHA	Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay	[PMID: 31865013]
U-266	IC₅₀	0.88 μM Compound: SAHA	Antiproliferative activity against human U266 cells after 48 hrs by MTT assay Antiproliferative activity against human U266 cells after 48 hrs by MTT assay	[PMID: 28757101]
U-266	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
U-266	IC₅₀	1.09 μM Compound: SAHA	Antiproliferative activity against human U266 cells after 48 hrs by MTT assay Antiproliferative activity against human U266 cells after 48 hrs by MTT assay	[PMID: 25462271]
U-266	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human U-266 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human U-266 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
U-266	IC₅₀	1.35 μM Compound: SAHA	Cytotoxicity against human U266 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human U266 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26349626]
U-266	IC₅₀	3070 nM Compound: SAHA	Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
U-266	IC₅₀	42.6 μM Compound: SAHA	Growth inhibition of human U266 cells after 72 hrs by MTT assay Growth inhibition of human U266 cells after 72 hrs by MTT assay	[PMID: 30594434]
U-266	IC₅₀	581 nM Compound: SAHA	Cytotoxicity against human U266 cells after 72 hrs by MTT assay Cytotoxicity against human U266 cells after 72 hrs by MTT assay	[PMID: 26443078]
U-87MG ATCC	IC₅₀	1.949 μM Compound: SAHA	Antiproliferative activity against human U-87 MG cells incubated for 48 hrs by MTT assay Antiproliferative activity against human U-87 MG cells incubated for 48 hrs by MTT assay	[PMID: 37563016]
U-87MG ATCC	IC₅₀	10 μM Compound: 5; SAHA	Antiproliferative activity against human U87 cells after 96 hrs by MTT assay Antiproliferative activity against human U87 cells after 96 hrs by MTT assay	[PMID: 31117517]
U-87MG ATCC	IC₅₀	11 μM Compound: 2	Cytotoxicity against human U87MG cells Cytotoxicity against human U87MG cells	[PMID: 17691763]
U-87MG ATCC	IC₅₀	15.71 μM Compound: 1; SAHA	Antiproliferation activity against human U-87 MG cells assessed as growth inhibition measured after 1 hr by MTT assay Antiproliferation activity against human U-87 MG cells assessed as growth inhibition measured after 1 hr by MTT assay	[PMID: 33744690]
U-87MG ATCC	IC₅₀	15.71 μM Compound: I; SAHA	Cytotoxicity against human U-87 MG cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human U-87 MG cells assessed as inhibition of cell growth by MTT assay	[PMID: 36630883]
U-87MG ATCC	IC₅₀	4.19 μM Compound: Vorinostat	Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 37875056]
U-87MG ATCC	IC₅₀	52 μM Compound: SAHA	Antiproliferative activity against human U-87 MG cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human U-87 MG cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
U-937	CC₅₀	0.78 μM Compound: Vorinostat	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 29541372]
U-937	CC₅₀	1050 nM Compound: 1	Antiproliferative activity against human U937 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human U937 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
U-937	EC₅₀	0.82 μM Compound: 1a, SAHA	Antiproliferative activity against human U937 cells after 48 hrs by cell titer-glo assay Antiproliferative activity against human U937 cells after 48 hrs by cell titer-glo assay	[PMID: 20218673]
U-937	EC₅₀	0.88 μM Compound: SAHA	Growth inhibition of human U937 cells after 44 hrs by MTT assay Growth inhibition of human U937 cells after 44 hrs by MTT assay	[PMID: 28337317]
U-937	EC₅₀	0.88 μM Compound: SAHA	Cytotoxicity against human U937 cells assessed as decrease in cell viability after 44 hrs by MTT assay Cytotoxicity against human U937 cells assessed as decrease in cell viability after 44 hrs by MTT assay	[PMID: 29150330]
U-937	EC₅₀	33 μM Compound: SAHA	Compound was tested for anti-proliferative activity in U-937 human leukemia cell line Compound was tested for anti-proliferative activity in U-937 human leukemia cell line	[PMID: 14698179]
U-937	GI₅₀	1.42 μM Compound: vorinostat, SAHA	Antiproliferative activity against human U937 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Antiproliferative activity against human U937 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25218912]
U-937	GI₅₀	1460 nM Compound: SAHA	Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay	[PMID: 26331334]
U-937	GI₅₀	390 nM Compound: SAHA	Growth inhibition of human U937 cells after 72 hrs by SRB assay Growth inhibition of human U937 cells after 72 hrs by SRB assay	[PMID: 20884208]
U-937	GI₅₀	450 nM Compound: SAHA, vorinostat	Antiproliferative activity against human U937 cells after 72 hrs by WST-1 assay Antiproliferative activity against human U937 cells after 72 hrs by WST-1 assay	[PMID: 21080647]
U-937	IC₅₀	0.19 μM Compound: Vorinostat	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
U-937	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
U-937	IC₅₀	0.37 μM Compound: SAHA, Zolinza	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 26100440]
U-937	IC₅₀	0.52 μM Compound: 1; SAHA	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 3 days by celltiter-glo luminescent assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 3 days by celltiter-glo luminescent assay	[PMID: 38456618]
U-937	IC₅₀	0.54 μM Compound: SAHA	Antiproliferative activity against human U937 cells after 72 hrs by MTT assay Antiproliferative activity against human U937 cells after 72 hrs by MTT assay	[PMID: 28419930]
U-937	IC₅₀	0.54 μM Compound: SAHA	Antiproliferative activity against human U937 cells after 72 hrs by MTT assay Antiproliferative activity against human U937 cells after 72 hrs by MTT assay	[PMID: 28601509]
U-937	IC₅₀	0.72 μM Compound: SAHA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 29954683]
U-937	IC₅₀	0.73 μM Compound: 1; SAHA	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 3 days in presence of atamparib by celltiter-glo luminescent assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 3 days in presence of atamparib by celltiter-glo luminescent assay	[PMID: 38456618]
U-937	IC₅₀	0.88 μM Compound: Vorinostat	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
U-937	IC₅₀	0.97 μM Compound: SAHA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 25462271]
U-937	IC₅₀	1 μM Compound: SAHA	Antiproliferative activity against human U-937 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37660833]
U-937	IC₅₀	1.235 μM Compound: SAHA	Antiproliferative activity against human U-937 cells assessed as cell growth inhibition after 72 hrs by CCK8 assay Antiproliferative activity against human U-937 cells assessed as cell growth inhibition after 72 hrs by CCK8 assay	[PMID: 34454126]
U-937	IC₅₀	1.24 μM Compound: Vorinostat	Antiproliferative activity against human U-937 cells measured after 72 hrs by CCK-8 assay Antiproliferative activity against human U-937 cells measured after 72 hrs by CCK-8 assay	[PMID: 37875056]
U-937	IC₅₀	1.41 μM Compound: Vorinostat	Antiproliferative activity against human U-937 cells by MTT assay Antiproliferative activity against human U-937 cells by MTT assay	[PMID: 37875056]
U-937	IC₅₀	1.45 μM Compound: SA, SAHA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 24694055]
U-937	IC₅₀	1.53 μM Compound: SAHA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 29500131]
U-937	IC₅₀	1.53 μM Compound: SAHA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 30879863]
U-937	IC₅₀	1.58 μM Compound: SAHA	Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36996717]
U-937	IC₅₀	1.64 μM Compound: SAHA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 28757101]
U-937	IC₅₀	100 μM Compound: SAHA, Vorinostat	Cytotoxicity against human U937 cells assessed as reduction in cell viability Cytotoxicity against human U937 cells assessed as reduction in cell viability	[PMID: 26264503]
U-937	IC₅₀	2.3 μM Compound: 1, SAHA	Inhibition of human U937 cell proliferation after 48 hrs by MTT assay Inhibition of human U937 cell proliferation after 48 hrs by MTT assay	[PMID: 23493449]
U-937	IC₅₀	2.83 μM Compound: SAHA, Zolinza	Antiproliferative activity against human U937 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human U937 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
U-937	IC₅₀	2.83 μM Compound: Vorinostat	Antiproliferative activity against human U937 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human U937 cells incubated for 72 hrs by MTT assay	[PMID: 25953722]
U-937	IC₅₀	3.35 μM Compound: SAHA	Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26349626]
U-937	IC₅₀	4.33 μM Compound: SAHA	Cytotoxicity against human U937 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human U937 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C4MD00203B
U-937	IC₅₀	4.82 μM Compound: 1, SAHA	Cytotoxicity against human U937 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human U937 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 26122774]
U-937	IC₅₀	5.49 μM Compound: 6, SAHA	Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25906087]
U-937	IC₅₀	907.5 nM Compound: SAHA	Antiproliferative activity against p53 null human U937 cells after 72 hrs by MTT assay Antiproliferative activity against p53 null human U937 cells after 72 hrs by MTT assay	[PMID: 27505848]
U2932	IC₅₀	1.1 μM Compound: SAHA	Antiproliferative activity against human U2932 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human U2932 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
U2932	IC₅₀	2.7 μM Compound: SAHA	Antiproliferative activity against human U2932 cells after 72 hrs by MTT assay Antiproliferative activity against human U2932 cells after 72 hrs by MTT assay	[PMID: 29150335]
U2OS	IC₅₀	2.23 μM Compound: SAHA	Anticancer activity against human U2OS cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay Anticancer activity against human U2OS cells assessed as cell growth inhibition incubated for 3 days by methylene blue staining based colorimetric assay	[PMID: 36244186]
U2OS	IC₅₀	5.7 μM Compound: Vorinostat	Cytotoxicity against human U2OS cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human U2OS cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 32791404]
UACC-257	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human UACC257 cells after 72 hrs by MTS assay Growth inhibition of human UACC257 cells after 72 hrs by MTS assay	[PMID: 22435669]
UACC-62	GI₅₀	0.4 μM Compound: SAHA, Zolinza	Growth inhibition of human UACC62 cells after 72 hrs by MTS assay Growth inhibition of human UACC62 cells after 72 hrs by MTS assay	[PMID: 22435669]
UO-31	GI₅₀	0.5 μM Compound: SAHA, Zolinza	Growth inhibition of human UO31 cells after 72 hrs by MTS assay Growth inhibition of human UO31 cells after 72 hrs by MTS assay	[PMID: 22435669]
Vero	EC₅₀	5.2 μM Compound: SAHA	Cytotoxicity against african green monkey Vero cells cells assessed as cell proliferation after 70 hrs by MTS assay Cytotoxicity against african green monkey Vero cells cells assessed as cell proliferation after 70 hrs by MTS assay	[PMID: 25974739]
Vero	IC₅₀	0.9 μM Compound: SAHA, vorinostat	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
Vero	IC₅₀	1.03 μM Compound: SAHA	Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
Vero	IC₅₀	1.375 μg/mL Compound: SAHA	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS assay	[PMID: 20669972]
Vero	IC₅₀	1.45 μM Compound: 1; SAHA	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 33077264]
Vero	IC₅₀	1.45 μM Compound: SAHA	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 30245394]
Vero	IC₅₀	1200 ng/mL Compound: SAHA	Cytotoxicity against african green monkey Vero cells after 1 to 2 days by neutral red assay Cytotoxicity against african green monkey Vero cells after 1 to 2 days by neutral red assay	[PMID: 19914074]
Vero	IC₅₀	2.85 μM Compound: SAHA	Antiproliferative activity against green monkey Vero cells assessed as inhibition of cell growth incubated for 3 to 5 days by CCK-8 assay Antiproliferative activity against green monkey Vero cells assessed as inhibition of cell growth incubated for 3 to 5 days by CCK-8 assay	[PMID: 38367494]
Vero	IC₅₀	261.6 ng/mL Compound: SAHA	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method	[PMID: 19914074]
Vero	IC₅₀	4.1 μM Compound: SAHA	Antiproliferative activity against african green monkey Vero cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against african green monkey Vero cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 25993269]
Vero	IC₅₀	4.1 μM Compound: SAHA	Antiproliferative activity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33965842]
Vero	IC₅₀	4.465 μM Compound: SAHA	Cytotoxicity against African Green monkey Vero cells assessed as inhibition of cell viability after 72 hrs by MTS assay Cytotoxicity against African Green monkey Vero cells assessed as inhibition of cell viability after 72 hrs by MTS assay	[PMID: 32061484]
Vero	IC₅₀	478.9 ng/mL Compound: SAHA	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method	[PMID: 19914074]
WI-38	GI₅₀	6080 nM Compound: SAHA	Antiproliferative activity against human WI38 cells after 72 hrs by CCK8 assay Antiproliferative activity against human WI38 cells after 72 hrs by CCK8 assay	[PMID: 26331334]
WI-38	IC₅₀	10.07 μM Compound: 1; SAHA	Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
WI-38	IC₅₀	49.87 μM Compound: SAHA	Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
WI-38	IC₅₀	> 30 μM Compound: SAHA; NSC759852	Cytotoxicity against human WI-38 cells assessed as reduction in cell survival incubated for 30 mins by methylene blue staining based analysis Cytotoxicity against human WI-38 cells assessed as reduction in cell survival incubated for 30 mins by methylene blue staining based analysis	[PMID: 36306372]
YAC-1	IC₅₀	0.199 μM Compound: Vorinostat	Antiproliferative activity against mouse YAC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse YAC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 37875056]
Z-138	IC₅₀	0.7 μM Compound: SAHA	Antiproliferative activity against human Z138 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay Antiproliferative activity against human Z138 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	[PMID: 34772529]
ZR-75-1	IC₅₀	1629 nM Compound: 1; SAHA	Antiproliferative activity against human ZR-75-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human ZR-75-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
ZR-75-1	IC₅₀	6.86 μM Compound: SAHA; 6	Antiproliferative activity against human ZR-75-1 cells incubated for 72 hrs by celltiter-glo luminescent assay Antiproliferative activity against human ZR-75-1 cells incubated for 72 hrs by celltiter-glo luminescent assay	[PMID: 39178382]

In Vitro

Vorinostat efficiently suppresses MES-SA cell growth at a low dosage (3 μM) already after 24 hours treatment. HDACs class I (HDAC2 and 3) as well as class II (HDAC7) are preferentially affected by this treatment. Vorinostat significantly increases p21^WAF1 expression and apoptosis in MES-SA cells^[1].
Vorinostat inhibits SK-N-SH and SK-N-Be(2)C with the IC₂₅ values of 1 μM and 0.5 μM, respectively^[2].
Vorinostat is an effective inhibitor of HPV-18 DNA amplification, reduces oncoproteins E6 and E7 activities and triggers apoptosis in HPV-infected, differentiated cells^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Vorinostat (50 mg/kg/day) reduces tumor growth by more than 50% in nude mice injected with 5×10⁶ MES-SA cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

264.32

Formula

C₁₄H₂₀N₂O₃

CAS No.

149647-78-9

Appearance

Solid

Color

White to light yellow

SMILES

O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (378.33 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.7833 mL	18.9165 mL	37.8329 mL
5 mM	0.7567 mL	3.7833 mL	7.5666 mL
10 mM	0.3783 mL	1.8916 mL	3.7833 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution
Protocol 2

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution
Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 4

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 5

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (7.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 20% HP-β-CD in Saline
Solubility: 3.33 mg/mL (12.60 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.96%

Select Batch:

Data Sheet (278 KB) SDS (420 KB)

COA (243 KB) HNMR (238 KB) RP-HPLC (286 KB) LCMS (96 KB)

Handling Instructions (2659 KB)

References

[1]. Hrzenjak A et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer. 2010 Mar 4;9:49. [Content Brief]

[2]. Lautz TB, et al. The effect of vorinostat on the development of resistance to NSC 123127 in neuroblastoma. PLoS One. 2012;7(7):e40816. [Content Brief]

[3]. Richon VM, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7. [Content Brief]

[4]. Xu WS, et al. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007 Aug 13;26(37):5541-52. [Content Brief]

[5]. Pérez-Cañamás A, et al. Sphingomyelin-induced inhibition of the plasma membrane calcium ATPase causes neurodegeneration in type A Niemann-Pick disease. Mol Psychiatry. 2017 May;22(5):711-723. [Content Brief]

[6]. Wang J, et al. Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1. Nat Commun. 2017 Dec 20;8(1):2207. [Content Brief]

[7]. Banerjee NS, et al. Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification. Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):E11138-E11147. [Content Brief]

Cell Assay ^[1]	Cell lysates are prepared by using RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS), and the protein concentration is determined by Bio-Rad DC Protein Assay. Protein lysates are separated by SDS-PAGE and transferred to nitrocellulose membrane. Following antibodies and dilutions are used: rabbit anti HDAC1 (1 μg/mL); rabbit anti HDAC2 (1 μg/mL); rabbit anti HDAC3 (9 μg/mL); rabbit anti HDAC7 (3 μg/mL); mouse anti p21WAF1 (0.5 μg/mL). As secondary antibodies, the rabbit anti-mouse and swine anti-rabbit HRP-coupled antibodies at a final concentration of 1 μg/mL. An overnight incubation at 4°C is used for all primary antibodies, followed by washing and 2-hours incubation at RT with secondary antibodies. Specific protein bands are visualized by enhanced chemiluminescence assay. To demonstrate equal loading of protein samples all western blots are probed for β-tubulin. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Twelve weeks old male mice (n=14) are anesthetized with Isofluran and 5×10⁶ MES-SA cells are injected subcutaneously into the right flank of the animal. Mice from a control group receives placebo containing 300 μL of empty HOP-β-CD (2-hydroxypropyl-β-cyclodextrin) vesicles. Another group of mice receives vorinostat dissolved in HOP-β-CD at a concentration of 50 mg/kg/day. Both, empty vesicles and vorinostat are administered intraperitoneally, starting on the day 4 after the injection of MES-SA tumor cells. Mice body weight and tumor size (w² × l × 0.52; measured by caliper) are estimated twice a week. All mice are treated for 21 days and afterwards sacrificed by cervical dislocation. Each tumor is isolated as a whole and different tumor parameters are determined. Finally, tumor slices are cryo preserved and formalin fixed (4%) for further analyses. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Hrzenjak A et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer. 2010 Mar 4;9:49. [Content Brief] [2]. Lautz TB, et al. The effect of vorinostat on the development of resistance to NSC 123127 in neuroblastoma. PLoS One. 2012;7(7):e40816. [Content Brief] [3]. Richon VM, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7. [Content Brief] [4]. Xu WS, et al. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007 Aug 13;26(37):5541-52. [Content Brief] [5]. Pérez-Cañamás A, et al. Sphingomyelin-induced inhibition of the plasma membrane calcium ATPase causes neurodegeneration in type A Niemann-Pick disease. Mol Psychiatry. 2017 May;22(5):711-723. [Content Brief] [6]. Wang J, et al. Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1. Nat Commun. 2017 Dec 20;8(1):2207. [Content Brief] [7]. Banerjee NS, et al. Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification. Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):E11138-E11147. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.7833 mL	18.9165 mL	37.8329 mL	94.5823 mL
	5 mM	0.7567 mL	3.7833 mL	7.5666 mL	18.9165 mL
	10 mM	0.3783 mL	1.8916 mL	3.7833 mL	9.4582 mL
	15 mM	0.2522 mL	1.2611 mL	2.5222 mL	6.3055 mL
	20 mM	0.1892 mL	0.9458 mL	1.8916 mL	4.7291 mL
	25 mM	0.1513 mL	0.7567 mL	1.5133 mL	3.7833 mL
	30 mM	0.1261 mL	0.6305 mL	1.2611 mL	3.1527 mL
	40 mM	0.0946 mL	0.4729 mL	0.9458 mL	2.3646 mL
	50 mM	0.0757 mL	0.3783 mL	0.7567 mL	1.8916 mL
	60 mM	0.0631 mL	0.3153 mL	0.6305 mL	1.5764 mL
	80 mM	0.0473 mL	0.2365 mL	0.4729 mL	1.1823 mL
	100 mM	0.0378 mL	0.1892 mL	0.3783 mL	0.9458 mL

Vorinostat Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Vorinostat149647-78-9SAHA Suberoylanilide hydroxamic acidHDACAutophagyMitophagyFilovirusApoptosisHPVHistone deacetylasesMitochondrial AutophagyHuman papillomavirusInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Vorinostat (Synonyms: SAHA; Suberoylanilide hydroxamic acid)

Customer Review

Other Forms of Vorinostat:

Vorinostat Related Antibodies

159 Publications Citing Use of MCE Vorinostat

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HDAC Isoform Specific Products:

View All Filovirus Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Vorinostat Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Vorinostat Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report